Characterization of the ubiquitin-like protein Hub1 and its role in pre-mRNA splicing in human cells by Ammon, Tim
  
 
Characterization of the ubiquitin-like protein Hub1  
and its role in pre-mRNA splicing in human cells 
 
Dissertation der Fakultät für Biologie 
der Ludwig-Maximilians-Universität München 
 
 
vorgelegt von 
Diplom Biologe 
Tim Ammon 
 
 
September 2013 
Erklärung 
 2 
Eidesstattliche Erklärung 
Hiermit erkläre ich an Eides statt, dass ich die vorliegende Dissertation selbständig 
und ohne unerlaubte Hilfe angefertigt habe. Ich habe weder anderweitig versucht, 
eine Dissertation einzureichen oder eine Doktorprüfung durchzuführen, noch habe 
ich diese Dissertation oder Teile derselben einer anderen Prüfungskommission 
vorgelegt. 
 
München, den 30.09.2013 
(Unterschrift)   
 
 
 
Die vorliegende Arbeit wurde zwischen Oktober 2005 und September 2013 unter 
Anleitung von Prof. Dr. Stefan Jentsch am Max-Planck-Institut für Biochemie in 
Martinsried durchgeführt. 
 
 
 
Aus Teilen dieser Arbeit sind die folgenden Publikationen hervorgegangen: 
 
Mishra, S.K., Ammon, T., Popowicz, G.M., Krajewski, M., Nagel, R.J., Ares, M., 
Holak, T.A., and Jentsch, S. (2011). Role of the ubiquitin-like protein Hub1 in splice-
site usage and alternative splicing. Nature 474, 173–178. 
 
Bergink, S., Ammon, T., Kern, M., Schermelleh, L., Leonhardt, H., and Jentsch, S. 
(2013). Role of Cdc48/p97 as a SUMO-targeted segregase curbing Rad51-Rad52 
interaction. Nat Cell Biol 15, 526–532. 
 
Ammon, T., Mishra, S.K., Kowalska, K., Popowicz, G.M., Holak, T.A., and Jentsch, 
S. (2013). The conserved ubiquitin-like protein Hub1 plays a critical role in splicing in 
human cells. Submitted 
 
 
 
Promotionsgesuch eingereicht am: 30.09.2013 
Datum der mündlichen Prüfung: 04.12.2013 
Erster Gutachter: Prof. Dr. Stefan Jentsch 
Zweiter Gutachter: Prof. Dr. Angelika Böttger 
 
Table of contents 
 3 
Table of contents 
Eidesstattliche Erklärung _____________________________________________________ 2?
Table of contents ___________________________________________________________ 3?
1? Summary ______________________________________________________________ 5?
2? Introduction ____________________________________________________________ 6?
2.1? Transcription and pre-mRNA processing ___________________________________________ 6?
2.2? Introducing pre-mRNA splicing ___________________________________________________ 9?
2.3? Biochemistry of the splicing reaction ______________________________________________ 10?
2.4? Constituents of the spliceosomal machinery ________________________________________ 11?
2.5? The splicing cycle ____________________________________________________________ 14?
2.6? Alternative splicing ____________________________________________________________ 16?
2.7? Posttranslational modification by ubiquitin __________________________________________ 19?
2.8? Ubiquitin and ubiquitin-like proteins _______________________________________________ 20?
2.9? The ubiquitin-like protein Hub1 __________________________________________________ 23?
3? Aim of this study _______________________________________________________ 26?
4? Results ______________________________________________________________ 27?
4.1? Identification of human Hub1 interactors by yeast two-hybrid screening __________________ 27?
4.2? Hub1 binds the spliceosomal protein hSnu66 in vivo _________________________________ 28?
4.3? A conserved motif in hSnu66 mediates Hub1 interaction ______________________________ 29?
4.4? Mutations in the HIND abolish Hub1-hSnu66 interaction ______________________________ 32?
4.5? Hub1 localizes to splicing-associated nuclear domains _______________________________ 34?
4.6? hSnu66 actively recruits Hub1 to splicing speckles ___________________________________ 37?
4.7? Characterization of hSnu66’s functional domains ____________________________________ 39?
4.8? Distinct and conserved protein properties of Hub1 ___________________________________ 43?
4.9? Molecular tools for the characterization of Hub1 in human cells _________________________ 45?
4.10? In vivo depletion of Hub1 causes cell cycle defects and apoptotic cell death _______________ 46?
4.11? Hub1 RNAi entails DNA damage, mitotic catastrophe, and apoptotic cell death ____________ 51?
4.12? The functional C-terminal surface is crucial to mediate the vital activity of Hub1 ____________ 55?
4.13? Altered distribution of splicing factors and retention of mRNA upon Hub1 depletion in vivo ____ 59?
4.14? Identification of splicing defects upon Hub1 knockdown using splicing reporter systems _____ 63?
4.15? The splicing factor Hub1 is crucial for efficient and faithful pre-mRNA splicing in human cells _ 65?
4.16? Identification of Hub1-dependent alternatively spliced transcripts by exon-specific microarray 
analysis ________________________________________________________________________ 71?
4.17? Antagonistic interactions between the transcription inhibitor actinomycin D and Hub1 RNAi ___ 74?
5? Discussion ____________________________________________________________ 78?
5.1? Identification of binding factors by yeast two-hybrid link Hub1 to splicing-associated complexes 78?
5.2? Hub1 binding is mediated via a conserved Hub1 interaction domain in hSnu66 _____________ 80?
5.3? Hub1 and hSnu66 reside in nuclear splicing speckles ________________________________ 86?
5.4? Conserved and evolved protein features of Hub1 ____________________________________ 92?
5.5? Different surfaces on Hub1 facilitate distinct interactions ______________________________ 94?
5.6? In vivo depletion of Hub1 causes cell cycle defects and apoptotic cell death _______________ 96?
5.7? Hub1 RNAi leads to aberrant splicing and mRNA retention ____________________________ 97?
5.8? Human Hub1 is crucial for specific splicing events ___________________________________ 98?
5.9? Hub1 knockdown desensitizes cells to actinomycin D _______________________________ 101?
5.10? The Hub1-dependent splicing model ____________________________________________ 103?
Table of contents 
 4 
6? Material and Methods __________________________________________________ 107?
6.1? Cell biology ________________________________________________________________ 107?
6.1.1? Human cell lines and transfections __________________________________________________ 107?
6.1.2? Mammalian expression plasmids and siRNA ___________________________________________ 107?
6.1.3? Flow cytometry __________________________________________________________________ 108?
6.1.4? Immunofluorescence, FISH and live cell microscopy _____________________________________ 108?
6.1.5? Cell lysis and immunoprecipitation ___________________________________________________ 109?
6.1.6? Antibodies _____________________________________________________________________ 110?
6.1.7? Exon-specific alternative splicing microarray ___________________________________________ 110?
6.1.8? Yeast strains and plasmids ________________________________________________________ 111?
6.2? Molecular biology ____________________________________________________________ 112?
6.2.1? Preparation and transformation of chemically competent E. coli ____________________________ 112?
6.2.2? Isolation of plasmid DNA __________________________________________________________ 113?
6.2.3? Polymerase chain reaction and site directed mutagenesis ________________________________ 113?
6.2.4? DNA restriction, ligation and cloning _________________________________________________ 113?
6.2.5? RNA-purification, RT-PCR and splicing gels ___________________________________________ 114?
6.2.6? Gel electrophoresis of DNA and purification from agarose gels _____________________________ 114?
6.2.7? DNA sequencing ________________________________________________________________ 114?
6.2.8? Plasmids for recombinant protein expression in E. coli ___________________________________ 114?
6.2.9? Purification of recombinant proteins from E. coli ________________________________________ 114?
6.2.10? Determination of protein concentrations ______________________________________________ 116?
6.2.11? CNBr coupling _________________________________________________________________ 116?
6.2.12? Antibody purification _____________________________________________________________ 116?
6.2.13? Polyacrylamide gel electrophoresis and immunoblotting _________________________________ 117?
6.2.14? Structure determination of the human Hub1-HIND complex ______________________________ 117?
6.2.15? Software ______________________________________________________________________ 118?
7? Figure Index _________________________________________________________ 120?
8? References __________________________________________________________ 121?
9? Abbreviations ________________________________________________________ 142?
10? Acknowledgement ____________________________________________________ 143?
11? Curriculum Vitae _____________________________________________________ 144?
12? Appendix ___________________________________________________________ 145?
12.1? Affymetrix Human Exon 1.0 ST microarray data ____________________________________ 145?
12.2? Microarray mRNA expression analysis ___________________________________________ 146?
12.3? Data collection and refinement statistics __________________________________________ 147?
 
 
Summary 
 5
1 Summary 
For faithful gene expression eukaryotic transcripts are subjected to a series of 
processing steps in which the precursor messenger RNA (pre-mRNA) is maturated 
and subsequently exported to the cytoplasm for translation and protein synthesis. 
Therefore, the excision of intervening, non-coding sequences from nascent pre-
mRNAs is essential, which is catalyzed by a complex macromolecular machine, the 
spliceosome. In a highly regulated and dynamic process the spliceosomal subunits 
assemble in a stepwise manner and are subjected to major structural and 
compositional rearrangements in their RNA and protein interaction network in order 
to form the catalytically active spliceosome. The accurate recognition of splice sites 
and the coordinated assembly of spliceosomes are vital processes to ensure high 
splicing fidelity and efficiency in order to prevent aberrantly spliced transcripts that 
encode misfolded, non-functional, or toxic proteins in cells.  
This study comprises the detailed characterization of the small, ubiquitin-like 
protein Hub1 in mammalian cells and reveals its crucial role in pre-mRNA splicing. In 
vivo depletion of Hub1 from human tissue culture cells leads to cell cycle arrest, 
mitotic defects and subsequent apoptotic cell death. Biochemical and cell biological 
analyses elucidated that Hub1 is essential for faithful pre-mRNA splicing of distinct 
introns and proper alternative splicing in human cells. Importantly, Hub1 does not 
influence general splicing, but facilitates processing of certain splicing events in 
particular pre-mRNAs. Moreover, the study demonstrates that knockdown of Hub1 
causes an altered nuclear distribution of splicing factors and nuclear retention of 
mRNA species, further indicating defective mRNA splicing in vivo. In this study Hub1 
was identified as a component of nuclear splicing speckles where it interacts with the 
conserved spliceosomal tri-snRNP protein hSnu66. Mapping and binding studies led 
to the characterization of the Hub1 interaction motif in hSnu66, which is sufficient and 
necessary to mediate binding of Hub1. The underlying molecular mechanism of this 
interaction between the non-canonical ubiquitin-like protein Hub1 and the splicing 
protein hSnu66 was resolved by determining the crystal structure of the complex. 
Additionally, mutational analysis elucidated that, although binding to hSnu66 
facilitates the recruitment of Hub1 to nuclear speckles, the interaction is neither 
essential for viability nor Hub1’s crucial function in pre-mRNA splicing. In contrast, it 
became apparent that another surface on Hub1 opposing the Hub1-hSnu66 interface 
conveys the pivotal activity of Hub1 in mRNA splicing. 
Finally, the experimental data and derived conclusions are integrated into a 
revised pre-mRNA splicing model proposing a central function for Hub1 during 
spliceosomal complex formation. In summary, this study represents the first compre-
hensive characterization of the ubiquitin-like protein Hub1 in human cells and reveals 
the essential role of Hub1 as a non-covalent “modifier” of the splicing machinery.  
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2 Introduction 
2.1 Transcription and pre-mRNA processing  
Eukaryotic gene expression is a highly coordinated and dynamic process 
accomplished by an intricate network of macromolecular protein complexes, RNA-
containing ribonucleoparticles (RNPs) and their regulatory circuits. During RNA 
synthesis by RNA polymerase II (RNA pol II), precursor messenger RNA (pre-mRNA) 
has to undergo several processing steps, namely 5’-capping, splicing and 
polyadenylation to give rise to the stable, mature gene product, which can be 
exported from the nucleus to the cytoplasm for later translation into proteins.  
Upon transcription initiation TATA-box binding protein (TBP) and several 
associated factors (TAF) are recruited to the core promoter sequences, where 
general transcription factors TFIIA and TFIIB facilitate loading and engaging of the 
RNA pol II machinery onto DNA. This pre-initiation complex (PIC) is finally completed 
by the joining of multimeric mediator, TFIIH, and TFIIE complexes. In order to allow 
productive transcription, the densely packed chromatin has to be accessible and 
opened up by chromatin remodeling enzymes (Ho and Crabtree, 2010). Among this 
group of enzymes, acetyl- or methytransferases are crucial to posttranslationally 
modify nucleosomal histones for subsequent reorganization of the chromatin 
structure. Upon histone acetylation (histone 3 at K9 and K14, histone 4 at K16) as 
well as methylation (histone 3 at K4), RNA pol II is released from its promoter to start 
productive mRNA synthesis.  
The sequential steps of initiation, elongation, and termination during 
transcription are accompanied by different posttranslational modifications of a distinct 
C-terminal domain of the RNA pol II, the CTD. In humans the CTD, comprised of 52 
heptad repeats of Y1-S2-P3-T4-S5-P6-S7 residues, serves as a regulatory interaction 
platform for the various mRNA processing factors and thus directly couples 
transcription to subsequent mRNA maturation. Manipulation of the CTD by using 
mutant allels or deletions directly impinges on splicing, capping and polyadenylation, 
respectively (McCracken et al., 1997). Site-specific phosphorylation of serines within 
the CTD controls and promotes distinct phases of RNA polymerase action, 
resembling the so-called serine code (Fong and Bentley, 2001). While RNA pol II is 
mainly phosphorylated at serine S5 during transcription initiation, the serine S2 
phosphorylation serves as the predominant modification in the elongation phase and 
serine S7 is found in paused or terminating RNA pol II complexes. This code is 
established by CTD-associated kinases like P-TEFb (positive transcription elongation 
factor) with Cyclin-dependent kinase CDK9 and TFIIH/CDK7, respectively, and 
subsequently read by RNA processing factors and elongation supporting co-factors 
(Dahmus, 1996). For productive transcription initiation the TFIIH/CDK7 complex acts 
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as the major S5 kinase, while the P-TEFb/Cdk9 subunit inactivates the inhibitory DSIF 
and NELF complexes to stimulate RNA polymerase activity (Missra and Gilmour, 
2010). Upon RNA synthesis the nascent chain and the CTD S5 phosphorylation mark 
are recognized by the 5’-capping enzyme complex (CEC) to transfer a 7-
methylguanosine (m7G) cap to the emerging 5’ end of the mRNA. As the first mRNA 
processing step, 5’-capping is crucial for nuclear export, translation and stability as it 
prevents premature degradation by exonucleases (Anderson and Parker, 1998).  
Introduction Figure I: Co-transcriptional mRNA processing 
During distinct phases of the transcription cycle RNA polymerase II is phosphorylated at specific sites 
(yellow) in the C-terminal domain (CTD). The CTD serves as a platform to recruit specific mRNA 
processing complexes to the nascent pre-mRNA (red) in order to orchestrate 5’ mRNA capping by the 
capping enzyme complex (CEC, dark red), pre-mRNA splicing with excision of introns (black) by the 
spliceosome (SF= splicing factors, green) and finally 3’ cleavage with polyadenylation by cleavage 
stimulatory factor (CSF), polyadenylation specificity factor (CPSF) and the polyadenylate polymerase 
(PAP). (See text for more detail) 
 
After co-transcriptional 5’-capping the RNA pol II machinery undergoes the 
transition to elongation phase with concomitant S2 phosphorylation. As the majority of 
eukaryotic genes contain intervening non-coding sequences (so called introns) in 
their open reading frames (ORFs), these RNA segments have to be removed in a 
complex process called pre-mRNA splicing (Ruskin et al., 1984). The excision of 
intronic fragments with the concurrent ligation of coding sequences (exons) is 
catalyzed by an intricate macromolecular machinery of ribonucleoparticles, the 
spliceosome (detailed in chapter 2.3). The serine S2 phosphorylated RNA pol II CTD 
serves as a platform to recruit auxiliary splicing factors like ASF/SF2 or SC35, which 
facilitate the recognition of exon-intron boundaries and cis-acting regulatory elements 
to promote the accurate and dynamic spliceosomal assembly on nascent mRNA 
(Millhouse and Manley, 2005; Morris and Greenleaf, 2000; Lin et al., 2008). Once a 
splice site is defined, subunits of the spliceosome, so called snRNPs (small nuclear 
ribonucleoproteins), bind specifically to crucial RNA sequences to assemble the 
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catalytically active spliceosome in a highly coordinated manner. The 
transesterification reaction, which excises the intron and ligates coding exons, 
involves global rearrangements of RNA-RNA, RNA-protein and protein-protein 
interaction networks mediated by powerful enzymes like GTPases and RNA-
dependent helicases (Chang et al., 2013). After introns are removed and splicing 
reactions are completed, bound spliceosomes disassemble and the nascent mRNA 
undergoes its final co-transcriptional processing step, the polyadenylation. 
Downstream of the protein coding sequence most mRNAs contain a poly (A) signal 
sequence (5’AAUAAA-3’) together with a GU-rich stretch at the 3’ region, which is 
recognized by the polyadenylation machinery (Proudfoot, 2011). Again, RNA pol II 
CTD mediates the recruitment of RNA processing complexes and acts as a scaffold 
for the cleavage and polyadenylation specificity factor (CPSF) and the cleavage 
stimulatory factor (CSF). The emerging poly (A) signal sequence and the CTD S2 
phosphorylation recruit CPSF and CSF complexes, which induce polymerase 
pausing and cleavage of the transcript. After the mRNA is cleaved polyadenylate 
polymerase (PAP) supported by polyadenylated binding factor (PAB2) extends the 
free 3’ end with a polyadenosine tail (250-300 adenines in human cells, 70-80 in 
yeast (Elkon et al., 2013)). As final step of co-transcriptional mRNA processing the 
attachment of a poly (A) tail is a prerequisite for efficient nuclear export, mRNA 
stability and productive translation.  
 
 
Introduction Figure II: Interplay of the gene expression network  
In order to ensure accurate gene expression mRNA maturation is highly regulated at several layers. The 
coordination of cellular processes including transcription, RNA processing, mRNA export and 
surveillance is accomplished by a complex interwoven network of direct physical and functional 
interactions between RNA-directed molecular machineries (indicated by black arrows). (Adapted from 
Maniatis, T., and Reed, R. (2002))  
 
 Taken together, the tight connection between transcription and RNA 
processing highlights the importance of the different pre-mRNA maturation steps as 
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regulatory elements of eukaryotic gene expression. Distinct RNA binding complexes 
like spliceosomal subunits are recruited to the nascent transcript and catalyze 
reactions in a highly coordinated and dynamic manner. Although the molecular 
capping, splicing and adenylation machineries perform discrete functions during pre-
mRNA processing in vivo, their actions are interwoven and interdependent in an 
extensive RNA maturation network (Introduction Figure II) (Maniatis and Reed, 
2002). Accurate and faithful mRNA processing is essential to ensure proper gene 
expression and synthesis of functional proteins. Defects in pre-mRNA maturation, like 
truncated polyadenylation or defective splicing, entail mRNA degradation, impaired 
nuclear export and aberrant transcripts that encode misfolded or non-functional 
proteins. Dysregulation of mRNA processing and particularly splicing has a strong 
implication in tumorigenesis as it substantially alters cellular homeostasis and 
biochemical pathways which affect proliferation, cell differentiation and cell viability 
resembling hallmarks of human cancer (Venables, 2004; Liu and Cheng, 2013). 
 
2.2 Introducing pre-mRNA splicing 
Based on early studies in prokaryotes, mRNA was considered as a complementary 
template copy of genomic information. In 1977 gene expression studies on 
adenoviral mRNAs revealed intriguing differences between the viral genome 
sequences and its transcripts at late stages of infection (Berk and Sharp, 1977; Chow 
et al., 1977). The discovery of those sequence arrangements in RNA:DNA 
hybridization assays together with subsequent advances in mRNA biology 
revolutionized the view on gene structure, transcription and mRNA maturation 
(Witkowski, 1988).  
Most eukaryotic genes contain intervening non-coding sequences, so-called 
introns, which have to be removed after transcription by a process termed pre-mRNA 
splicing in order to obtain the mature and functional mRNA. Therefore, all eukaryotes 
evolved a highly conserved and sophisticated network of pre-mRNA splicing factors 
and enzymes to conduct this essential processing step (Ast, 2004).  
In the human genome splicing is crucial for over 92-94% of transcripts, as they 
contain exons separated by at least one intron. The average human transcript 
comprises 8.8 relatively short exons (ca. 120 nt), while introns with an average size 
of >5400 nt are rather long (Sakharkar et al., 2004). In contrast, in Saccharomyces 
cerevisiae only three percent of the genes carry introns (ca. 253) with only six 
transcripts containing two introns (Barrass and Beggs, 2003). Although the fission 
yeast Schizosaccharomyces pombe represents the intermediate genomic state with 
43% of intron-containing genes, both yeasts exhibit rather short introns with an 
average size of 40-75 nt (Ast, 2004). Despite the differences in splicing prevalence 
between lower eukaryotes like S. cerevisiae and mammals, which led to formulation 
of the exon- and intron-definition model (Robberson et al., 1990), the basic 
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biochemistry of pre-mRNA splicing is highly conserved. In a stepwise process the 
macromolecular spliceosome assembles on the pre-mRNA and recognizes crucial 
sequences within the pre-mRNA that determine the intron boundaries. The 
spliceosome machinery consists of an intricate network of distinct ribonucleoproteins 
(RNP) in complex with small nuclear RNA (snRNA), which guide and facilitate the 
transesterification reaction. Upon spliceosome activation in a cascade of major 
rearrangements, RNA-RNA, RNA-protein and protein-protein interactions are 
disrupted and re-assembled as novel intermediates to catalyze the intron excision 
with concomitant exon ligation. Based on the orchestrated activities of over 300 
proteins including kinases, helicases and ATPases, intertwined with pre-mRNA 
bound ribonucleoprotein particles, the human spliceosome is considered to be 
among the most complex macromolecular machines in the cell (Nilsen, 2003). 
 
2.3 Biochemistry of the splicing reaction 
After transcription the splicing machinery assembles on the nascent pre-mRNA and 
recognizes crucial sequences within the pre-mRNA that define the exon-intron 
boundaries as 5’ splice site (5’ss) and 3’ splice site (3’ss). In addition, the intronic 
sequence harbors the crucial adenosine residue embedded in the branch point 
sequence (BPS), which serves as the acceptor site during the splicing reaction. In 
metazoans an additional element with 10-12 pyrimidine bases, the polypyrimidine 
track (PPT), is located in between the BPS and the 3’ss. In contrast, a minor fraction 
of introns (ca. 1% of all human introns) that are spliced via the minor U12-dependent 
spliceosome lack the polypyrimidine track, while PPTs are generally absent in S. 
cerevisiae (Burge et al., 1998; Will and Lührmann, 2005).  
Introduction Figure III The pre-mRNA splicing reaction 
a) Schematic representation of conserved sequence elements in metazoan and budding yeast pre-
mRNAs, respectively. Consensus sequences of 5’ splice sites (5’ss), 3’ splice sites (3’ss), branch point 
sequences (BPS) and polypyrimidine track (PPT) are indicated. Bases abbreviations Y = pyrimidine, R = 
purine. b) The two transesterification steps of the splicing reaction. The branch point adenosine attacks 
the phosphodiester bond (p) at the 5’ss guanosine generating the lariat intermediate. Subsequently the 
liberated 3’ hydroxyl group of the 5’ exon reacts with the phosphodiester bond on the 3’ss resulting in 
the ligation of the two exons. (Adapted from Patel and Steitz (2003)).  
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The intron is excised in a two-step manner with two consecutive 
transesterification reactions (see Introduction Figure III). First, the 2’ hydroxyl group 
of the branch point adenosine performs a nucleophilic attack on the phosphodiester 
bond at the guanosine of the 5’ss. This liberates a 3’ hydroxyl group at the 5’ exon, 
while the 5’ end of the intron forms a lariat intermediate with the branch point. In the 
second step, the free 3’ hydroxyl group of the 5’ exon reacts with the phosphodiester 
bond on the 3’ss resulting in the ligation of the two exons, excision of the intron-lariat 
and completion of the splicing reaction.  
 
2.4 Constituents of the spliceosomal machinery 
The enzymatic excision of non-coding introns from pre-mRNA is performed by the 
multi-subunit ribozyme complex, the spliceosome (Collins and Guthrie, 2000). The 
subunits can be categorized into snRNP and associated non-snRNP protein 
complexes.  
The snRNPs are the major building blocks of the spliceosome and are 
characterized by the five uridine-rich small nuclear RNAs (U1, U2, U4, U5, U6) and 
their respective ribonucleoproteins. While each U1, U2 and U5 snRNA form distinct, 
solitary snRNPs, U4 and U6 snRNA share extensive base-paring forming the dimeric 
U4/U6 snRNP complex (Bringmann et al., 1984; Nilsen, 1994). All non-U6 snRNAs 
are transcribed by RNA pol II and exported by the PHAX/CBC (phosphorylated 
adaptor of export protein / cap binding complex) to the cytoplasm. During cytoplasmic 
maturation snRNAs undergo modifications like 3’ end processing and the addition of 
the characteristic 2,2,7-trimethylguanosine cap (3mG) at the 5’ end. Each snRNA 
contains a conserved sequence motif, the Sm site, which is recognized and 
encompassed by the Sm proteins (SmE, SmG, SmD3, SmB, SmD1, SmD2, SmF) 
that form a heteroheptameric ring around the snRNA during biogenesis (Seraphin, 
1995; Urlaub et al., 2001). Both the Sm ring assembly and 3mG capping are crucial 
for nuclear re-import and incorporation into functional snRNP in Cajal bodies (Will 
and Lührmann, 2001; Fischer et al., 2011). In contrast, U6 snRNA derives from RNA 
pol III transcription and matures entirely within the nucleus. Although the U6 snRNA 
lacks a canonical Sm-binding motif, Sm-like (Lsm2-8) proteins analogous to the Sm 
proteins are recruited to an uridine-rich sequence at the 3’ end instead. Beside the 
Lsm ring the U6 snRNA carries an unique γ-monomethyl guanosine 5’-cap and 
undergoes extensive RNA modifications like 3’ pseudouridylation and 2’-O-
methylation (Karijolich and Yu, 2010). These maturation steps orchestrate the 
recruitment of snRNA-specific proteins, determine subnuclear localization to the 
nucleolus or Cajal bodies and mediate U6 snRNP recycling by SART3/p110 
(Mroczek and Dziembowski, 2013). 
During spliceosome assembly the 5’ss is recognized by the U1 snRNP which 
contains a rather small number of U1 specific proteins, namely U1-70K, U1-A and 
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U1-C in addition to the Sm ring. The auxiliary factors SF1/BBP in cooperation with 
U2AF65 and U2AF35 recruit the U2 snRNP to the branch point upstream of the 3’ss. 
The stable association to the BPS is supported by more than twelve U2 snRNP 
proteins including A’, B’’, as well as the SF3a and SF3b complexes. In particular, 
SF3b155 together with SF3b14/p14 play crucial roles as they physically interact with 
the BPS and ensure proper formation of the prespliceosomal complex A (see chapter 
2.5).  
 The U5 snRNP comprises eight U5 proteins including pivotal enzymes like 
the DEAD box helicase hPrp28, the GTPase Snu114, the DExD/H-box protein 
hBRR2 and the multidomain protein hPRP8.  
Introduction Figure IV: The human spliceosomal snRNPs 
Composition of the major snRNP complexes depicting the uridine-rich snRNAs with respective 
secondary structures and the associated snRNP specific proteins. (Adapted from Will and Lührmann 
(2011)). 
 
In contrast to the singular U1 and U2 snRNPs, complementary domains 
within the U4 and U6 snRNA allow RNA base-paring which creates the platform for 
the dimeric U4/U6 snRNP complex associated with Sm, LSm, as well as snRNP 
specific proteins hPrp3, hPrp4, hPrp31, CypH and 15.5K (Schneider et al., 2002). 
The catalytic core subunit of the spliceosome is formed when the preassembled U5 
snRNP joins the U4/U6 snRNP and thereby generates the U4/U6.U5 tri-snRNP 
complex. The tri-snRNP formation is accompanied by the recruitment of three 
additional complex-specific proteins 27K, hSad1 and hSnu66, while the U5 factor 
52K dissociates during this transition (Gottschalk et al., 1999). 
In addition to the different U1, U2, and U4/U6.U5 tri-snRNP complexes the 
spliceosomal activity is supported by a large number of non-snRNA containing RNPs. 
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The major non-snRNP complex which associates with the spliceosome during the 
formation of the precatalytic complex B is the PRP19/CDC5L or nineteen complex 
(NTC) in S. cerevisiae (Tarn and Steitz, 1994; Ajuh et al., 2000). The PRP19/CDC5L 
complex consists of at least seven proteins; while the central proteins hPRP19 
(Prp19), CDC5L (Cef1), PRL1 (Prp46) and SPF27 (Snt309) are conserved, the 
subunits human AD002, CTNNBL1 (β-catenin-like 1) and HSP73 are not found in 
yeast. PRP19/CDC5L is crucial for pre-mRNA splicing in human cells and 
immunodepletion of this complex interferes with the first catalytic step in HeLa 
nuclear extracts (Makarova et al., 2004). After the U4/U5.U6 tri-snRNP joins the 
prespliceosomal complex A, PRP19/CDC5L mediates the dissociation of the U4 
snRNP, which in turn allows the stable association of the U5 and U6 snRNPs with 
the spliceosome on the pre-mRNA during catalysis (Chan et al., 2003). Interestingly, 
the central Prp19 protein resembles an active ubiquitin E3 ligase comprising WD40 
and U-box domains (Ohi et al., 2003; Vander Kooi et al., 2010), which mediates the 
ubiquitylation of hPrp3 and its association with hPrp8 to further stabilize the 
U4/U6.U5 tri-snRNP (Song et al., 2010). After precatalytic complex B formation, 
PRP19/CDC5L stays with the spliceosome until the splicing reaction is completed 
and the mRNA-bound post-spliceosomal complex disassembles with the release of 
the lariat intermediate. 
In addition to the large PRP19/CDC5L complex, a large number of splicing 
factors associate only transiently with the spliceosome to precisely mediate 
rearrangements or support different steps during the transesterification reaction 
(Wahl et al., 2009). During spliceosomal activation RNA-RNA and RNA-protein 
interaction networks undergo extensive rearrangements that are facilitated by the 
coordinated action of various enzymes. The tri-snRNP itself contains the GTPase 
hSnu114, DExD/H-box helicases hBrr2 and hPrp28, and multi-domain protein hPrp8, 
which are considered to act as the “molecular motor” (Häcker et al., 2008) during 
U4/U6 unwinding for spliceosome activation. However, beside the activity of the tri-
snRNP components, additional ATP-dependent helicases hPrp2, hPrp5, 
Sub2/UAP56, hPrp16, hPrp22, hPrp43 are crucial for individual steps during the 
splicing cycle (see Introduction Figure V). For example, the non-snRNP helicase, 
hPrp2, supports the U4/U6 unwinding activity of hBrr2 and, moreover, converts the 
precatalytic complex B to an activated spliceosome which then catalyzes the first 
splicing reaction step. On the other hand, other DExD/H-box proteins hPrp5 and 
Sub2/UAP56 mediate the stable association of the U2 snRNP at the BPS (Chang et 
al., 2013).  
Another group of non-snRNP proteins, the serine/arginine (SR)-rich proteins 
and hnRNP (heterogeneous nuclear ribonucleoproteins), are RNA binding factors 
with regulatory functions. They are characterized by one to two RNA binding 
modules, RNA recognition motifs (RRMs) or hnRNP K-homology (KH) domains, 
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accompanied by their respective functional domains (Manley and Tacke, 1996; 
Krecic and Swanson, 1999); in case of SR proteins the RS-domain and in hnRNPs 
the more divergent RGG boxes, glycine-, acidic- or proline rich domains. Proteins of 
these two families are crucial regulators of alternative splicing, as they influence 
splice site recognition and usage by fostering the recruitment of the splicing 
machinery to the respective splice site or repress assembly, respectively (see 
chapter 2.6). 
 
2.5 The splicing cycle 
Due to the intricate and highly dynamic nature of the splicing cycle, the splicing 
machinery follows basic principles to allow profound structural and compositional 
rearrangements for accurate pre-mRNA processing. Firstly, in order to allow high 
flexibility of the snRNP complexes, the majority of interactions within the spliceosome 
network show rather low binding affinity, which is compensated by a strong avidity 
formed by the combination of multiple interaction surfaces. Secondly, the correct 
timing during the coordinated assembly and dissociation of spliceosomal complexes 
ensures high fidelity. Each crucial step during splicing activation is under the control 
of ATP-dependent DExD/H-box helicases like hPrp2 or hBrr2 to avoid pre-mature 
unwinding of snRNAs, misaligned base pairing or defective splicing reactions. 
Thirdly, the spliceosome ensures correct recognition of the reactive sites within the 
pre-mRNA like the BPS, and 5’ss and 3’ss at multiple check points. This is important, 
due to the highly divergent recognition sequences at the 5’ss in metazoan introns, 
while in yeast splice sites are almost invariant. Therefore, in addition to auxiliary 
splice site recognition factors like the SR protein family, the 5’ss is contacted by the 
U1 snRNA as well as the U6 and the U5 snRNP to ensure faithful and precise pre-
mRNA splicing. However, the underlying biochemical principles of the splicing 
reaction are highly conserved from yeast to human and summarized in the following 
section (see Introduction Figure V). 
In the initial step of the splicing cycle the U1 snRNP interacts with the 5’ 
splice site forming the commitment complex (complex E) supported by RNA-binding 
serine-arginine-rich proteins. Here, short motifs in the U1 snRNA base pair with the 
splice donor site at the exon-intron boundary. Next, the branch point sequence is 
bound and marked by SF1/BBP accompanied by U2AF35 and U2AF65, which 
recognize the polypyrimidine track (PPT) and the AG motif of the 3’ss. The 
commitment complex is converted to prespliceosomal complex A by loading of the 
U2 snRNP. The DExD/H-box helicases UAP56 and hPrp5 mediate the stable 
interaction and snRNA-mRNA base pairing of the U2 snRNP with the BPS. 
Therefore, the SF1/BBP is replaced from the branch point adenosine by the p14 
subunit of the SF3b complex. The following recruitment and incorporation of the 
U4/U6.U5 tri-snRNP gives rise to the pre-catalytic spliceosome (complex B). The U5 
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DExD/H-box helicase hPrp28 facilitates the displacement of the U1 snRNP allowing 
the later hybridization of the U6 snRNA with the intronic 5’ss. During this catalytic 
activation the activated spliceosome (complex Bact) undergoes profound 
conformational changes, in which the global RNA-RNA network is rearranged and 
protein interactions are disrupted and newly established. This conversion is triggered 
by hPrp8 and the DExD/H-box helicase hBrr2, which unwinds the tightly 
interconnected U4/U6 snRNA dimer.  
 
 
Introduction Figure V: The stepwise assembly of the spliceosome during splicing cycles 
The snRNPs (colored circles) recognize crucial sequences within the intron-containing pre-mRNA and 
mediate the assembly of the catalytically active spliceosome on in a stepwise fashion. During 
spliceosome formation and activation major rearrangements of the RNA and protein interaction network 
are catalyzed by GTPases, DExD/H-box helicases and ATPases as indicated at different transition 
steps. For intelligibility, transient and auxiliary non-snRNP proteins like the Prp19 complex are not 
included. See text for more details. (Adapted from Will and Lührmann (2011)). 
 
 The free U6 snRNA is then able to form extensive base pairing with the U2 
snRNA and the pre-mRNA’s 5’ss at the same time, which arranges the BPS 
adenosine into close proximity with the splice site. The GTPase hSnu114 further 
supports the dissociation of the U1 snRNP and U4 snRNA from the spliceosome 
together with several tri-snRNP-associated proteins like hSnu66 and hPrp38. Another 
ATP-dependent DExD/H-box helicase hPrp2 (DHX16) is crucial for further activation 
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and transition from the Bact to the catalytically activated spliceosome (B* complex) by 
a jet unknown mechanism. Stabilized by the interplay of U6, U2, and U5 snRNAs, the 
catalytically activated spliceosome catalyzes the first transesterification reaction, in 
which the BPS adenosine attacks the 5’ss and forms the lariat intermediate. In the 
subsequent second reaction step the exon ligation and excision on the lariat by the 
catalytic complex C is fostered by complementary action of the hPrp16 and hPrp22 
helicases. Finally, the spliced mRNA is released and the post-spliceosomal complex 
disassembles with the help of hPrp43 to allow recycling of the remaining U5, U6 and 
U2 snRNPs for another splicing cycle, while the intron-lariat is degraded. 
The human transcriptome comprises many pre-mRNAs that are characterized 
by multiple long introns (with more than several hundreds of nt) separating rather 
short exons with 100-150 nt. As these distances challenge the coordinated 
spliceosomal assembly, mammalian cells have evolved an alternative process in 
addition to the linear 5’ to 3’ assembly (Robberson et al., 1990). During the so-called 
exon-definition, the early complex (ED-E complex) is formed by recruiting the U1 
snRNP, which in turn facilitates the association of the U2 auxiliary factors U2AF with 
SF1/BBP to the 5’ end of the same exon. In contrast to intron-definition here, the 3’ss 
U2AF/SF1 and the later U2 snRNP (ED-A complex), respectively, resemble a 
functional unit with the cross-exon downstream 5’ss U1 snRNP instead of the 
upstream cross-intron 5’ss (Schellenberg et al., 2008). The U4/U6.U5 tri-snRNP 
associates with the ED-A complex which then can convert into a B-like spliceosomal 
complex (Schneider et al., 2010). Thus, splicing via exon-definition uncouples the 
early spliceosome assembly from protracted intron transcription and allows shuffling 
of exons by mutual exclusion or inclusion in a process called alternative splicing 
(Bonnal et al., 2008; Sharma et al., 2005).  
 
2.6 Alternative splicing 
The initial recognition of the 5’ss and the BPS / 3’ss by the recruitment of the U1 and 
U2 snRNPs to form a pre-spliceosomal complex determines the efficiency of pre-
mRNA splicing. In metazoans an additional layer of post-transcriptional expression 
regulation utilizes differential splice site recognition to extend the repertoire of the 
human genome by generating multiple mRNA isoforms from a single gene in a 
process called alternative splicing (AS). While alternative splicing is a rare event in 
lower eukaryotes like S. cerevisiae (three known AS genes), in humans over 95% of 
intron-containing transcripts undergo alternative splicing, giving rise to multiple 
mRNA isoforms (Pan et al., 2008). The prevalence of AS correlates with the high 
degree of degenerated splice site sequences found in metazoan genomes (Ast, 
2004). Exons containing strong splice sites, which resemble the consensus 
sequence, stably base pair with the corresponding snRNA and are efficiently 
recognized by U1 snRNP and U2AF complexes. In contrast, divergent non-canonical 
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splice site sequences weaken exon recognition and subsequent spliceosomal 
assembly. In addition to the intrinsic splice site strength, metazoan pre-mRNAs 
contain cis-regulatory sequences, which can negatively or positively affect splice site 
recognition and usage. Dependent on their localization, these elements are termed 
exonic or intronic splicing enhancers and silencers, respectively.  
 
Introduction Figure VI: Different types of alternative splicing 
Basic types of alternative splicing can generate various mRNA isoforms including the sequential 
incorporation of constitutive exons, skipping or retention of individual exon cassettes (exon exclusion or 
inclusion), retention of distinct introns or usage of alternative 5’ or 3’ splice sites. 
 
 They serve as specific recognition motifs for RNA binding factors that either 
facilitate recruitment of snRNP subunits or repress spliceosomal assembly. Splicing 
enhancers attract positive regulators of the serine/arginine (SR)-rich protein family 
(SR protein) like SC35, ASF/SF2 or SRp20 (Shepard and Hertel, 2009). In the current 
model, the RS-domain mediates the direct physical interaction with spliceosomal 
subunits and binds other RS-domain containing factors (like U2AF35/U2AF65) to 
support splice site usage (Zhou and Fu, 2013). In contrast, the antagonistic group of 
heterogeneous nuclear ribonucleoproteins (hnRNP) associates with pre-mRNA via 
splicing silencer motifs where they interfere with the spliceosomal assembly at the 
respective splice site (Krecic and Swanson, 1999). Several members of this 
multifaceted family of RNA binding proteins including hnRNP A1 or PTBP1 (hnRNP1) 
can repress the engagement or progression of early prespliceosomal assemblies at 
respective exons and thereby avoid splice site usage.  
Another layer of alternative splicing regulation modulates the activity of SR 
proteins and hnRNPs in human cells. Regulatory splicing factors are under tight 
control of SR-kinases, e.g. CLK1-4, SRPK1-2, AKT and counteracting phosphatases 
(PP1), which affect subnuclear distribution and recruitment to active splice sites (Ngo 
et al., 2005). Furthermore, many SR and hnRNP proteins are expressed in a tissue-
specific manner (Ellis et al., 2012; Grosso et al., 2008) or upon certain stimuli 
(Paronetto et al., 2011; Li et al., 2006) and thereby switch between mRNA splice 
variants that express protein isoforms tailored to the individual needs of differentiated 
cell types. In the cellular context, alternative splicing regulation is an even more 
complex process. Considering the tight association between the transcription 
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machinery and pre-mRNA splicing, global alternative splicing patterns are 
significantly affected by parameters like promoter strength, RNA polymerase 
processivity and pausing as well as posttranslational histone modifications (Kornblihtt 
et al., 2013; Luco et al., 2011). In summary, alternative splicing is a complex and 
highly regulated process, in which the interplay between stimulatory splicing 
enhancers and negative silencers, spliceosomal activity and fidelity together with the 
intrinsic splice site strength determine the prevalent fate of each individual splicing 
event.   
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2.7 Posttranslational modification by ubiquitin  
Posttranslational modifications serve as regulatory switches to alter the activity, 
stability, localization or function of proteins and constitute crucial control mechanisms 
in virtually all biochemical and cellular pathways. In addition to the attachment of 
small chemical substituents, e.g. during phosphorylation, acetylation, methylation or 
glycosylation, proteins can be modified by the covalent conjugation to another 
polypeptide.  
Initially, a small, highly conserved protein called ubiquitin was identified serving 
as a molecular tag to target protein substrates for degradation via the 26S 
proteasome (Ciechanover et al., 1984; Hough et al., 1986; Wilkinson et al., 1980; 
Goldstein et al., 1975). Later, additional functions of ubiquitin were elucidated, 
showing that it is implicated in various cellular pathways including endocytosis, cell 
signaling, DNA replication, and repair (Strous et al., 1996; Hoege et al., 2002; 
Jentsch et al., 1987; Kölling and Hollenberg, 1994; Ea et al., 2006; Chen and Sun, 
2009). The covalent attachment requires an enzymatic cascade to activate, transfer 
and conjugate ubiquitin specifically to a lysine residue of its substrate (Jentsch, 
1992). Synthesized as an inactive precursor, ubiquitin has to be processed by 
ubiquitin C-terminal hydrolases (UCH) to liberate the free monomeric form (Pickart 
and Rose, 1985). In an ATP-dependent step, the E1 ubiquitin activating enzyme 
adenylates the C-terminus of ubiquitin in order to form a highly reactive E1~ubiquitin 
thioester bond in a subsequent reaction (Ciechanover et al., 1982). In the next step of 
the cascade, ubiquitin is transferred to a cysteine in the active center of the E2 
conjugating enzyme. The loaded E2 enzyme associates and cooperates with E3 
ubiquitin ligases, which convey substrate specificity. While RING E3 ligases mediate 
the direct ubiquitin transfer by spatially arranging the acceptor substrate in close 
proximity to the E2 enzyme, ligases of the HECT-family form an active intermediate 
complex in which the ubiquitin moiety is transiently forwarded to a reactive cysteine 
within the HECT domain before it is finally conjugated to the targeted protein 
(Hershko et al., 1983; Huibregtse et al., 1995). Here, the C-terminal carboxyl group at 
the double glycine motif of ubiquitin forms an isopeptide bond with an ε-amino group 
of a lysine residue on the substrate (Hershko et al., 1986). Through this enzymatic 
reaction, targeted proteins can be modified by a single ubiquitin moiety 
(monoubiquitylation) or via multiple separate ubiquitylation steps at different lysine 
positions (poly-monoubiquitylation). Furthermore, the conjugated ubiquitin molecule 
itself can serve as a platform for ubiquitylation forming an ubiquitin chain 
(polyubiquitylation). As ubiquitin contains several accessible lysine residues, they can 
be utilized by the conjugation machinery to attach multiple ubiquitin moieties via their 
respective C-terminal carboxyl group (Welchman et al., 2005). Dependent on the 
lysine position on the acceptor ubiquitin several types of linkages were identified and 
classified as K48, K63, K11, K33, K6, K27 and K29 polyubiquitylation chains while 
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mixed-chains were described in vivo as well (Nakasone et al., 2013; Xu and Peng, 
2006; Crosas et al., 2006). Upon ubiquitin attachment to the targeted protein the 
ubiquitylation code is read by ubiquitin binding factors, which harbor ubiquitin binding 
domains (UBD) and recognize the unique chain topology, binding affinity or avidity in 
order to determine the fate of the substrate. In contrast to proteins decorated with 
K48-linked chains that are subjected to rapid protein degradation via the ubiquitin 
proteasome system (UPS), monoubiquitylation or K63-linked ubiquitin chains are 
implicated in regulatory functions during protein sorting, cell cycle control, 
endocytosis, signaling transduction, transcription, replication and DNA repair 
(Komander and Rape, 2012). The UBDs can be grouped according to their structural 
binding properties and come in different flavors, e.g. UBA (ubiquitin associated 
domain), ubiquitin interaction motifs (UIM), or Cue domains (named after Cue2). The 
vast majority of UBDs associate with ubiquitin via the hydrophobic area around I44 
supported by L8 and V70 on sheets β3β4 (Dikic et al., 2009). In addition to canonical 
UBDs, other variously shaped domains have evolved like the Jab/MPN domain found 
in the U5 snRNP protein hPrp8 (Husnjak and Dikic, 2012). Thus, the ubiquitin system 
represents a versatile regulatory machinery that controls protein activity at various 
stages and, with its reversibility due to the action of de-ubiquitylating enzymes (DUB) 
(Clague et al., 2012), it enables cells to adapt to various stimuli, stresses and to 
maintain cellular homeostasis. 
 
2.8 Ubiquitin and ubiquitin-like proteins 
Ubiquitin is a small globular protein of 76 AA that is highly conserved from yeast to 
human. In recent years, additional so called ubiquitin-like proteins (UBL) were 
identified, which share the characteristic β-grasp fold, but show only low amino acid 
identity with ubiquitin (see Introduction Table). Most members of this UBL family 
contain a C-terminal double glycine motif and utilize an analogous conjugation 
machinery to covalently attach to their respective substrates like ubiquitin (Jentsch 
and Pyrowolakis, 2000). Similar to the ubiquitylation system, the small ubiquitin 
related modifier SUMO (Smt3 in S. cerevisiae) is conjugated to targeted lysines via 
an enzymatic cascade consisting of the SUMO E1 SAE1/SAE2 (AOS1/Uba2) and the 
E2 Ubc9 supported by various SUMO E3 ligases like PIAS or RanBP2 (Flotho and 
Melchior, 2013). SUMOylation can be reverted by the action of SUMO-specific 
proteases (SENP1-7 in humans, Ulp1-2 in yeast) that cleave SUMO moieties from 
the substrate (Mukhopadhyay and Dasso, 2007). Posttranslational modification with 
SUMO has been implicated in various cellular pathways including transcription, 
chromatin remodeling, DNA repair, nucleo-cytoplasmic transport, mitosis, and stress 
response (Müller et al., 2001). Similar to the non-covalent interaction between 
ubiquitin and UBDs, conjugated SUMO can mediate physical interactions by binding 
to linear SUMO interaction motifs (SIM) (Hay, 2013). Interestingly, beside the direct 
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competition for critical lysines on a substrate to modulate its activity, like in the case 
of PCNA (K164) (Hoege et al., 2002), ubiquitylation and SUMOylation can also act 
synergistically (Bergink and Jentsch, 2009). SUMO-targeted ubiquitin ligases 
(STUbLs) like the Ubiquitin E3 ligase RNF4 (Slx5/Slx8 in yeast) harbor several SIMs, 
which are essential for the recognition and subsequent ubiquitylation and degradation 
of SUMOylated substrates, e.g. PML or PARP-1 (Tatham et al., 2008). Thus, the 
SUMOylation and ubiquitylation systems do not represent two separate branches, 
but rather a tightly interconnected network for protein regulation with large functional 
overlaps (Denuc and Marfany, 2010).  
 
Ubiquitin-like protein Identity to 
ubiquitin (%) Substrate(s) Attributed functions H. sapiens S. cerevisiae 
UBL5 / mHub1? Hub1? 22? Unknown? Pre-mRNA splicing?
SUMO1? Smt3? 18? Many (e.g. PCNA, STAF65γ, 
TFII-I, PML, XRCC1, hSnu66)?
DNA damage repair, 
transcriptional regulation, 
protein targeting, stress 
response ?
SUMO2/3 #? -? 16? Many (e.g. Aurora-B, PML, 
Topoisomerase II, C/EBPβ1)?
Mitosis, protein targeting, 
transcriptional regulation,  
stress response?
URM1? URM1? 12? Ahp1, tRNA? Oxidative stress response, 
tRNA modification?
NEDD8? Rub1? 58? Cullins, p53, MDM2? Regulation of Cullin-E3s?
ISG15 / UCRP *? -? 29 / 37? JAK1, STAT1, ERK1/2, 
PLCγ1, serpin 2a?
Immune response,  
signal transduction?
FAT10 *? -? 29 / 36? p62/SQSTM1, p53? Immune response, cell 
cycle, protein degradation?
FUB1? -? 37? Bcl-G, TCR-α-like protein? T-cell activation?
LC3? Atg8? 10? Membrane lipids 
(Phosphatidylethanolamine)? Autophagy?
ATG12? Atg12? 17? Atg5? Autophagy?
Introduction Table: Ubiquitin-like proteins 
* ISG15 and FAT10 comprise two interconnected ubiquitin-like domains. # SUMO 2 and SUMO 3 share 
95% identity. (Modified from Welchman et al., (2005)). 
 
Another ubiquitin-like protein, Rub1 (NEDD8 in metazoans, Neural precursor 
cell expressed, developmentally down-regulated 8), shows the highest sequence 
similarity with ubiquitin and neddylation requires the action of specific E1, E2 and E3 
enzymes (Liakopoulos et al., 1998). After C-terminal processing of the NEDD8 
precursor by NEDP1 or UCHL3 its activation is catalyzed by the heterodimeric E1 
enzyme APPBP1 (NAE1) / UBA3. The E2 conjugating enzyme Ubc12 and Ube2F in 
concert with several E3 ligases like Rbx1 / Dcn1, Mdm2 or c-Cbl then transfer 
NEDD8 moieties to lysine residues of specific substrates (Rabut and Peter, 2008). 
The covalent conjugation can be reversed by NEDD8 isopeptidases in a process 
termed deneddylation, which is catalyzed by the CSN5 subunit of the COP9 
signalosome (CSN) (Cope and Deshaies, 2003). In contrast to ubiquitin and SUMO 
the diversity of NEDD8 substrates is rather limited. Rub1 / NEDD8 was shown to 
have regulatory functions by modifying the different cullin subunits of Skp1/Cullin/F-
box (SCF) E3 ligases (Liakopoulos et al., 1998). Repetitive cycles of neddylation and 
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deneddylation are crucial for the stability and activity of cullin-based ubiquitin ligases 
(Bosu and Kipreos, 2008).  
Ubiquitin-like proteins of the ATG family, Atg8 (alias MAP1LC3A-C in 
humans) and Atg12, play pivotal roles in the autophagy pathway. During this 
catabolic process, eukaryotic cells induce the formation of autophagosomal vesicles, 
which engulf proteins, aggregates or damaged organelles, and subject them to 
lysosomal degradation (Eskelinen, 2005). Interestingly, Atg8 and Atg12 share the 
same E1 activating enzyme Atg7, but in subsequent reactions Atg12 is conjugated to 
Atg5 via the E2 Atg10 in order to be incorporated in the multimeric Atg12-Atg5-Atg16 
complex that is crucial for autophagosomal membrane formation (Geng and Klionsky, 
2008). The other autophagy-related UBL, Atg8, undergoes a particularly interesting 
conjugation pathway, as it is covalently attached to the autophagosomal membrane 
lipid phosphatidylethanolamine, catalyzed by the E2 Atg3 and Atg12-Atg5-Atg16 
serving as the Atg8 E3 ligase (Shpilka et al., 2011). Lipidated Atg8 plays a dual role 
in autophagy; firstly, it stimulates autophagosomal membrane formation and 
expansion and secondly, Atg8 attracts and tethers adaptor proteins like 
p62/SQSTM1 or NBR1 with their respective cargo to the inner leaflet of the 
autophagosomal vesicle for subsequent degradation (Waters et al., 2009; Pankiv et 
al., 2007). While there is only a single Atg8 variant in S. cerevisiae, the human 
genome encodes seven Atg8 paralogs including ubiquitin-like proteins of the LC3 
group (microtubule-associated protein 1 light chain 3, MAP1LC3A-C), the GABARAP 
and GABARAPL1 proteins (γ-amino- butyric acid receptor-associated proteins) and 
GATE-16 (Golgi-associated ATPase enhancer of 16 kDa or GABARAPL2). Due to 
structural similarities, members of the human Atg8 family share multiple interaction 
partners with overlapping functions and thus are functionally closely interconnected 
within the autophagy network (Behrends et al., 2010).  
In contrast to the abovementioned UBLs, the molecular conjugation 
machinery and cellular function of other ubiquitin-like proteins remains poorly 
understood. Although the enzymatic cascade for ISG15 (Interferon stimulated gene 
15) with UbeL1 (E1), UbcH8 (E2), and Herc5 or EFP as E3 ligases is identified, the 
exact molecular mechanism of its action is still unclear (Sgorbissa and Brancolini, 
2012). Upon immunostimulatory endotoxins or interferons, ISG15 is highly induced in 
human cells, which triggers antiviral signaling events like JAK-STAT activation and 
ISGylation of viral and host cell proteins (Malakhov et al., 2003; Durfee et al., 2010). 
Among the ISG15 substrates, several enzymes of the ubiquitin conjugation 
machinery like Ubc13, EFP and UbcH6 were identified for which ISGylation is 
thought to negatively regulate their activity in order to modulate ubiquitin-dependent 
pathways during infection (Zhang and Zhang, 2011).  
Like ISG15 another UBL, FAT10, consists of two ubiquitin-like domains with a 
short linker region and is involved in the human immune defense system as well (Dye 
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and Schulman, 2007). Cells treated with interferon γ or tumor necrosis factor α 
activate FAT10 expression and its conjugation machinery with the E1 enzyme Uba6 
and the E2 USE1. During the immune response FAT10 has been implicated in 
transcriptional regulation via p53, NFκB signaling and the degradation of viral 
substrates serving as an alternative molecular tag for proteasomal degradation 
(Aichem et al., 2012). 
Based on in silico analysis, structural and sequencing data elucidated a close 
relationship between the prokaryotic sulfur transfer system and the eukaryotic 
ubiquitin/ubiquitin-like conjugation machinery. In bacteria, MoaD and ThiS proteins 
are crucial factors for the thiamine and molybdopterin synthesis (Chowdhury et al., 
2012) and share the characteristic ubiquitin-like β-grasp fold and C-terminal 
activation step (Pedrioli et al., 2008). Here, the ubiquitin related modifier 1 (Urm1) 
might represent the evolutionary link between the sulfur carrier function and ubiquitin-
like protein modification (Petroski et al., 2011). In eukaryotes Urm1 is adenylated by 
its E1 enzyme Uba4, which subsequently catalyzes the sulfur transfer to Urm1’s C-
terminus via its rhodanese-like domain with Nfs1 serving as a sulfur donor (Petroski 
et al., 2011). After the formation of this thiocarboxylate linkage with Uba4, Urm1 
plays a crucial role in the thiolation of several tRNAs at the wobble position U34 
(Leidel et al., 2009). In addition to its function in tRNA modification, Urm1 can utilize 
an alternative conjugation pathway in order to be conjugated to proteins (Furukawa et 
al., 2000; Wang et al., 2011). Oxidative cellular stress up-regulates the Urm1 
conjugation machinery including peroxiredoxin Ahp1, MOCS3 (Uba4 in yeast), the 
thiouridylases CTU1 and CTU2 (Ncs6 and Ncs2 in S. cerevisiae) and specifically 
induces additional urmylation substrates like the DUBs USP15, USP47, and the 
nucleo-cytoplasmic shuttling factor CAS (van der Veen et al., 2011). As oxidative 
stress affects both thiolation of tRNAs and protein urmylation, further investigation 
will be necessary to elucidate the interplay of Urm1-dependent pathways and the 
cellular function of the Urm1 modification. 
 
2.9 The ubiquitin-like protein Hub1 
Among the ubiquitin-like protein family Hub1 (homologous to ubiquitin 1, alias UBL5 
or Beacon in metazoans) represents a special member, as it shares common 
features of UBLs, but it is not conjugated like canonical modifiers. Covalent 
conjugation of an UBL to a substrate’s target residue is ATP-dependent, involves an 
enzyme cascade, and usually requires a free di-glycine motif at the C-terminus. Hub1 
shares only 22% sequence identity with ubiquitin, but is highly conserved from yeast 
to human (64.4%, 80.8% from C. elegans to H. sapiens) (Friedmann et al., 2001). 
Although structurally very similar to ubiquitin (Ramelot et al., 2003; McNally et al., 
2003), Hub1 does not function as a covalent modifier as it lacks the protruding C-
terminal tail as well as the characteristic double glycine motif (Jentsch and 
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Pyrowolakis, 2000). Comprehensive studies affirmed that Hub1 is not conjugated, but 
binds proteins only non-covalently, and independently of ATP or the double tyrosine 
motif (Luders et al., 2003; Yashiroda and Tanaka, 2004).  
Introduction Figure VII: Human Hub1 among other ubiquitin-like proteins 
Structural ribbon representations of Hub1 (this study, (McNally et al., 2003)), human ubiquitin (1UBQ), 
SUMO1 (2ASQ) and NEDD8 (2KO3) (upper panel, respective PDB codes in brackets). Protein 
sequence alignment of HUB1 with ubiquitin, SUMO1 (AA21-97) and NEDD8 from H. sapiens. The 
scissors symbol indicates the processing site after the di-glycine motif in ubiquitin, NEDD8 and SUMO1. 
Hub1 shares the compact ubiquitin-like fold, but lacks the typical C-terminal extension and the di-glycine 
motif of conventional ubiquitin-like proteins. 
 
Recently, yeast Hub1 was shown to interact with the spliceosomal protein 
Snu66, a protein of the U4/U6.U5 tri-snRNP complex (Mishra et al., 2011; Wilkinson 
et al., 2004). In S. cerevisiae, Hub1 is not essential for viability and is apparently also 
not required for general splicing as judged by splicing-sensitive microarray assays 
(Mishra et al., 2011). Intriguingly, Hub1 affects splicing directly through non-covalent 
interactions and hub1Δ cells fail to promote alternative splicing of SRC1, which is one 
of the rare cases of S. cerevisiae genes for which alternative splicing has been 
reported (Mishra et al., 2011). Abolishing Hub1-Snu66 interaction by mutation affects 
SRC1 alternative splicing as well, suggesting that binding of Hub1 to Snu66 is critical 
for Hub1 function in S. cerevisiae. Since SRC1 is also not essential for viability, it 
seems possible that the function of Hub1 in S. cerevisiae is restricted to SRC1. By 
contrast, in S. pombe, in which splicing is much more prevalent than in S. cerevisiae, 
Hub1 affects splicing of several pre-mRNAs and is essential for viability. 
In spite of these detailed findings, much less is known about Hub1 from higher 
eukaryotes. Human Hub1 appears to be exported from the nucleus upon hypo-osmic 
shock (Hatanaka et al., 2006), and is known to bind certain protein kinases (Kantham 
et al., 2003). Genetic analyses have correlated HUB1 gene expression and single 
nucleotide polymorphisms with predisposition to obesity, diabetes and other factors 
of the metabolic syndrome (Bozaoglu et al., 2006; Jowett et al., 2004). Other studies 
postulate a regulatory role in the hypothalamus and in the secretion of corticosterone 
and cortisol from cultured zona fasciculata/reticularis cells, respectively (Ziolkowska 
et al., 2004; Brailoiu et al., 2003). In proteomic approaches using high-throughput 
mass spectrometry, Hub1 has been detected in purified, in vitro assembled human 
spliceosomes (Deckert et al., 2006) and reported to meet Cajal bodies as well (Švéda 
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et al., 2013), but Hub1’s function remained unexplored. In the nematode C. elegans, 
Hub1 was identified in a genetic screen for genes implicated in the unfolded protein 
response in mitochondria (UPRmt) (Benedetti et al., 2006). Moreover, co-
immunoprecipitation experiments from cell extracts suggested that C. elegans and 
mammalian Hub1 associate with the DVE-1 transcription factor responsible for the 
UPRmt pathway (Haynes et al., 2007). However, neither of these studies have 
addressed the molecular function of Hub1 directly, thus its implication in cellular 
pathways or the relevance of Hub1 for human cells remained obscure.  
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3 Aim of this study 
Ubiquitin and ubiquitin-like proteins play pivotal roles in a multitude of cellular 
pathways, including signal transduction, protein sorting, DNA repair, and cell cycle 
regulation. Canonical members of this protein family are enzymatically conjugated to 
other proteins, thereby functioning as covalent protein modifiers affecting the stability, 
localization or function of their substrates.  
Although the highly conserved protein Hub1 shares the characteristic 
ubiquitin-like fold, it does not function as a covalent modifier but binds proteins only 
non-covalently. Thus far, little is known about the molecular function as well as the 
cellular pathways in which the ubiquitin-like protein Hub1 is implicated particularly in 
mammalian cells.  
The aim of this study was to investigate the function of human Hub1 in 
mammalian tissue culture cells. The unique feature of Hub1 lacking a C-terminal 
extension and thus solely resembling the ubiquitin-like fold raised the question of how 
Hub1 associates with other proteins. Therefore, various protein interaction assays 
were conducted in order to identify potential binding partners and to characterize the 
minimal Hub1 interaction domain. Additionally, Hub1 localization was studied in 
human cell lines by microscopy to shed light onto the cellular pathways and the 
functional context Hub1 is implicated in. Moreover, RNA interference techniques 
were applied to deplete Hub1 from human cells providing further insights into the 
relevance and function of the ubiquitin-like protein in vivo. Phenotypical 
characterization of Hub1-depleted cells by microscopy and flow cytometry was 
combined with a comprehensive biochemical analysis to identify Hub1-dependent 
pathways. Subsequently, the cellular responses to Hub1 inactivation were described 
and the detailed examination of altered biochemical processes elucidated the 
underlying molecular basis. Furthermore, complementation assays, in which mutant 
variants of Hub1 were reintroduced into Hub1-depleted cells, were conducted in 
order to functionally characterize crucial sites on the ubiquitin-like protein.  
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4 Results 
4.1 Identification of human Hub1 interactors by yeast two-hybrid 
screening 
As little was known about Hub1 and its cellular function, an unbiased approach to 
identify novel interaction partners of Hub1 was conducted. The yeast two-hybrid 
(Y2H) technique allows screening of protein-protein interactions based on human 
cDNA libraries from different tissues. A previous report indicated that Hub1, though 
ubiquitously expressed in human tissue, is highly up-regulated in brain, heart, 
skeletal muscle, kidney, and liver (Friedmann et al., 2001). Thus, libraries of fetal 
brain tissue and HeLa cell cDNAs with high transcript coverage were expressed as 
AD-fusions, whereas the Hub1 BD-fusion protein served as bait for screening. After 
optimization of transformation efficiency to ensure maximum cDNA library coverage, 
332 positive candidate clones were obtained from the initial screening step.  
Figure 1: Identification of Hub1 interactors by mammalian yeast two-hybrid screen 
a) Schematic overview of the yeast two-hybrid screen for human Hub1 interactors. BD-Hub1 was used 
as bait for screening mammalian cDNA libraries from human fetal brain and HeLa cells. b) Confirmation 
and identification of high confidence candidates. AD-Plasmids of candidate cDNAs fulfilling stringent 
criteria were isolated, sequenced and co-transformed with BD-Hub1 for re-confirmation. c) Yeast two- 
hybrid interaction studies of identified AD-candidates with different HUB1 orthologs. BD-fusions of Hub1 
from S. cerevisiae (S.c.), S. pombe (S.p.) and H. sapiens (H.s.) were co-transformed with AD-constructs 
identified in the cDNA library screen expressing hSnu66, Clk3, PIM2, USPL1, AP2β, Golgin a 5, or HIV-
EBP, respectively. Serial dilutions of cells were spotted on control or selective plates. 
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High confidence candidates which fulfilled the stringent criteria including 3-AT 
resistance (at 3 mM, 5 mM or 10 mM), β-galactosidase activity or growth on adenine-
lacking (-Ade) plates were revalidated and tested for auto-activation after FOA-
shuffle (Figure 1a). Subsequent DNA sequencing of the AD constructs revealed the 
identity of Hub1’s Y2H interactors, namely spliceosomal tri-snRNP protein hSnu66, 
Cdc2/Cdc28-like dual specificity protein kinase Clk3, proto-oncogenic 
serine/threonine-protein kinase PIM-2, SUMO/ubiquitin-specific peptidase-like 1 
USPL1, endocytosis receptor adapter protein complex AP-2 β subunit 1 α (AP-2β1α), 
actin-binding cytoskeleton protein tropomyosin 2 β (TPM2β) ,  Golgi-associated 
protein Golgin a 5, and human zinc-finger transcription factor HIV-EP1 (Figure 1b).  
 Further interaction studies, in which the newly identified candidates were 
tested with HUB1 orthologs from S. cerevisiae, S. pombe and H. sapiens, showed 
that the spliceosomal protein hSnu66 is the only common binding partner of all Hub1 
variants despite Hub1’s high conservation from yeast to human (Figure 1c). This 
finding indicates an important and conserved link between Snu66 is of Hub1 with a 
strong implication in pre-mRNA splicing.  
 
4.2 Hub1 binds the spliceosomal protein hSnu66 in vivo 
In order to validate the interaction between Hub1 and hSnu66 in vivo, co-
immunoprecipitation experiments with tissue culture cells were conducted. For this, 
mammalian expression constructs encoding tagged Hub1 and hSnu66 proteins were 
transfected into human cells. 
Figure 2: Hub1 and the tri-snRNP protein hSnu66 interact in vivo 
a) hSnu66 co-precipitates with Hub1. HEK 293T cells were co-transfected with GFP-tagged Hub1 or 
free GFP and FLAG-tagged hSnu66 or FLAGluciferase. Cells were harvested, lysed and proteins were 
immunoprecipitated using anti-FLAG M2 IgGs coupled to agarose. Inputs and FLAG-precipitates were 
analyzed by immunoblotting using anti-GFP and anti-FLAG antibodies. b) Hub1 co-precipitates with 
hSnu66. HEK 293T cells were co-transfected with Myc-tagged Snu66 and FLAG-tagged Hub1 or 
FLAGluciferase. Cells were harvested, lysed and proteins were immunoprecipitated using anti-FLAG IgGs 
coupled to agarose. Inputs and FLAG-precipitates were analyzed by immunoblotting using anti-Myc and 
anti-FLAG antibodies. Actin served as a loading control. 
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24-48 h post transfection cells were harvested, lysed and the epitope tagged proteins 
were purified with tag-specific antibodies immobilized on beads. The 
immunoprecipitation of FLAGhSnu66 co-purified GFP-labeled Hub1, whereas the 
control using FLAGluciferase or free GFP remained negative (Figure 2a). Vice versa, 
FLAGHub1 immunoprecipitated Myc-tagged hSnu66 and verified the binding, while 
luciferase served as negative control (Figure 2b). Consistent with the identification of 
Hub1-hSnu66 interaction in unbiased yeast two-hybrid screens these co-purification 
experiments indicate a tight association between the ubiquitin-like protein and the 
spliceosome-associated factor. 
 
4.3 A conserved motif in hSnu66 mediates Hub1 interaction 
After the initial findings of Hub1’s conserved interaction with hSnu66 in vivo, the 
question of how the Hub1-hSnu66 interaction is mediated arose. Bioinformatics 
analyses indicated that hSnu66 is an intrinsically unstructured protein with low 
complexity regions, which has been proposed to be characteristic for a large fraction 
of spliceosome-associated factors, as this allows structural flexibility and different 
conformational stages (Korneta and Bujnicki, 2012). However, a previous report 
described a putative leucine zipper domain, which might mediate direct binding of 
Snu66 to DNA (Makarova et al., 2001). Moreover, protein sequence alignments of 
Snu66 from different species elucidated two highly conserved domains located at the 
amino- and carboxy-terminus, with no obvious homology to known protein domains. 
Compared to yeast, the human homolog hSnu66 gained additional domains (Figure 
3a) like its amino-terminal arginine-serine rich domain (RS-domain, AA41-108) 
(Makarova et al., 2001), which can serve as a protein-protein interaction motif (Kohtz 
et al., 1994; Wu and Maniatis, 1993) or mediate binding to mRNA directly e.g. at 
regulatory exonic enhancer sequences (Shen and Green, 2006; Shen et al., 2004; 
Rudner et al., 1998). Besides the leucine zipper and nuclear localization signals, 
hSnu66 encodes another DNA directed domain, namely a putative transcription 
factor engrailed homology domain 1 (EH1). Interestingly, although Snu66 in yeast 
lacks the RS-domain, a short stretch of 18 AA within the N-terminal domain is highly 
conserved among species. 
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Figure 3: Mapping of the Hub1 interaction domain in hSnu66 
a) The Hub1 Interaction Domain (HIND) is conserved from yeast to human. Schematic representation of 
ScSnu66 and hSnu66 and their putative domains. HIND: Hub1-interaction domain, LZ: leucine zipper, 
CTD: Carboxy-terminal domain, RS: arginine-serine rich domain, EH1: engrailed homology domain 1, 
NLS: nuclear localization signal, YxxF: AP-dependent endocytosis motif. Below: Alignment of putative 
HIND sequences in Snu66 orthologs as indicated aside. Amino acids which are identical with human 
HIND are shaded in black to highlight conservation. b) Binding of Hub1 is mediated via a N-terminal 
domain in hSnu66. Mapping of the Hub1 interaction domain in hSnu66 using FLAG-immunoprecipitation 
of 3xFLAGHsHub1 after co-expression of GFP-tagged hSnu66 truncations (as indicated) or GFP as control 
in HEK 293T cells. Immunoprecipitates were immunoblotted with anti-FLAG and anti-GFP antibody. c) A 
short conserved N-terminal motif in hSnu66 (HIND) is sufficient for direct interaction with Hub1. GST 
pull-down assay with recombinant GST-HIND fusion protein and 6xHis-tagged Hub1. Free GST served 
as a control. Two different buffer conditions (Prep A: Tris-based B: HEPES based) were used. 
Comassie blue staining is shown. 
 
In order to identify the domain or motif mediating Hub1-hSnu66 direct 
interaction, several truncations of hSnu66 were generated comprising the N-terminus 
(AA1-185) with its arginine-serine rich domain (RS-domain) and the highly conserved 
stretch of 18 AA (AA111-139), the central region (AA 186-430, encoding for a 
putative leucine zipper (LZ) and nuclear localization sequences (NLS)) or C-terminal 
fragments, which overlap with the LZ and NLS (AA 325-800) or cover domains from 
AA439 to the end of the protein (AA439-800). These GFP-tagged truncations were 
co-expressed with 3xFLAGHub1 to map down the binding motif by FLAG-
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immunoprecipitation. The hSnu66 N-terminal fragment (AA1-185) was able to bind 
and co-purify with Hub1, but, notably, the short highly conserved stretch within 
hSnu66’s N-terminus (AA111-139) was already sufficient for the interaction with 
Hub1 (Figure 3b). Like the negative control, free GFP, neither the central region of 
hSnu66 nor C-terminal fragments were able to co-purify with Hub1.  
Importantly, the interaction between Hub1 and the short highly conserved 
stretch, which was termed HIND (for Hub1 interaction domain), was verified with 
purified recombinant proteins to exclude any bridging factor, thereby proving direct 
binding. After 6xHis-tagged Hub1, GST-HIND and free GST were isolated from E. 
coli by affinity-chromatography, Hub1 was incubated with either GST-HIND or GST 
as control and pull-down assays were conducted. Indeed, the isolated HIND was 
proficient in direct Hub1 binding and clearly precipitated Hub1 in GST-pull-down 
studies (Figure 3c). 
 This data indicated an intriguing mode of non-covalent interaction between a 
ubiquitin-like protein (Hub1) and a spliceosomal core component (Snu66). In order to 
obtain molecular insights, the crystal structure of human Hub1 in complex with 
hSnu66’s HIND was solved. For this, HIND peptides, comprising AA 117-135 of 
hSnu66, were chemically synthesized (by MPIBC core facility) and incubated with 
recombinant 6xHis-tagged Hub1 for crystallization. In close collaboration with the 
NMR department at the MPIBC the crystallization and structure determination was 
conducted by K. Kowalska. 
 
Figure 4: The crystal structure of the Hub1-HIND complex  
a) Crystal structure of the human Hub1 in complex with the hSnu66 HIND peptide at 2 Å resolution 
shown as a ribbon plot. The human HIND - Hub1 interaction is mediated by a salt bridge between R11 
of HIND (R127 in hSnu66) and D22 of HsHub1 accompanied by several hydrophobic contacts formed 
by aliphatic residues of HIND and Hub1. b) Overlay of crystal structures comparing human Hub1-HIND 
(blue, purple) interaction superimposed with yeast ScHub1-ScHIND II (yellow, cyan) complex shows 
high conservation on molecular level. NMR data was obtained in collaboration with K. Kowalska. 
  
Results 
 32 
 As described previously (McNally et al., 2003), Hub1 shares the β-grasp fold 
of ubiquitin and ubiquitin-like proteins with their typical ββαβαβ secondary structure 
pattern (Figure 4a). This new structure with a resolution of 2 Å clearly explains the 
nature of the human HIND - Hub1 interaction that is mediated via a salt bridge 
between R11 of HIND (R127 in hSnu66) and D22 of Hub1 accompanied by several 
hydrophobic contacts formed by aliphatic residues of the HIND (L2, I4, T7, L10, R11 
(Cβ and Cγ), L14, L16, L19) and Hub1 (M1, V16, K17 (Cβ, Cγ, Cδ), C18, N19 (Cβ, 
Cγ), K29 (Cβ, Cγ, Cδ), V30, L33). Upon HIND binding the main-chain fold of Hub1 
does not change significantly, but several side chains change their orientation 
representing an induced-fit conformation. 
The direct comparison of human and yeast Hub1-HIND complexes (HsHub1-
HsHIND (blue, purple), ScHub1-ScHIND II (yellow, cyan, PDB: 3PLV (Mishra et al., 
2011)) emphasizes the similarity of the two structures with a root mean squared 
deviation of 0.716 Å for the main chain heavy atoms (Figure 4b). The interaction 
interface, formed by the salt bridge (R127-D22) among hydrophobic contacts 
between hSnu66 and Hub1, is almost identical and illustrates the high conservation 
of this interaction module at molecular level. Despite the high conservation and 
structural similarities between yeast and human Hub1, a unique patch appears to be 
particularly interesting. The loop formed by α2-β3 in human Hub1 contains two 
hydrophobic residues, W47 and Y48, which are strikingly exposed to the solvent. 
Moreover, although this unusual aromatic patch is highly conserved in all metazoan 
orthologs, it is not present in S. cerevisiae Hub1.  
 
4.4 Mutations in the HIND abolish Hub1-hSnu66 interaction 
The structural data gives detailed information about crucial amino acid residues that 
are important for the interaction surface between Hub1 and hSnu66. Beside the 
contributing hydrophobic contacts formed by aliphatic residues, the central interaction 
bond is created via the salt bridge between R127 of HIND in hSnu66 and D22 of 
Hub1. In order to validate this finding, co-immunoprecipitation experiments were 
performed, in which mutant alleles of hSnu66 and Hub1 leading to interaction-
deficient variants were ectopically expressed. For this, human tissue culture cells 
were transfected with either FLAGhSnu66 WT or R127A mutant form together with 
GFP-labeled Hub1 WT or D22A point mutant (Figure 5a). When both wild type 
proteins were expressed and FLAG-immunoprecipitation was performed, binding of 
Hub1 to hSnu66 was evident. However, mutant alleles with point mutations at 
interaction surface residues abrogated binding of Hub1 WT in FLAGhSnu66 R127A 
immunoprecipitations. Vice versa, the interaction with hSnu66 WT was also disrupted 
when the crucial residue in Hub1 was mutated (D22A).  
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Figure 5: Single point mutations in the HIND interface disrupt Hub1 - hSnu66 interaction 
a) Single point mutations in Hub1 (D22A) or hSnu66 (R127A) abolish interaction in vivo. GFP-tagged 
WT or D22A mutant Hub1 was co-transfected with FLAG-tagged hSnu66 WT or R127A mutant into HEK 
293T cells. Cells were harvested, lysed and proteins were immunoprecipitated using anti-FLAG M2 
IgGs. Inputs and FLAG-precipitates were analyzed by immunoblotting using anti-GFP and anti-FLAG 
antibodies. b) Hub1 interacts with endogenous hSnu66 in vivo depending on the D22 surface. U2OS WT 
or cells stably expressing N-terminally GFP-tagged Hub1 WT, Hub1 D22A, C-terminally GFP-tagged 
Hub1 or a GFP-control were harvested, lysed and proteins were immunoprecipitated using anti-GFP 
antibodies. Inputs and GFP-precipitates were analyzed by immunoblotting using anti-GFP and anti-
hSnu66 antibodies. Untreated U2OS and anti-U2AF65 served as controls. c) Point mutations in the 
HIND disrupt yeast two-hybrid interaction. Cells expressing human Hub1 (N-terminal BD-fusion) with 
either hSnu66 WT or mutant hSnu66 R127A or ΔHIND as an AD-fusion. Whereas all strains grew on 
control plates, growth was restricted to cells co-expressing BD-Hub1 and AD-hSnu66 WT confirming the 
HIND-dependent interaction between Hub1 and hSnu66. d) Yeast two-hybrid interaction studies with 
Hub1 mutants and candidates from the mammalian cDNA library screen. BD-Hub1 WT, D22A or R9A 
were co-transformed with AD-constructs expressing hSnu66, Clk3, USPL1 or AP2β, respectively. Cells 
were spotted on control plates or selective plates. 
 
Considering the fact that conventional transient transfection techniques lead 
to high protein expression due to strong promoters and high copy numbers, it was 
important to characterize the interaction in vivo under more physiological conditions. 
In order to address this point, several U2OS cell lines stably expressing GFP-Hub1 
WT, the binding-deficient mutant GFP-Hub1 D22A, C-terminally tagged Hub1-GFP 
and GFP-control, respectively, were generated. After testing the moderate 
expression of the GFP-fusion proteins, these cell lines were used for further 
interaction studies. Indeed, wild type Hub1 clearly co-purified with endogenous 
hSnu66 in GFP-immunoprecipitation assays, whereas the D22A mutation in Hub1 
abolished the interaction. Notably, either of the amino- or carboxy-terminally GFP-
tagged versions of Hub1 were able to precipitate hSnu66 under physiological 
conditions, indicating that both versions are properly folded proteins and their GFP-
tag does not abrogate hSnu66 binding via the Hub1-HIND interaction surface.  
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As the initial findings had been obtained from the mammalian Y2H screen, another 
line of evidence came from yeast two-hybrid interactions studies. For this experiment, 
BD-Hub1 was co-transformed with AD-constructs encoding for hSnu66 WT, hSnu66 
R127A mutant or a variant in which the whole HIND is deleted (hSnu66ΔHIND), 
respectively. Yeast spottings on selective plates confirmed previous results, as only 
wild type Hub1 and hSnu66 showed an interaction, whereas both mutations in 
hSnu66 (R127A and ΔHIND) were negative (Figure 5c). Interestingly, interfering with 
the HIND interaction surface on Hub1 by mutating D22 to alanine disrupted hSnu66 
binding specifically. Other candidates identified in the two-hybrid screen like Clk3, 
USPL1 or AP2β, did not show any alterations in Hub1 binding when Hub1 WT and 
Hub1 D22A were compared. Furthermore, all two-hybrid interactions were 
reconfirmed in a snu66Δ yeast strain to rule out any bridging effects of endogenous 
Snu66 (data not shown). In contrast, introducing an alanine substitution of R9 into 
Hub1 (Hub1 R9A) did not negatively affect hSnu66 binding, but the interaction with 
Clk3 and AP2β was absent (Figure 5d). These data suggest that, besides the HIND-
associated surfaces other motifs on Hub1 serve as additional interaction domains to 
mediate binding to alternative protein complexes. 
 
4.5 Hub1 localizes to splicing-associated nuclear domains 
The physical interaction of Hub1 with spliceosomal components like hSnu66 and SR 
protein kinase Clk3 (present study and Kantham et al., 2003) links Hub1 to the pre-
mRNA splicing machinery, which is mainly located in the nucleus. Exploiting the 
stable U2OS cell lines, which stably express GFP-Hub1, the localization of Hub1 in 
human cells was determined. When standard immunofluorescence protocols were 
applied, GFP-tagged Hub1 showed a plain cellular distribution in the cytoplasm as 
well as in the nucleus without a distinct localization, which resembles the pattern of 
free GFP (Figure 7b). Nevertheless, introducing a pre-extraction step before fixation, 
the newly established immunofluorescence staining revealed a distinct, speckle-like 
localization of Hub1 within the nucleus. Immunofluorescence co-stainings elucidated 
that Hub1 is found in so-called nuclear speckles (also named SC35-domains or 
interchromatin granule clusters). Here, it co-localizes with nuclear speckle marker SR 
protein SC35 (Spector, 2003; Spector and Lamond, 2011), small nuclear 
ribonucleoparticle (snRNP) component U1A (Saitoh et al., 2004) or Sm proteins of 
snRNPs, which are recognized by Smith-antigen antibody Y12 (Boerbooms et al., 
1985) (Figure 6a), but not with other nuclear domains like PML bodies or the 
nucleolus using PML, fibrillarin or UBF (data not shown). Nuclear speckles are highly 
dynamic structures from where splicing factors shuttle to active site of transcription 
(and concomitantly pre-mRNA splicing) (Spector et al., 1991; Ferreira et al., 1994; 
Wei et al., 1999). This nuclear compartment is thought to be important for splicing 
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factor maturation and modification as well as formation and storage of sub-
complexes.  
Figure 6: Co-localization of Hub1 and hSnu66 with nuclear speckle proteins 
a) Hub1 localization in U2OS cells stably expressing GFP-Hub1 (green). Cells were pre-extracted, fixed 
and stained for splicing proteins (red) using antibodies against nuclear speckle marker phospho-SC35, 
snRNP protein U1A and SR proteins using Y12, respectively. Scale bar represents 10 μM. b) Co-
localization studies with U2OS cells stably expressing hSnu66-GFP (green). Cells were pre-extracted, 
fixed and stained for splicing proteins (red) using anti-phospho-SC35, anti-U1A and anti-PRPF4 
antibodies, respectively. Images show z-stack projections of seven optical sections and are merged with 
DAPI as nuclear counterstain. Scale bar represents 10 μM. 
 
In addition, another U2OS cell line stably expressing C-terminally GFP-
tagged hSnu66 was generated and used for localization studies. In these cells 
hSnu66 is efficiently imported into the nucleus where it is recruited to the same 
nuclear speckle compartment as observed in previous experiments with Hub1. 
Immunofluorescence studies with antibodies recognizing SR protein SC35, U1 
snRNP factor U1A or tri-snRNP protein PRPF4 revealed co-localization with hSnu66-
GFP (Figure 6b). In addition, hSnu66 is also found in the nucleolus, which was 
confirmed by co-stainings with nucleolar protein fibrillarin and upstream-binding 
factor 1 (UBF1) (data not shown). Hence, the co-localization data further support a 
close link of Hub1 and hSnu66 to pre-mRNA processing and splicing.  
To further address Hub1 function and the interplay between Hub1 and 
hSnu66 in living cells, stable U2OS cell lines expressing the hSnu66-binding mutant 
GFP-Hub1 D22A or C-terminally GFP-tagged Hub1 (Hub1-GFP) were examined 
(Figure 7a). As shown before, GFP-Hub1 WT localization resembles the nuclear 
speckle pattern and co-localizes with the marker protein SC35. Interestingly, when 
the hSnu66-binding mutant was tested in immunofluorescence co-stainings, it 
became evident that GFP-Hub1 D22A still localizes to splicing speckles and overlaps 
with SC35-positive domains and thereby does not show significant differences to 
Hub1 WT. On the contrary, C-terminally GFP tagged Hub1 WT (Hub1-GFP), which 
was fully functional in hSnu66 binding (see Figure 5b), was not retained in nuclear 
substructures (Figure 7a). Thus, without proper incorporation into structural protein 
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complexes Hub1-GFP (like GFP serving as control) was washed out from the 
nucleus and staining was negative, while SC35 immunostaining was not altered and 
identical to previous samples. 
 
 
Figure 7: Hub1 recruitment to nuclear speckles depends on C-terminal surface 
a) Co-localization studies in U2OS cells stably expressing GFP-Hub1, GFP-Hub1 D22A, Hub1-GFP or 
free GFP (all green). Cells were pre-extracted, fixed and stained for nuclear speckle marker phospho-
SC35 (red). Note that Hub1-GFP and free GFP are washed out, whereas GFP-Hub1 and GFP-D22A are 
retained in nuclear speckles. DAPI (blue) was used as nuclear counterstain. Scale bar represents 10 
μM. b) Co-localization studies with stable cell lines similar to a). Cells were permeabilized after fixation 
(no pre-extraction) and stained for Sm-proteins using Y12 antibody (red). DAPI (blue) was used as 
nuclear counterstain. Scale bar represents 10 μM. c) Protein expression levels of GFP-fusion proteins 
(GFP-Hub1, GFP-Hub1 D22A, Hub1-GFP or free GFP) stably expressed in U2OS cells (as shown in a 
and b) were analyzed by immunoblotting using anti-GFP antibodies. Actin served as loading control. 
 
Moreover, besides the nuclear fraction a significant pool of Hub1 is found in 
the cytoplasm as well, as shown by immunofluorescence staining following the 
conventional fixation method with membrane permeabilisation after fixation and no 
pre-extraction. Despite the differences in nuclear localization after pre-extraction, 
here the different Hub1 fusion proteins show a similar diffuse distribution throughout 
the cell with no particular localization (Figure 7b). The protein levels of all fusion 
proteins were measured to ensure similar expression (Figure 7c).   
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4.6 hSnu66 actively recruits Hub1 to splicing speckles  
After the detailed molecular characterization of the Hub1-hSnu66 interaction and the 
observation that both Hub1 and hSnu66 are found in nuclear splicing speckles, co-
localization studies were conducted to determine the interdependency of the 
ubiquitin-like protein Hub1 and the splicing factor hSnu66 in vivo. Thus, after 
transient co-expression of tagged Hub1 WT or the binding mutant Hub1 D22A 
together with either hSnu66 WT or hSnu66ΔHIND fused to GFP cells were analyzed 
by immunofluorescence. Interestingly, although a minor fraction of Hub1 WT was 
detected in the cytoplasm, the majority was recruited to nuclear splicing speckles 
where it co-localized with hSnu66 WT (Figure 8a, upper panel).  
Figure 8: hSnu66 actively recruits Hub1 to nuclear speckles in a HIND-dependent manner 
a) hSnu66 attracts Hub1 to co-localize in nuclear splicing speckles and recruitment is HIND-dependent. 
Immunofluorescence of U2OS transiently co-expressing 3xFLAGHub1 WT or D22A mutant (red) with GFP-
tagged hSnu66 WT or hSnu66ΔHIND (green). Cells were fixed, permeabilized and stained with FLAG 
M2 antibody and DAPI as nuclear counterstain. Scale bar represents 10 μM. b) hSnu66-GFP interacts 
with 3xFlagHub1 in vivo shown by immunofluorescence and precipitations. Constructs used for 
immunofluorescence (as in a) are also functional in binding assays. HEK 293T cells were co-transfected 
with constructs expressing either GFP-tagged hSnu66 WT or hSnu66 R127A in combination with 
3xFLAGHub1 WT or D22A mutant. Cells were harvested, lysed and proteins were immunoprecipitated 
using anti-FLAG M2 antibodies. Inputs and precipitates were analyzed by immunoblotting using 
antibodies against GFP and FLAG.  
 
In contrast, in cells expressing the binding-deficient mutant alleles Hub1 
D22A or hSnu66ΔHIND, where Hub1-hSnu66 interaction is disrupted, the 
accumulation of Hub1 in nuclear speckles was largely diminished, whereas hSnu66 
localization in splicing speckles was unaltered (Figure 8a, lower two panels). 
Immunofluorescence co-stainings of Hub1 D22A with hSnu66 WT showed that while 
hSnu66 was found in nuclear speckles, Hub1 D22A was widely and equally 
distributed throughout the cytoplasm and nucleus with no distinct accumulation in 
nuclear subcompartments like splicing speckles. In line with these data, co-
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expression of Hub1-binding deficient hSnu66ΔHIND with Hub1 WT showed similar 
results. hSnu66ΔHIND efficiently localized to nuclear speckles, while Hub1 WT was 
not specifically enriched in SC35 domains, when compared to cells which co-
expressed WT hSnu66. These data indicate that hSnu66 is targeted to the nuclear 
speckles in a Hub1-independent manner. Furthermore, hSnu66 itself can actively 
recruit Hub1 to nuclear speckles via its Hub1-interaction domain, as this 
accumulation of Hub1 in nuclear speckles depends on the HIND interface. 
The finding that Hub1-binding is not crucial for hSnu66’s nuclear localization 
raised the question, if Hub1 might modulate the protein interaction network of 
hSnu66. To address this point, co-immunoprecipitation studies with GFP-tagged 
hSnu66 WT or the Hub1 binding-deficient mutant version (hSnu66ΔHIND) were 
conducted and compared by immunoblotting and mass spectrometry (Figure 9).  
Figure 9: hSnu66 is incorporated into the tri-snRNP complex in a Hub1-independent manner 
a) Interaction with tri-snRNP or nucleolar proteins is not altered in the Hub1 binding-deficient mutant 
hSnu66ΔHIND. HEK 293T cells were co-transfected with constructs expressing either GFP-tagged 
hSnu66 WT or hSnu66ΔHIND in combination with 3xFLAGHub1 WT or D22A mutant. Cells were 
harvested, lysed and proteins were immunoprecipitated using anti-GFP antibodies. Inputs and GFP-
precipitates were analyzed by SDS-PAGE and subsequent immunoblotting using antibodies against 
GFP, FLAG, PRPF6 and fibrillarin. b) FLAG-tagged variants of hSnu66 (WT, R127A, ΔRS (deletion of 
AA1-78) or ΔHIND) or FLAGluciferase as control were expressed in HeLa cells. After harvesting cells 
were lysed and FLAG M2 immunoprecipitation was performed. Inputs and immunoprecipitates were 
analyzed by immunoblotting using antibodies against spliceosomal tri-snRNP proteins PRPF8, PRPF6 
and PRPF3. Actin served as loading control. Asterisk indicates antibody heavy chain. c) Qualitative 
analysis of hSnu66 or hSnu66ΔHIND immunoprecipitates via mass spectrometry. GFP-tagged hSnu66, 
hSnu66ΔHIND or free GFP were immunoprecipitated from transfected HeLa lysates using GFP-trap 
affinity matrix. GFP-precipitates were analyzed by mass-spectrometry and hSnu66 WT interacting 
proteins were compared to hSnu66ΔHIND after normalization and filtering of unspecific binding factors 
(free GFP sample) were subtracted. Identified RNA processing associated proteins co-purifying with 
hSnu66 and hSnu66ΔHIND and their signal intensities are plotted.  
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It became evident that the interaction with Hub1 is neither essential for 
hSnu66 binding to tri-snRNP components, nor for the association with nucleolar 
factors (Figure 9a), as both hSnu66 WT and hSnu66ΔHIND were able to efficiently 
co-purify factors like PRPF6 and fibrillarin. 
Additional experiments confirmed that incorporation of hSnu66 into the tri-
snRNP complex is independent of Hub1-binding. The association of hSnu66 with 
core spliceosomal proteins of the tri-snRNP complex was tested by co-purification of 
different hSnu66 variants (WT, R127A, ΔRS (N-terminal ΔAA1-78) or ΔHIND) with U4 
snRNP protein PRPF3 and the U5 snRNP proteins PRPF6, and PRPF8, respectively 
(Figure 9b). Other than the slight decrease of PRPF8 in hSnu66ΔRS samples, no 
significant alteration in tri-snRNP binding could be identified. Furthermore, in an 
unbiased proteomic approach hSnu66 or hSnu66ΔHIND immunoprecipitates were 
analyzed qualitatively via mass spectrometry. Indeed, this data set affirmed only 
marginal alterations between WT or Hub1-binding deficient hSnu66, when co-
purifying factors were compared (Figure 9c). These findings suggest other domains 
within hSnu66 being important for proper incorporation into the tri-snRNP, while Hub1 
binding might mediate another, yet unknown, regulatory mechanism. 
 
4.7 Characterization of hSnu66’s functional domains 
In order to gain further insights into the function of the Hub1 interaction partner 
hSnu66, which is a spliceosomal protein with many low complexity regions and 
poorly characterized domain structure, several truncated hSnu66 GFP-fusion 
proteins were generated bearing the different putative motifs (Figure 10c). In line with 
the abovementioned data, microscopic analysis highlighted the dual localization of 
hSnu66 WT or hSnu66ΔHIND in nucleoli and nuclear speckles, which was confirmed 
by co-staining with SC35 in HeLa cells (Figure 10a). Even the direct linear fusion of 
Hub1 to the hSnu66’ N-terminus (Hub1~hSnu66) did not alter the localization and 
resembled hSnu66 WT nuclear staining. Interestingly, the N-terminus of hSnu66 
alone (AA1-139), comprising the RS-domain and the Hub1-binding domain HIND, is 
sufficient to be efficiently recruited to nuclear speckles and nucleoli (Figure 10a). 
Besides the nuclear import signals encoded by the N-terminus, an additional 
domain in hSnu66’s central part is responsible for incorporation into nuclear 
speckles. N-terminal truncations lacking the first 325 amino acids (AA325-800) led to 
a slightly less efficient nuclear import, but still allowed recruitment to splicing 
speckles (Figure 10b). Further deletions within the central domain (AA375-800) 
destroying the leucine zipper (AA365-386) interfered with proper localization to 
splicing foci and resulted in a pan-nuclear and cytoplasmic staining (Figure 10b). 
Constructs expressing C-terminal hSnu66 fragments did not show an association 
with any particular nuclear nor cytoplasmic subcompartment and exhibit a diffuse 
cellular distribution similar to free GFP (Figure 10b: AA439-800, AA678-800, GFP). In 
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addition to immunofluorescence localization studies, the GFP-tagged hSnu66 
truncations were utilized in co-immunoprecipitation assays to identify novel 
interaction domains within hSnu66. Indeed, a central domain in hSnu66 (AA325-439) 
comprising the LZ and NLS is crucial to associate and to co-purify with tri-snRNP 
proteins like PRPF6 (Figure 10d).  
 
Figure 10: Mapping and characterization of hSnu66 domains  
a-b) The N-terminus and the central leucine zipper in hSnu66 mediate recruitment to nuclear speckles. 
HeLa cells were transfected with constructs expressing hSnu66 truncations tagged with GFP (green). 
Cells were fixed, permeabilized and stained for nuclear speckle marker phospho-SC35 (red) and DAPI 
(blue). Scale bar represents 10 μM. c) Schematic representation of GFP-tagged hSnu66 truncations and 
their putative domain structure used previous experiments. d) The central domain in hSnu66 (AA325-
439) is crucial for binding to tri-snRNP protein PRPF6. HEK 293T cells were transfected with different 
hSnu66 truncations tagged with GFP as indicated (see c). Cells were harvested, lysed and proteins 
were immunoprecipitated using the GFPtrap matrix. Inputs and GFP-precipitates were analyzed by 
immunoblotting using antibodies against GFP and PRPF6. 
 
Notably, although hSnu66’s N-terminus (AA1-185) containing the RS- and HIND 
motifs is sufficient for recruitment to nuclear speckles, it does not co-precipitate with 
PRPF6. This data supports the model of hSnu66 acting as a platform with at least 
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two independent interaction modules; while its N-terminus binds Hub1 and contains 
the RS-domain, the central module mediates association with spliceosomal 
complexes like the tri-snRNP protein PRPF6.  
As the abovementioned N-terminal fragments contain functional HINDs and 
are thereby potential Hub1 binders, a more detailed characterization was performed 
to determine whether Hub1-binding alters their nuclear import or localization (Figure 
11a). 
 
Figure 11: Hub1 binding retains N-terminus of hSnu66 in nuclear compartment 
a) The N-terminal RS-domain of hSnu66 is sufficient to localize to nuclear speckles. HeLa cells were 
transfected with constructs expressing hSnu66 RS-domain (AA1-78), N-terminus containing the HIND 
(AA1-139) or the isolated HIND (AA111-139) as GFP-fusion proteins (green). Cells were fixed, 
permeabilized and nuclei were stained with DAPI (blue). Scale bar represents 10 μM. b) Hub1 binding 
facilitates nuclear retention of hSnu66 N-terminus. DsRed-Hub1 (red) expressing HeLa cells were co-
transfected with constructs encoding GFP-tagged hSnu66 N-termini (AA1-139) (green) with either WT 
HIND or bearing the Hub1-binding mutation R127A (R127A=RA). Cyto-nuclear shuttling of hSnu66 
fragments was enforced by linear fusion with a nuclear export signal (NES) of export receptor CRM1 to 
GFP tagged hSnu66 constructs. Cells were fixed, permeabilized and nuclei were stained with DAPI 
(blue). Scale bar represents 10 μM. c) The HIND-containing N-terminus of Snu66 binds endogenous 
Hub1. GFP-tagged hSnu66 truncations (AA1-139 or AA1-185) were expressed as WT or Hub1 binding- 
deficient mutant version (RA) in HeLa cells. After transfection, cells were harvested, lysed and GFP-
fusion proteins were immunoprecipitated using the GFPtrap matrix. Inputs and GFP-precipitates were 
analyzed by immunoblotting using antibodies against GFP and Hub1. Tubulin served as a loading 
control.  
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Further segmentation of hSnu66’s N-terminus into RS-domain and HIND 
revealed that the RS-domain alone (AA1-78) is a potent nuclear import domain, 
which is efficiently recruited to nuclear speckles and nucleoli, similar to the extended 
fragment (AA1-139) comprising RS-domain and HIND. The HIND alone does not 
facilitate nuclear import by itself, as shown by the diffuse localization throughout the 
cyto- and nucleoplasm of the cell similar to free GFP. 
Although Hub1 binding is not crucial for hSnu66 interaction with the tri-
snRNP, full-length hSnu66 actively recruits Hub1 to nuclear speckles (Figure 8a and 
10d). Furthermore, the HIND containing N-terminus is efficiently imported and 
associated with SC35 domains, but it remained unclear if Hub1 travels along. To 
address this point, hSnu66-GFP truncations were co-expressed with DsRed-tagged 
Hub1 and analyzed by microscopy (Figure 11b).  
In line with the abovementioned data, full-length hSnu66 recruited and 
accumulated DsRed-Hub1 in nuclear speckles leading to almost cytoplasmic 
depletion of free Hub1 in HeLa cells. Co-expression of the hSnu66 N-terminal 
fragment clearly showed a similar effect by binding and importing Hub1 into the 
nucleus and speckles. When the Hub1-interaction domain was mutated (changing 
salt bridge residue R127 to alanine (RA)) abolishing Hub1 binding, the N-terminal 
fragment still localized to nuclear speckles and nucleoli, but DsRed-Hub1 was not 
recruited nor enriched in speckles (Figure 11b, upper and middle panel). In order to 
counterbalance the strong nuclear import of hSnu66 N-terminal fragment by the RS-
domain the nuclear export sequence (NES) of the export receptor CRM1 (Engelsma 
et al., 2004) was linearly fused to hSnu66 truncations as GFP tagged protein. When 
the WT N-terminal fragment of hSnu66 with NES (N-term WT NES) was co-
expressed with Hub1, it still localized to SC35 domains where it co-localizes with 
Hub1. As expected, due to the NES the cytoplasmic fraction also increased, but the 
major fraction resided in the nucleus. In contrast, when the Hub1-binding deficient N-
terminus with NES (N-term RA NES) was examined, the equilibrium of nucleo-
cytoplasm shuttling was shifted toward the cytoplasm and nuclear depletion of the 
fusion protein. Instead of splicing speckles the cytoplasm and nuclear rim were now 
stained, whereas the nucleoplasm was depleted of the hSnu66 N-terminal RA NES 
fragment. This had no effect on DsRed-Hub1 localization as it still remained nuclear 
and cytoplasmic.  
Taken together, these data indicate that Hub1 supports the incorporation and 
retention of hSnu66 in nuclear speckles additionally to its RS-domain. While the RS-
motif helps targeting hSnu66 to SC35 domains, the HIND creates an additional 
interaction surface with Hub1 that might contribute to a proper complex formation 
with other splicing-associated factors. 
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4.8 Distinct and conserved protein properties of Hub1 
Recent work on Hub1 has focused on lower eukaryotes using model organisms like 
S. cerevisiae and S. pombe since its identification in the year 2000 (Jentsch and 
Pyrowolakis, 2000). Whereas knockout of HUB1 in S. cerevisiae (hub1Δ) shows only 
minor phenotypes and cells are viable, its gene deletion in S. pombe is lethal (Luders 
et al., 2003; Yashiroda and Tanaka, 2004). Interestingly, rescue assays in which 
hub1Δ S. pombe strains were supplemented with constructs expressing HUB1 
orthologs from S. cerevisiae (S.c.), S. pombe (S.p.) and H. sapiens (H.s.), revealed 
significant differences between yeasts and human Hub1 in survival assays (Figure 
12a). After FOA shuffling out the URA4-bearing plasmid, encoding the “back-up” 
copy of SpHUB1, the HUB1 orthologs were the only remaining source of Hub1 in 
hub1Δ S. pombe cells.  
 
 
Figure 12: Functional complementarity of yeast and human HUB1 orthologs  
a) Rescue of hub1Δ in S. pombe by complementation with HUB1 orthologs from S. cerevisiae, S. pombe 
and H. sapiens. Serial dilutions of hub1Δ cells expressing HUB1 orthologs grown on control or FOA 
plates (hub1Δ with one copy of spHUB1 encoded on an URA4-bearing plasmid for shuffle out). Protein 
expression of HUB1 orthologs is shown in the right panel using anti-Hub1 antibodies. b) Rescue of 
synthetic sickness of hub1Δprp8* in S. cerevisiae by expressing HUB1 orthologs in cell growth assays 
at indicated temperatures. Protein expression of Hub1 orthologs is shown in the right panel using anti-
Hub1 antibodies. c) Complementation of altered alternative splicing of SRC1 in hub1Δprp8* cells by 
HUB1 orthologs (according to b). Protein expression of TAP-tagged Src1-L and Src1-S isoforms as well 
as Hub1 versions were monitored by western blotting using anti-TAP and anti-Hub1 antibodies. 
Complementation experiments with S. pombe and S. cerevisiae hub1Δ cells were performed in 
collaboration with S.K. Mishra. 
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 As shown previously (Yashiroda and Tanaka, 2004), the shuffle out resulted 
in Hub1 depletion and caused the lethal phenotype, when cells were supplemented 
with the empty vector control and no ectopically expressed Hub1 was present. 
Complementation with either S. pombe or H. sapiens HUB1 fully rescued lethality 
and restored cell growth in spotting assays. In contrast, constructs expressing S. 
cerevisiae HUB1 were not able to fully complement S. pombe hub1Δ, leading to 
growth defects at indicated temperatures. This effect was not attributable to reduced 
protein levels, as expression of the different HUB1 orthologs was monitored by 
immunoblotting (Figure 12a, right panel). 
Recent data described a strong genetic interaction between hub1Δ  and a 
mutant allele of the tri-snRNP protein PRP8 (point mutation P1384L called prp8*) in 
S. cerevisiae (Dahlmann, 2008; Mishra et al., 2011). Based on the hub1Δprp8* 
genetic background, HUB1 complementation experiments were conducted similar to 
previous assays in S. pombe hub1Δ. For this, hub1Δ  prp8* cells were transformed 
with constructs expressing yeast and human HUB1 orthologs, and corresponding 
spottings were incubated at indicated temperatures (Figure 12b). While the empty 
vector control could not support growth of the hub1Δ  prp8* strain, ScHUB1 and 
SpHUB1 fully rescued the growth defect at restrictive temperatures. HsHUB1, on the 
other hand, partially complemented at lower temperatures (25°C and 30°C), but was 
not able to support growth at 37°C. Again, all HUB1 orthologs were expressed at 
similar protein levels (Figure 12b, right panel).  
In addition to survival assays, an additional complementation read-out was 
used in S. cerevisiae. Recent data elucidated an important role of Hub1 in splice site 
usage and alternative splicing in yeast (Mishra et al., 2011). In S. cerevisiae the 
SRC1 gene gives rise to two mRNA isoforms due to alternatively splicing, termed 
SRC1-L (long isoform, larger protein) and SRC1-S (short isoform, smaller protein). 
The SRC1 transcript contains crucial sequences directly at the two overlapping 5’ 
splice sites, whose usage determines which isoform will be generated. It has been 
shown that Hub1 is important for proper splicing of certain 5’ splice sites and thereby 
pivotal for alternative splicing e.g. of SRC1 pre-mRNA (Mishra et al., 2011). WT cells 
generate both SRC1-L and SRC1-S isoforms and this equilibrium is not altered when 
different HUB1 orthologs are expressed ectopically (Figure 12c). According to Hub1’s 
role in 5’ splice site usage, hub1Δ cells are defective in alternative splicing of SRC1 
and only the distal splice site is used which produces the SRC1-L isoform (Figure 
12c). This splicing defect can be completely complemented by the ectopic expression 
of ScHUB1. Introducing the HUB1 ortholog from S. pombe largely rescues the 
altered alternative splicing pattern and both isoforms are detectable as well. In line 
with the genetic interaction in hub1Δ  prp8* cells, the human HsHUB1 was only able 
to partially complement the splicing defect, although its protein expression was 
similar to all other Hub1 orthologs tested (Figure 11c).  
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Based on the complementation data from S. cerevisiae and S. pombe it 
appears that, despite Hub1’s high conservation, human and fission yeast Hub1 own 
a distinct protein property, which is absent in Hub1 of S. cerevisiae. This activity 
might have developed later in evolution, when Hub1 gained additional or more 
prevalent functions in eukaryotic cells.  
 
4.9 Molecular tools for the characterization of Hub1 in human cells 
Due to the recent research on Hub1, no molecular tools for further characterization of 
Hub1 were yet commercially available. To address the cellular function of Hub1 in 
human tissue culture cells it was necessary to establish a Hub1 depletion system by 
RNA-interference (RNAi) using short interfering RNAs. Furthermore, the knockdown 
efficiency and specificity needed to be validated by immunoblotting with Hub1-
specific antibodies. In collaboration with the immunization service of the MPIBC, 
rabbits were injected with recombinant 6xHis-tagged human Hub1 and boosted twice 
to induce anti-Hub1 specific antibody synthesis. The isolated serum was incubated 
with a Hub1 matrix, where recombinant 6xHis-Hub1 was covalently tethered to 
activated CNBr-sepharose beads. After specific antibodies were isolated using the 
Hub1 affinity matrix, they were eluted and tested by immunoblotting. In a second 
purification step, the first round antibody eluate was incubated with another Hub1 
matrix, where recombinant GST-Hub1 was covalently attached to a HiTrap NHS HP 
column. Like before, bound antibodies were eluted and Hub1-specificity tested 
(Figure 13a). 
 
Figure 13: Generation of Hub1-specific antibodies and verification of Hub1 RNAi specificity. 
a) Schematic overview of Hub1 antibody purification. b) Verification and specificity of the purified Hub1 
antibody. For Hub1 detection, whole-cell extracts of WT or Hub1-RNAi treated HeLa cells as well as 
ectopically expressed 3xFLAG-tagged Hub1 in lysate and after FLAG-immunoprecipitation were 
analyzed by immunoblotting. c) Validation of Hub1 knockdown efficiency after RNAi using different 
siRNA oligonucleotides. 48 h after HeLa cells were transfected with siRNA, cells were harvested and 
lysed in denaturating RIPA buffer. Whole-cell lysates were analyzed by SDS-PAGE and immunoblotting 
using anti-Hub1 antibody. Tubulin served as a loading control.  
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Immunoblotting using the doubly affinity-purified anti-Hub1 antibody detected a 
specific band with a molecular weight of ca. 8 kDa, which corresponded to the size of 
endogenous Hub1 in whole-cell extracts (Figure 13b, first lane). Moreover, epitope-
tagged and immunopurified 3xFLAGHub1 from transfected HeLa cells was detected as 
a supershifted protein band in immunoblotting as well (Figure 13b). 
This newly generated antibody was used to validate and affirm in vivo 
depletion of Hub1 by RNAi. Several small interfering RNA oligonucleotides (siRNA 
oligos) were designed according to previously described criteria (Birmingham et al., 
2007; Reynolds et al., 2004). Cells transfected with Hub1-targeting siRNA or control 
oligo were analyzed by immunoblotting. Five different RNAi sequences were tested 
for successful knockdown in various cell types and endogenous Hub1 protein levels 
were significantly decreased when siRNA oligo iHub1.1 and iHub1.3 were 
transfected (Figure 13c). Furthermore, whole-cell extracts of Hub1 RNAi treated cells 
were subjected to immunoblotting and served as ideal control for Hub1-antibody 
specificity. Extracts from HeLa cells co-transfected with Hub1 siRNA and constructs 
expressing RNAi-resistant 3xFLAG-tagged Hub1 clearly showed efficient depletion of 
endogenous Hub1, while ectopically expressed 3xFLAGHub1 was detectable (Figure 
13b, third lane).  
 
4.10 In vivo depletion of Hub1 causes cell cycle defects and apoptotic 
cell death  
The aforementioned data indicate a special role of the ubiquitin-like protein Hub1 in 
human cells. Unlike other UBLs it is not conjugated to proteins but binds hSnu66 via 
a distinct unconventional interaction domain. In addition, Hub1 associates with 
nuclear speckles and splicing-related factors suggesting a role in pre-mRNA splicing 
in mammalian cells. After establishing the Hub1-targeted RNAi the key question of 
what might be the effect of Hub1-depletion in human cell lines was addressed. 
Initially, Hub1 knockdown cells were phenotypically characterized. For this, 
HeLa cells stably expressing GFP-tagged histone 2B (H2B-GFP) were transfected 
with siRNAs against either Hub1 or non-targeting control and monitored using live 
cell fluorescence microscopy. Intriguingly, 48 h post transfection Hub1 knockdown 
cells started to exhibit delays in cell cycle progression with subsequent mitotic 
defects, whereas in knockdown control cells no alterations were detectable (Figure 
14a). For example, while several control RNAi treated cells underwent cell divisions 
successfully in the depicted time-window of six hours, the Hub1-RNAi treated cells 
rarely divided, and, if they did, showed abnormal mitosis e.g. defects in metaphase 
plate formation or chromosome missegregation (Figure 14a). Live cell fluorescence 
microscopy with HeLa H2B-GFP demonstrated misaligned chromosomes during the 
arrangement of condensed chromosomes in metaphase and aberrant chromosome 
segregation during anaphase after Hub1 depletion.   
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 This phenotype was affirmed when cell cycle progression was quantified by 
measuring the time from nuclear envelope breakdown until successful telophase 
(Figure 14b). Control H2B-GFP HeLa cells completed mitosis faithfully after 
approximately 1.6 hours (mean: 105.6 min), whereas it took Hub1-depleted cells 
around 4.3 hours (mean: 283.6 min) to undergo mitosis. Frequently, transfected cells, 
which exhibit a significant delay in cell cycle, induced and underwent apoptosis at 
later time points (in particular when associated with mitosis) after prolonged 
incubation of Hub1 RNAi (Figure 14c).  
 
Figure 14: Knockdown of Hub1 causes cell cycle defects and mitotic catastrophe 
a) Live cell microscopy of H2B-GFP HeLa cells after RNAi either against Hub1 or non-targeting control. 
The images represent stills of time-lapse video microscopy at representative time points. Scale bar 
represents 10 μM. b) Quantification of cell cycle progression after Hub1 knockdown. Time in mitosis 
measured by live cell microscopy of H2B-GFP HeLa cells. Data represent mean and s.d. for control 
RNAi: mean 105.6 min (n=29) and Hub1 RNAi mean: 283.6 min (n=55). c) Quantification of cells 
undergoing apoptosis associated with mitosis. Counting of events during live cell imaging experiments 
with control of Hub1 RNAi H2B-GFP HeLa cells (n= 112). 
 
A more precise way to characterize defects in cell cycle progression is to use 
cell cycle synchronization and release methods. Here, RNAi-transfected HeLa cells 
were arrested in S-phase by two cycles of thymidine blocks and subsequently 
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released to undergo cell cycle synchronously. At the indicated time points, cells were 
harvested, fixed and stained for flow cytometry analysis (Figure 15a). While cells 
treated with control RNAi exhibited a typical wild type cell cycle distribution in the 
asynchronous sample with a major fraction in G1 phase (2n DNA content) and minor 
S-phase and G2/M phase (>2n and 4n DNA content), respectively, thymidine treated 
cells showed a clear S-phase arrest indicated by an accumulation of cell counts at 
the corresponding DNA content (>2n S-phase <4n). During the following release, 
cells progressed through cell cycle after completing S-phase, entering G2 and mitotic 
phase after five hours. After nine hours, a large fraction of cells had successfully 
undergone mitosis and cytokinesis, thus a prominent population of cells in G1 phase 
became apparent.  
Figure 15: In vivo depletion of Hub1 causes G2/M arrest  
a) Hub1 depletion leads to defects in cell cycle progression. HeLa cells were transfected with siRNA 
against Hub1 or control oligo and their cell cycles were synchronized by double thymidine block. After a 
second round of synchronization cells were released, harvested at indicated time-points, fixed and DNA 
content was stained for flow cytometry using propidium iodid. The overlay shows a time course of 
synchronized cell cycle progression after Hub1 or control knockdown. b) Cell cycle synchronization 
indicates deregulation of cell cycle proteins in Hub1 RNAi treated cells. After release from 
synchronization (as in (a)) HeLa cells were harvested and whole-cell lysates were analyzed by 
immunoblotting. Hub1 as well as cell cycle proteins Cyclin B1 and CDK1 as markers for G2 and M 
phase were detected by immunoblotting with their respective antibodies.  
 
Although Hub1 knockdown cells were successfully synchronized in S-phase, 
their release showed significant differences when cells reached G2/M phase, 
compared to control siRNA treated cells. Even after nine hours of release Hub1 RNAi 
cells were largely restricted to G2/M and only a marginal G1 population was 
detectable (Figure 15a). This cell cycle arrest was verified when asynchronous Hub1-
depleted HeLa cells were analyzed and a clear accumulation of cells in G2/M phase 
was detectable, confirming the cell cycle arrest observed in live cell microscopy 
(Figure 14).  
The eukaryotic cell cycle is highly regulated by a complex network of protein 
kinases, phosphatases and proteolysis factors like the APC/C (Pesin and Orr-
Weaver, 2008; Fisher et al., 2012). Cyclins and cyclin-dependent kinases (CDKs) are 
key players that coordinate temporal progression to ensure faithful DNA replication, 
segregation and cell division. As cyclin expression and CDK activity oscillate during 
the cell cycle (Hochegger et al., 2008), they are used as marker proteins to monitor 
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different cell cycle stages. Parallel to the flow cytometry assays, RNAi treated and 
synchronized cells were harvested at various time points and their extracts were 
analyzed by immunoblotting. Cyclin B1 protein levels started to rise in late S-phase 
and peaked in late G2 to early M phase, where CDK1 activity was highest as well, 
whereas both factors were expressed low in asynchronous and G1 cells (Porter, 
2008), as reflected in control RNAi transfected cells (Figure 15b). Hub1 knockdown 
cells exhibited an altered protein expression profile of Cyclin B1 and CDK1 in 
synchronized cell extracts. Here, Cyclin B1 and CDK1 did not accumulate over time 
during S to G2/M transition and no climax was detectable. Apparently, these Hub1 
depleted cells lacked the coordinated expression of cell cycle proteins, which is in 
line with the observed abnormal cell cycle progression after Hub1 RNAi. 
 For a more quantitative time-course, cells transfected with RNAi against Hub1 
or non-targeting control oligo were analyzed by flow cytometry after 48 hours and 72 
hours. The cell cycle profile of control cells remained unchanged over time and 
resembled the wild type profile with a large G1 fraction (> 40%) and minor mitotic 
populations in G2/M (around 15%). After 48 hours, Hub1-depleted cells displayed 
alterations in cell cycle progression and the G2/M arrest manifested with an increase 
of the G2/M population to over 35% (Figure 16a).  
Figure 16: Rescue of Hub1 knockdown-mediated cell cycle defects affirm RNAi specificity 
a) Time-course analysis of cell cycle distribution and induction of apoptosis after Hub1 depletion. 48 h 
and 72 h after Hub1 or control siRNA transfection HeLa cells were harvested, fixed, stained with 
propidium iodide and analyzed by flow cytometry. Cell cycle phases and apoptotic sub G1 fractions 
were quantified and are indicated next to the corresponding flow cytometry profile. b) Severe cell cycle 
phenotypes and apoptosis after RNAi are Hub1 knockdown specific. Complementation assays of Hub1 
RNAi by either expression of siRNA-resistant human Hub1 cDNA encoding for WT or HUB1 orthologs 
from S. cerevisiae (ScHUB1) or S. pombe (SpHUB1) were conducted. 24 h after transfection with siRNA 
targeting Hub1 or control, cells were co-transfected with respective constructs and incubated for 40 h. 
Cells were harvested, fixed and DNA content was stained for flow cytometry analysis.  
 
Interestingly, after 60-72 h an additional fraction among Hub1 knockdown 
cells became more prominent. In contrast to cycling cells, this population contains 
damaged or aberrant cells, which have underwent apoptotic cell death (Lecoeur, 
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2002). Among others, one particular hallmark of this cellular process is the nuclear 
fragmentation and DNA cleavage executed by specific DNases like Caspase-
activated DNase, CAD (Nagata, 2000). Apoptotic cells are detectable by flow 
cytometry as a population with DNA content size below that of intact G1 cells and are 
therefore termed “sub G1” fraction.  
Whereas the sub G1 fraction was marginal in control cells, in Hub1 RNAi 
samples this cell population increased drastically (≤ 4% in WT, > 12% in Hub1 RNAi). 
Notably, the subpopulation of G2/M arrested cells after 48 hours (around 35%) 
corresponded to the now apoptotic sub G1 fraction (ca. 13%) and the remaining 
G2/M population (ca. 20%) at the 72 hours time point. This further indicates that cells 
facing defects after Hub1 depletion arrest in the mitotic phase and cannot faithfully 
progress through the cell cycle. As the Hub1 deficiency persists and defects are not 
corrected, arrested cells are subjected to cell death via apoptosis. 
RNA interference is accomplished by the formation of a double-stranded RNA 
duplex between the transfected siRNA and the targeted mRNA, which is then 
recognized and degraded by the RNA-induced silencing complex (RISC) to achieve 
post-transcriptional gene silencing (Fire et al., 1998). To rule out any off-target effect 
of the designed siRNA oligo, complementation assays with expression constructs 
encoding siRNA-resistant cDNAs of Hub1 were conducted. Here, the complementary 
sequence within the Hub1 cDNA is changed by silent mutations, which makes it 
insusceptible to siRNA-mediated RISC-dependent, degradation while the 
endogenous Hub1 transcript is still efficiently knocked down.  
First, a co-transfection protocol had to be established to achieve high 
knockdown efficiency with, at the same time, sufficient plasmid transfection 
coverage. In the following experiments, cells were co-transfected with control or 
Hub1 targeting siRNAs and expression constructs encoding siRNA-resistant Hub1 or 
empty vectors. The flow cytometry analysis highlighted that control knockdown with 
concomitant Hub1 overexpression did not alter the cell cycle profile (as depicted in 
Figure 16b, first panel). As expected, Hub1 depletion (with co-expression of a control 
vector) caused severe cell cycle defects and an increase of cell death, which was 
reflected by the strong induction of apoptosis (see sub G1 fraction) and collapsed G1 
and G2 population peaks. Notably, this strong phenotype was rescued by 
complementation when siRNA-resistant human Hub1 had been co-transfected with 
Hub1 RNAi (Figure 16b). Here, the ectopically expressed Hub1 compensated the 
knockdown of endogenous Hub1 and the cell cycle profile was restored resembling 
cells with no G2 arrest nor major apoptosis events like control cells (protein levels of 
knockdown and ectopic expression shown in Figure 17c). The complementation of 
Hub1 RNAi by siRNA-resistant Hub1 cDNA confirmed the specificity of the siRNA 
oligo and proved that the observed cellular phenotypes were, indeed, related to the 
Hub1 depletion. Another interesting observation during the complementation 
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experiments was the rescuing capacity of different HUB1 orthologs (Figure 16b, 
fourth and fifth panel). Instead of co-transfecting siRNA resistant human Hub1 cDNA, 
Hub1-RNAi was now combined with mammalian expression constructs encoding for 
HUB1 from S. cerevisiae (ScHub1) or S. pombe (SpHub1). Interestingly, ScHub1 
was not capable of complementing Hub1 knockdown, which led to severe cellular 
defects and induction of apoptosis as monitored by a drastic increase in the sub G1 
fraction and reduced G1 and G2/M peaks. In contrast, S. pombe Hub1 efficiently 
rescued endogenous Hub1 depletion and fully restores cell cycle progression and 
Hub1-dependent activities. In line with the yeast complementation data, the RNAi 
rescue experiments underscore the finding that ScHub1 significantly differs from 
human and SpHub1 that own crucial protein properties that are essential for the vital 
functionality of Hub1 in higher eukaryotes. 
 
4.11 Hub1 RNAi entails DNA damage, mitotic catastrophe, and 
apoptotic cell death  
The morphological description by live cell imaging and flow cytometry analysis 
allowed the phenotypical characterization of cellular defects after Hub1 depletion by 
RNAi. An additional approach to identify Hub1 function and its pivotal role for cell 
viability is the molecular investigation of signaling cascades, which appear to be 
altered upon Hub1 knockdown. Thus, whole-cell extracts of RNAi treated cells were 
subjected to immunoblotting in order to monitor changes in key regulators levels and 
their activation.  
A profound cell cycle arrest is a hallmark of the Hub1 depletion phenotype, 
therefore DNA surveillance and cell cycle checkpoint pathways were tested. Here, 
the tumor suppressor p53 plays a central role, as it is activated upon DNA damage, 
DNA replication stress or various cellular stresses, e.g. hypoxia (Reinhardt and 
Schumacher, 2012). The p53 protein is not only transcriptionally regulated, but also 
under tight control by the ubiquitin-proteasome system, which constantly degrades 
inactive p53 via the ubiquitin E3 ligase HMD2 (Mdm2 in mouse). After its activation, 
p53 is stabilized and acts as a transcriptional regulator for a whole network of genes 
including either “repair and survival” factors like negative regulators of cell cycle 
progression (e.g. 14-3-3σ, p21WAF and Growth Arrest and DNA Damage gene 
GADD45a) or “cell death execution” factors of the Bcl-2 antagonist family like BAX, 
BAK and p53 up-regulated modulator of apoptosis (PUMA) (Vogelstein et al., 2000). 
It has been shown that p53 does not only control G1 or S-phase progression (Bartek 
and Lukas, 2001; Agarwal et al., 1998), but can also induce and maintain G2/M 
arrests, senescence and apoptosis (Bunz, 1998; Taylor and Stark, 2001). 
Proliferating, cycling U2OS cells transfected with non-targeting RNAi control 
do not face cellular stresses and thus exhibit low p53 and p21 protein levels, 
indicating inactive checkpoints (Figure 17).  
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In order to stimulate p53 activation, control cells were incubated with the 
transcriptional inhibitor actinomycin D (ActD), which binds DNA directly and 
abrogates transcription by blocking elongation of the emerging RNA strand during 
synthesis by RNA polymerase II (Bacchetti and Whitmore, 1969; Sobell, 1985). This 
triggers an increase in p53 stability and protein levels (Renton et al., 2003), but 
uncouples the transcriptional response targets like p21WAF (Ljungman et al., 1999; 
Zhu et al., 2007). Indeed, control knockdown cells showed high levels of p53, but only 
moderate levels of p21 after ActD treatment (Figure 17a). In contrast, Hub1 depletion 
in U2OS cells alone already led to p53 stabilization and an increase of p21 levels, 
when compared to control cells. Furthermore, the transcriptional inhibition with 
actinomycin D in combination with Hub1 knockdown again reduced p21 expression, 
while p53 remained up-regulated (Figure 17a).  
It appears that Hub1 is a crucial factor to ensure genome stability as indicated 
by microscopy and p53 data, thus, additional factors involved in DNA maintenance 
and repair were investigated. Beside exogenous factors like DNA attacking 
chemicals or UV- and gamma irradiation, defects in the DNA synthesis machinery, 
DNA replication stress or reactive oxygen species are intrinsic sources of DNA 
damage (Yi and He, 2013). After recognition of these damages by chromatin-
associated enzymes, signaling cascades initiate the activation of repair processes in 
order to excise and replace defective nucleotides or repair even severe DNA double-
strand breaks (DSBs) (Branzei and Foiani, 2008). The DSBs repair signal is 
transduced by the PI3 kinases DNA-dependent protein kinase (DNAPK), ataxia 
telangiectasia mutated (ATM) and its relative, ATR, which phosphorylate the histone 
variant H2AX at S139 (then termed γH2AX) and thereby generate a platform for 
subsequent recruitment of the DNA repair machinery (Lavin, 2008). Another branch 
of DNA repair deals with base lesions after cyclobutane pyrimidine dimer (CPD) or 
pyrimidine-pyrimidone photoadduct (6-4PP) formation as well as chemically modified 
nucleotides e.g. after alkylation and intrastrand crosslinks (Naegeli and Sugasawa, 
2011). Moreover, these genomic insults constitute severe obstacles that can block 
the transcription machinery and lead to stalling of RNA polymerases on the DNA. 
Proteins of the xeroderma-pigmentosum-related gene family (XP) have been shown 
to be crucial for the detection and subsequent repair of abovementioned DNA 
damages (transcription-coupled nucleotide excision repair, TC-NER (Mellon, 2005; 
Nouspikel, 2009)). While XPE (or DDB2) and DDB1 recognize lesions (Wittschieben 
et al., 2005), XPC in concert with hRad23B (Masutani et al., 1994) initiates local DNA 
unwinding by TFIIH (Sugasawa et al., 2009) and excision via XPF-ERCC1 with XPG 
(Bessho et al., 1997; O'Donovan et al., 1994).  
As depicted in Figure 17b, whole-cell extracts of RNAi treated cells were 
tested for changes in γH2AX and XPC levels. Intriguingly, Hub1 depletion alone led 
to an activation of DNA damage signaling, as a strong induction of γH2AX was 
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detectable, while control cells were unaffected and exhibited only low levels of the 
modified histone variant. The extent of H2AX phosphorylation in cells lacking Hub1 
was similar to that of actinomycin D treated control cells, but additional Hub1 
knockdown did not stimulate further phosphorylation of H2AX levels.  
Figure 17: Nuclear disintegration and DNA damage are characteristics of Hub1 knockdown and 
entail apoptosis 
a) Cell cycle regulator p53 is stabilized in Hub1-depleted cells. U2OS cells were transfected with RNAi 
targeting Hub1 or control and incubated for 60 h. After treatment with 5 μM actinomycin D (ActD) or 
DMSO (vehicle) for 6 h cells were harvested and whole-cell lysates were analyzed by immunoblotting 
using antibodies against p53, p21 or Hub1. b) Hub1 knockdown induces DNA damage mark γH2AX and 
abates nucleotide excision repair factor XPC. HeLa cells were transfected with Hub1 or control RNAi 
and incubated for 50 h. After treatment with 5 μM ActD or DMSO for 6 h cells were harvested and 
whole-cell lysates were analyzed by immunoblotting using antibodies against γH2AX, XPC or Hub1. 
Actin served as loading control. c) Hub1 RNAi induced DNA damage is rescued by siRNA-resistant 
Hub1 co-transfection. After RNAi targeting Hub1 or control HeLa cells were either co-transfected with 
siRNA-resistant 3xFLAGHub1 or treated with ActD (5 μM) for 6 h. Cells were harvested and whole-cell 
lysates were analyzed by immunoblotting using antibodies against γH2AX, Hub1, hSnu66 or PRPF8. d) 
Representative image of the abnormal (fragmented) nuclear morphology in human cells resulting from 
Hub1 depletion. 72 h after RNAi transfection HeLa cells were fixed and stained with α-Tubulin 
antibodies and DAPI. Scale bar represents 10 μM. e) Activation of the apoptotic cascade monitored by 
caspase 7 cleavage after RNAi. HeLa cells were transfected with RNAi targeting Hub1, hSnu66 or 
control and co-transfected with a plasmid expressing hSnu66-GFP, respectively. Cells treated with 
kinase-inhibitor staurosporine (STS, 2μM for 6 h) served as positive control. Immunoblots using 
antibodies against caspase 7 (detecting pro-caspase 7 and its activated (cleaved) form, Hub1, hSnu66 
and loading control PRPF8 are shown (similar results were obtained when assayed for caspase 3). 
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In addition, the nucleotide excision repair factor XPC, which facilitates 
recognition and repair of DNA lesions, was specifically down-regulated upon Hub1 
RNAi, even when cells were challenged with the drug Act D (Figure 17b and c). The 
complementation of Hub1 knockdown by the co-expression of siRNA-resistant Hub1 
cDNA prevented ATM/ATR activation and γH2AX induction, again confirming the 
specificity of the knockdown and the cellular alterations caused by Hub1 depletion 
(Figure 17c).  
The aforementioned role of Hub1 as crucial factor for genome stability 
became prominent after prolonged cultivation of Hub1-depleted cells (in U2OS cells 
>72 h, HeLa > 60 h). Although, initially arrested in G2/M phase, human cells depleted 
for Hub1 were able to overcome the cell cycle checkpoint and to exit from this 
blockage in cell cycle progression, which has been described as mitotic slippage (Di 
Leonardo et al., 1997; Riffell et al., 2009). Because of this unlicensed release with 
unsatisfied checkpoints these cells underwent aberrant mitosis, resulting in 
abnormal, fragmented nuclei and subsequent induction of apoptosis, as appreciated 
in live cell imaging as well as immunofluorescence staining (Figure 17d). In contrast 
to wild type or control RNAi cells, where nuclei were integer and regular in shape with 
a typical outspread α-tubulin network, Hub1 RNAi treated cells exhibited deformed 
and disintegrated nuclei, segmented and strangulated into multiple micronuclei, that 
were radially arranged around central dense α-tubulin material (Figure 17d, upper 
panel). The antibody staining of clustered α-tubulin emphasized structural 
abnormalities and nuclear rearrangements in Hub1-depleted cells.  
Shortly after aberrant mitosis, Hub1-depleted cells are not able to recover and 
undergo apoptotic cell death concomitant with caspase cascade activation. Upon 
profound cellular damage (here: genomic instability upon Hub1 inactivation) the 
intrinsic pathway of apoptosis is triggered and “initiator caspases” (caspase 2, -8, -9 
and -10) transduce the signal to “effector caspases” (caspase 3, -6 and -7) and 
activate them by proteolytic cleavage. These processed effector caspases act as 
highly active proteases that degrade the intracellular proteome and execute the cell 
death program (Riedl and Shi, 2004).  
To address this point, HeLa cells were transfected with RNAi targeting Hub1 or 
hSnu66 and co-transfected with hSnu66-GFP expression constructs, respectively. 
60-72 h post transfection, cells were harvested and lysed gently to avoid disruption of 
mitochondria (according to Deveraux et al., 1999) for caspase activation analysis. In 
cell lysates from control siRNA treated samples exclusively the uncleaved isoform of 
caspase 7, inactive pro-casp 7, was appreciated (Figure 17e). As a positive control, 
HeLa cells were treated with staurosporine (STS), which is a ATP-competitive kinase 
inhibitor and potent inducer of apoptosis (Okazaki et al., 1988). Indeed, STS 
treatment caused a massive activation of caspase 7 and thereby the appearance of 
the shorter isoform referring to proteolytically cleaved caspase 7. When Hub1 was 
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knocked-down, a similar activation was observed and pro-caspase was cleaved, 
indicating induction of apoptosis in these cells. Interestingly, hSnu66 knockdown also 
entailed severed defects in cell cycle progression and subsequent mitosis, leading to 
caspase-dependent apoptosis. Furthermore, neither Hub1 co-depletion with hSnu66 
by RNAi nor overexpression of the tri-snRNP protein could suppress the Hub1 
knockdown-dependent cell cycle defects and apoptosis (Figure 17e). Similar results 
were obtained when extracts were assayed for caspase 3 (data not shown) and in 
luminescence-coupled enzymatic cleavage experiments (see Figure 26c). 
 
4.12 The functional C-terminal surface is crucial to mediate the vital 
activity of Hub1 
After the phenotypical and molecular characterization of Hub1 knockdown it became 
evident that the Hub1-dependent activity is essential for human cells. Depletion of 
Hub1 leads to genomic instability and causes severe cell cycle defects, aberrant 
mitosis with subsequent nuclear segmentation and disintegration that finally entails 
apoptotic cell death. 
Taking advantage of the established complementation assay, where siRNA-
resistant Hub1 expression constructs were reintroduced into Hub1 knockdown cells, 
it was now possible to screen for loss-of-function mutations in Hub1, in order to 
address the question which surface on the protein is crucial to mediate its vital 
activity. Therefore, protein alignments of Hub1 orthologs were combined with the 
structural data obtained from the Hub1-HIND interaction studies. Residues D22 and 
K17 were particularly interesting, as they are involved in salt-bridge and interface 
formation between Hub1 and hSnu66 (Figure 18a). Moreover, the protruding R9 
residue located in the turn between β-sheet β1-2 was of interest, as it is important for 
yeast two-hybrid interaction with Clk3 (see Figure 5d). Besides the highly conserved 
residues (R9, K17 and D22) (see Figure 18b for alignment), another surface appears 
particularly interesting. On the opposing side of the Hub1-HIND interface, human 
Hub1 exposes three hydrophobic residues (W47, Y48, and F51) as a WYxxF motif 
on the “shoulder” formed by a loop between α2 and β3 to aqueous solvent (Figure 4a 
and 18a). As hydrophobic residues are usually buried inside the protein for 
stabilization or involved in the formation of hydrophobic interaction interfaces, this 
exposure of aromatic amino acids is thermodynamically unfavoured and unusual. 
While a motif, similar to the human WYxxF, is found in lower eukaryotes like S. 
pombe (comprising WHxxF) already, S. cerevisiae Hub1 does not contain the 
aromatic patch, but contains two glycines and leucine instead at these positions 
(S.c.: GGxxL).  
Various amino acid substitutions were introduced into the Hub1 coding 
sequence by site-directed mutagenesis and multiple mammalian expression 
constructs were generated for Hub1 RNAi complementation studies. In order to 
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ensure proper folding and expression of the different Hub1 mutant variants, protein 
levels were examined (Figure 18c). After RNAi treatment, cells were co-transfected 
with tagged (3xFLAG or GFP) Hub1 WT or mutant versions (D22A, R9A, W47G 
Y48G (WY-GG), W47G Y48G F51L (WYF-GGL) or combinations R9A D22A (RD), 
D22A W47G Y48G (D22A WY-GG), R9A W47G Y48G (R9A WY-GG), D22A W47G 
Y48G F51L (D22A WYF-GGL) and C-terminally tagged Hub1 (Hub1-GFP), 
respectively (Figure 18c).  
 
 
Figure 18: Characterization of crucial residues in Hub1 by mutational analysis 
a) Position of crucial amino acid residues within the human Hub1-HIND complex. Three different 
perspectives of the Hub1-HIND crystal structure highlighting special amino acid side chains. Amino 
acids of HIND are labeled in italics. Three classes of residues are grouped: crucial for Hub1-HIND 
interaction (D22A, K17, R127A, S117), C-terminal surface (R9 and C-terminal tags), and hydrophobic 
patch (W47, Y48 and F51). b) Protein sequence alignment of Hub1 orthologs from yeast to human. 
Amino acids identical with human Hub1 are shaded in light grey. Residues mentioned in a) and c) are 
highlighted in dark grey and labeled above. Further mutational analysis was performed on residues 
depicted below in light grey, data not shown. c) Expression of Hub1 point mutants in RNAi 
complementation assays. HeLa cells were co-transfected with either Hub1 or control RNAi and 
constructs encoding siRNA-resistant Hub1 WT, point mutants (single or combined) or GFP vector 
control. All mutants were experimental tested as N-terminally 3xFLAG- and GFP-tagged versions of 
Hub1. 60 h post-transfection cells were harvested and whole-cell lysates were analyzed by 
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immunoblotting using anti-GFP, anti-FLAG M2 and anti-Hub1 antibodies. hSnu66 and actin served as 
loading controls. 
 
In summary, none of the amino acid substitutions affected Hub1 protein 
stability negatively and mutant versions were expressed to similar extent, although, 
interestingly, alterations in the aromatic WY patch increased Hub1 protein levels. 
Beside the abovementioned mutations in Hub1, additional particularly interesting 
residues in putative motifs were tested (see Figure 18b, labeled grey below 
alignment), but will need further investigation (data not shown). For example, another 
central patch containing amino acids T35, G36, R38 and W39 play a potential role in 
human Hub1 oligomerization in vitro, whereas residues flanking T23 (DDTI) resemble 
an ideal polo-like kinase 1 (Plk1) phosphorylation consensus motif (D/E-x-S/T-
φ, with φ being a  hydrophobic residue) (Nakajima et al., 2003) implicated in cell cycle 
regulation and pro-apoptotic pathways.  
In the following experiments, Hub1 mutant versions were screened for their 
complementation capacities in RNAi treated cells. Initially, the focus was set on 
mutant alleles which interfere with the interaction between the ubiquitin-like protein 
Hub1 and the tri-snRNP protein hSnu66 via a conserved domain termed HIND, which 
is mediated via a salt bridge formed by D22 of Hub1 and R127 of hSnu66 (Figure 4). 
Mutating these residues abrogates the physical interaction between Hub1 and 
hSnu66 (Figure 5), the hSnu66-dependent recruitment of Hub1 to nuclear speckles 
(Figure 8) and Hub1-dependent nuclear retention of the N-terminal RS-domain 
(Figure 11). Reintroducing Hub1 WT into RNAi treated cells was able to fully rescue 
the Hub1-depletion phenotype, restore cell cycle progression and suppress the 
induction of apoptosis (Figure 19a, first three panels). Notably, performing the same 
experiment with the Hub1 D22A mutant largely complemented cell cycle defects and 
cell death. However, the rescue efficiency is significantly lower than that of WT Hub1, 
as indicated by the reproducibly restrained flow cytometry profile and underscored by 
quantification (see graph in Figure 19a). In further experiments, 3xFlag-tagged Hub1 
variants with additional single and double mutations (R9A, RDAA, D22AWYGG or 
D22AWYFGGL) were tested. None of the candidate Hub1 variants failed to rescue, 
but rather showed similar or even higher complementation capacity compared to the 
D22A single mutant (Figure 19b).  
To rule out any tag-specific effects on the Hub1 fusion protein, the same 
experiments and read-out were performed with GFP-tagged Hub1 and corresponding 
mutations (Figure 19c). Again, similar results were obtained and tagged Hub1 
mutants (D22AWYGG, D22AWYFGGL, R9AWYGG, R9AD22AWYFGGL) were able 
to complement to some extent. In fact, the complex triple-surface mutation 
R9AD22AWYFGGL, which interferes with the Clk3 association, hSnu66 binding and 
alters the hydrophobic patch, exhibited a more constricted flow cytometry profile than 
Results 
 58 
single or double mutations, without affecting protein stability negatively (Figure 19c 
and 18c.  
Interestingly, the most striking phenotype was observed when Hub1’s C-
terminus was decorated with bulky (GFP) or highly charged (FLAG) tags. Although 
these versions of Hub1 were expressed and folded properly (as shown by hSnu66 
binding, Figure 5b) they were not capable of rescuing the Hub1 RNAi-mediated 
defects and subsequent apoptosis. In contrast to control transfected cells with few 
apoptotic cells (sub G1 fraction: 1.9%), cell death and apoptotic sub G1 fraction 
increased upon Hub1 knockdown (sub G1: 16.2%).  
Figure 19: Complementation of Hub1 RNAi cytotoxicity by co-expression of Hub1-point mutants 
a) hSnu66-binding mutant Hub1 (D22A) partially rescues Hub1 RNAi-mediated cell death. Complemen-
tation of Hub1 RNAi by either expression of siRNA-resistant human Hub1 cDNA encoding for WT or 
D22A mutant. 24 h after transfection with siRNA targeting Hub1 or control, cells were co-transfected 
with respective constructs and incubated for 40 h. Cells were harvested, fixed and DNA content was 
stained for flow cytometry analysis. Right panel: Quantification of apoptotic sub G1 fraction in Hub1 
complementation assays. Mean and s.d. of at least three independent experiments are shown. b) Single 
or combined point mutations in Hub1 slightly reduce complementation capacity. HeLa cells were co-
transfected with either Hub1 or control RNAi and constructs encoding siRNA-resistant Hub1 WT or point 
mutants (single or combined) or GFP vector control. 60 h post transfection cells were harvested, fixed 
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and DNA content was analyzed by flow cytometry. Three groups of Hub1 mutations: Hub1-HIND 
interaction (D22A), C-terminal surface (R9) and hydrophobic patch (W47, Y48 and F51) and their 
combinations are shown. Protein expression levels were tested as shown in Figure 18 c). d) The C-
terminal surface is essential for Hub1 function. After Hub1 or control RNAi HeLa cells were transfected 
with siRNA-resistant Hub1 N- or C-terminally tagged with either FLAG or GFP, they were harvested, 
fixed and prepared for flow cytometry analysis. (vice versa experiments with exchanged tags e.g. using 
C-terminal FLAG resulted in the same deficiency). e) Quantification of apoptotic sub G1 fractions after 
RNAi in complementation assays with Hub1 mutants. Mean and SD of at least three independent 
experiments are shown. 
 
While N-terminally tagged Hub1 was able to efficiently compensate the 
deleterious depletion of endogenous Hub1 (sub G1 dropped to 3.1%), the C-terminal 
fusion (here Hub1-GFP) failed to reconstitute the Hub1-dependent, vital activity (sub 
G1: 21.8%) (Figure 19d).  
The same deficiencies in RNAi complementation were detected when Hub1 
was C-terminally FLAG-tagged (data not shown). Importantly, overexpression of C-
terminally tagged Hub1 (Hub1-GFP or Hub1FLAG) in human cells alone (without RNAi 
pre-treatment) did not show a dominant negative phenotype in any assay tested (flow 
cytometry, apoptosis induction, morphological changes, immunofluorescence). 
Altogether, those data indicate that hSnu66 binding via HIND and D22 contributes to 
Hub1’s activity, but its C-terminus appears to mediate the vital function of Hub1.  
 
4.13 Altered distribution of splicing factors and retention of mRNA 
upon Hub1 depletion in vivo  
In human cells Hub1 localizes to nuclear speckles and is tightly linked to central 
splicing-associated factors like tri-snRNP protein hSnu66 and SR-kinase Clk3. As 
shown by abovementioned RNAi experiments, depletion of Hub1 alters the 
intracellular homeostasis and thereby generates severe defects in cells, which lead 
to cellular responses like cell cycle arrest and subsequent cell death. As pre-mRNA 
processing and splicing are essential pathways in all eukaryotic cells, the fate of pre-
mRNA maturation in Hub1 knockdown cells was investigated. For this, 
immunofluorescence staining of nuclear speckle marker protein SC35 was combined 
with the RNA fluorescence in situ hybridization (RNA FISH) technique targeting the 
poly (A) tail of mRNA after polyadenylation using fluorescently labeled oligo-dT 
probes (Tokunaga and Tani, 2008). 
Already during RNA synthesis and co-transcriptional processing like capping, 
splicing and subsequent poly-adenylation, pre-mRNA is handed over to the nuclear 
export machinery and the mature transcript is released to the cytoplasm for 
translation into proteins where it is finally degraded (Maniatis and Reed, 2002). Thus, 
besides the cytoplasm and nucleoplasm polyadenylated mRNA has been found to 
pass nuclear speckles as well, as it was shown to co-localize with SC35-domains 
(Dias et al., 2010; Tokunaga et al., 2006).  
In line with previous reports, normal SC35 domains with many small foci 
distributed within the interchromatin space were visualized in control RNAi cells 
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(Figure 6 and 20a). Furthermore, RNA FISH visualized the exported cytoplasmic pool 
of polyadenylated mRNA as well as its nuclear fraction partially co-localizing with 
SC35 (Figure 20a, left panel). In contrast, when Hub1 knockdown cells were 
examined, an aberrant SC35 pattern was apparent with high enrichment in nuclear 
speckles and small distinct foci collapsed into enlarged assemblies (Figure 20a). 
Additionally, not only SR proteins like SC35 were affected, but also polyadenylated 
mRNAs as shown by FISH. Hub1 RNAi caused strong nuclear retention of RNA 
species, while the cytoplasmic signal concomitantly decreased. Interestingly, 
polyadenylated mRNA accumulated in enlarged nuclear speckles as shown by co-
localization in SC35 immunostaining (Figure 20a). 
Figure 20: In vivo depletion of Hub1 causes an altered distribution of splicing factors and 
nuclear retention of polyadenylated mRNA 
a) SR protein SC35 and mRNA exhibit an aberrant accumulation in nuclear speckles after Hub1 
knockdown. After transfection of Hub1 siRNA or control oligos, cells were fixed, permeabilized and 
immunostained with phospho-SC35 antibodies (red) combined with poly-dT FISH targeting 
polyadenylated mRNA (green). b) Several splicing-associated factors show an altered nuclear 
distribution after Hub1 knockdown. RNAi treated cells were fixed, permeabilized and immunostained for 
2,2,7-trimethylguanosine (3mG cap) of snRNAs, U1 snRNP protein U1A, or heterogeneous ribonucleo-
protein particle hnRNP1 (all red). Nuclei were counterstained with DAPI (blue). Scale bars represent 10 
μM.  
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 After focusing on splicing speckle marker proteins and to further prove that 
this nuclear retention and aberrant localization after Hub1 depletion is not restricted 
to SC35 or polyadenylated mRNA, additional factors of the splicing machinery were 
examined. As depicted in Figure 20b, several spliceosomal factors showed 
prominent changes in their localization and distribution. Immunostainings with 3mG-
specific antibodies recognizing the hypermethylated cap of non-U6 snRNAs (U1, U2, 
U4, U5, see chapter 2.4), elucidated major rearrangements and altered nuclear 
distribution after Hub1 RNAi compared to control knockdown cells (Figure 20b, upper 
panel). Similar defects and altered nuclear localization were observed for the U1A 
protein, which binds to the U1 snRNA stem loop and thereby acts as a marker for U1 
snRNPs localizing to Cajal bodies, nuclear speckles, and the nucleoplasm as well as 
for PTBP1 (alias pyrimidine track binding protein 1 or hnRNP1) that belongs to the 
hnRNP family of negative regulators for splice site selection.  
Based on data showing that pre-mRNA splicing and nuclear export are tightly 
interconnected (Reed and Hurt, 2002) and unprocessed or improperly spliced 
transcripts are retained in nuclear speckles (Kaida et al., 2007; Dias et al., 2010) the 
hypothesis that Hub1 is a crucial factor for faithful splicing and mRNA processing in 
human cells was supported by the finding that Hub1 depletion causes an altered 
distribution of various splicing factors like SC35 and nuclear retention of 
polyadenylated mRNA in enlarged nuclear speckles.  
As RNAi complementation experiments highlighted different functional 
surfaces on Hub1, stable cell lines expressing the corresponding, mutated versions 
of Hub1 were tested in SC35 localization assays. Therefore, U2OS cells stably 
expressing siRNA-resistant GFP-Hub1 WT, GFP-Hub1 D22A, Hub1-GFP or free 
GFP were transfected with control or Hub1 targeting RNAi. After incubation cells 
were pre-extracted, fixed and stained for nuclear speckle marker phospho-SC35 to 
examine its nuclear distribution. In control RNAi cells as well as Hub1 WT cells SC35 
and GFP-Hub1 localization was not altered and small splicing foci were equally 
distributed throughout the interchromatin space (Figure 21a). Moreover, in 
complementation assays GFP-Hub1 D22A also co-localizes with SC35 like Hub1 WT 
in small discrete nuclear speckles (like in Figure 7a, without RNAi treatment). 
However, after Hub1 knockdown in GFP control cells or in U2OS expressing the 
functionally inactive version of Hub1 (Hub1-GFP), SC35 accumulates in enlarged 
splicing speckles and displays an aberrant nuclear distribution. Moreover, in contrast 
to GFP-Hub1 WT and D22A, C-terminally GFP-tagged Hub1 was washed out during 
the pre-extraction step thus nuclear staining was negative, indicating that Hub1-GFP 
was not incorporated into protein complexes within nuclear substructures similar to 
free GFP. Altogether, Hub1 conveys an important activity to maintain proper 
dynamics of SR protein shuttling and pre-mRNA processing.  
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 Additionally, the impact of Hub1 on general mRNA export was compared to 
central components of the conserved TREX (TRanscription-EXport) complex and 
mRNA export machinery. In RNAi experiments two closely related major RNA 
helicases UAP56 and URH49 with redundant activities (Kapadia et al., 2006; 
Strasser et al., 2002) were co-depleted in vivo and polyadenylated mRNA was 
stained by poly-dT FISH (Figure 21b). 
Figure 21: Hub1 RNAi complementation restores aberrant nuclear localization of splicing factors 
with Hub1 functioning upstream of mRNA export  
a) Altered SC35 distribution is rescued in RNAi complementation assay. Hub1 or control RNAi 
transfected into U2OS cells stably expressing siRNA-resistant GFP-Hub1, GFP-Hub1 D22A, Hub1-GFP, 
or free GFP (all green). Cells were pre-extracted, fixed and stained for nuclear speckle marker phospho-
SC35 (red). DAPI (blue) was used as nuclear counterstain. b) Nuclear mRNA retention after Hub1 RNAi 
is less profound than in mRNA export knockdown cells. Cells were transfected with RNAi against Hub1, 
mRNA export helicases UAP56/URH49 or control. Fixed, permeabilized and polyadenylated mRNA was 
stained by poly-dT FISH (red) and nuclear counterstain (DAPI, blue). Scale bars represent 10 μM. 
 
Control RNAi cells presented the normal cellular distribution of polyadenylated mRNA 
in the nucleus (found in nuclear speckles and the nucleoplasm) and diffusely in the 
cytoplasm. Simultaneous knockdown of UAP56/URH49 efficiently blocked mRNA 
export and led to a strong accumulation of polyadenylated mRNA in the nucleus and 
nuclear speckles, while the cytoplasmic fraction was virtually absent (Yamazaki et al., 
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2010). In comparison cells depleted of Hub1 showed an intermediate phenotype with 
less profound mRNA export defect as polyadenylated mRNA was retained in the 
nucleus and accumulated in nuclear speckles, but reduced amounts of cytoplasmic 
transcripts were detectable.  
 In summary, although polyadenylated mRNA is retained in the nuclear 
compartments after Hub1 knockdown, Hub1 does not play a central role in mRNA 
transport, like the general mRNA export factors helicases UAP56/URH49, but its 
action appears to be important for crucial steps further upstream to ensure proper 
splicing and pre-mRNA processing. 
 
4.14 Identification of splicing defects upon Hub1 knockdown using 
splicing reporter systems 
The cell biological characterization of Hub1 depletion in human cells elucidated 
various alterations of cellular pathways involved in pre-mRNA processing. RNAi 
experiments showed that Hub1 is necessary for the proper localization of splicing 
factors and nuclear export of mRNA. If the pre-mRNA splicing machinery is impaired 
and aberrant transcripts accumulate, this interferes with downstream RNA 
processing and can lead to similar phenotypes (Girard et al., 2012; Kaida et al., 
2007). In order to address the function of Hub1 in pre-mRNA splicing, an artificial 
minigene splicing reporter was used. Minigenes are helpful and commonly used tools 
to characterize various aspects of pre-mRNA splicing, for example recognition and 
usage of different 5’ss, 3’ss, or pyrimidine tract sequences (Singh and Cooper, 2006; 
Stoss et al., 1999; Shapiro and Senapathy, 1987). In addition, minigenes allow the 
characterization of cis-regulatory elements like splice site enhancers or silencers in 
alternatively spliced transcripts and identification of trans-acting splicing factors e.g. 
hnRNP and SR proteins (Wang and Burge, 2008; Lopez, 1998).  
Here, the vector based fluorescent pGint / pRint reporter system was used 
(Bonano et al., 2007), in which the protein coding sequence for enhanced GFP 
(EGFP) was divided into two exons by a constitutively spliced intron (in the case of 
pGint). The same intron insertion was introduced into the open reading frame of RFP, 
generating the pRint constructs. The expression constructs carry an adenoviral intron 
of 125 nt in pGint and 122 nt in pRint, respectively, comprising consensus splice 
sites, strong branch point and polypyrimidine tract (Figure 22a). Based on the pGint 
reporter, various variants with different 5’ splice sites were generated by site-directed 
mutagenesis in order to modulate splice site strength (see table in Figure 22a), while 
pRint’s intron sequence remained unchanged, thereby serving as an internal control 
when co-transfected.  
For mRNA splicing assays cells were treated with RNAi targeted against 
Hub1 or control, and abovementioned reporters, pGint or its 5’ splice site variants, 
were co-transfected with pRint. After isolation of total RNA and cDNA synthesis via 
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reverse transcription, splicing reporter specific primers (located in flanking 5’ and 3’ 
exon of GFP and RFP, respectively) spanning the intron were used to detect spliced 
and unspliced transcripts. As expected, in RNA samples from control RNAi treated 
cells only the mature and properly spliced transcripts with a size of 320 nt for pGint 
and 375 nt for pRint were detectable (Figure 22b, upper right panel). In contrast, 
when pGint transcripts from Hub1 knockdown cells were analyzed, an additional RT-
PCR product was detectable beside the mature transcript. This product with a total 
fragment length of ca. 445 nt comprised additional 120 nt, resembling the size of an 
unspliced transcript with retained intron (Figure 22b, upper left panel). This 
accumulation of an unspliced transcript product was also detected in pRint control 
samples albeit to a lesser extent. Notably, minor variations at the 5’ splice site (pGint: 
GTGAGTA) generating strong, previously well characterized sequences (Burset et 
al., 2001; Roca et al., 2005), namely canonical human GTAAGTA, constitutive 
human GTATGTA or canonical S. cerevisiae GTATGTT, did not significantly affect 
splicing efficiency in this read-out (Figure 22). 
 
Figure 22: Splicing reporters indicate Hub1’s crucial role for efficient pre-mRNA splicing 
a) Schematic representation of splicing reporters (pGint/pRint) depicting exon-intron structure and 5’ 
splice site (5’ss) variations tested. Intron-containing GFP-encoding reporter pGint with alternative 5’ss 
sequences for strong splice sites (upper part of table) or mutated weak splice sites (lower table, 
percentage shows splice site usage in human transcripts (Burset et al., 2001)) was co-transfected with 
RFP-expression construct pRint serving as constant internal control. Sizes of mRNA products are given 
below: unspliced (US) or spliced (MS, mature spliced transcript). b) Hub1 is important for proper splicing 
of reporter pre-mRNAs. Splicing reporter constructs pGint or its 5’ss variants were co-transfected with 
pRint into Hub1 RNAi treated cells and total RNA was isolated for RT-PCR analysis. Specific primers 
spanning the intron for detection of spliced and splicing-defective mRNAs.  
 
Additional pGint constructs with mutated, weaker 5’ splice sites (Table in 
Figure 22a (Buratti et al., 2007; Burset et al., 2001) were tested, in order to determine 
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whether these substitutions would sensitize and further alter pre-mRNA splicing after 
Hub1 knockdown in human cells. While control RNAi treated cells did not show any 
alterations in splicing of these pGint variants, Hub1-depleted cells were not able to 
properly splice pGint transcripts, thus an additional, enlarged RT-PCR product was 
detectable besides the maturely spliced mRNA. However, weakening 5’ splice sites 
by introducing changes at the exon-intron boundary artificially did not lead to a further 
increase of unspliced mRNA after Hub1 RNAi. These splicing reporter assays 
underscore Hub1’s implication in the splicing machinery and further support its role 
as a crucial factor ensuring faithful pre-mRNA splicing in human cells.  
 
4.15 The splicing factor Hub1 is crucial for efficient and faithful pre-
mRNA splicing in human cells 
Although minigenes are commonly used for the characterization of splice sites and 
exon usage in constitutive and alternative splicing (Cooper, 1999; Singh and Cooper, 
2006; Cooper, 2005), endogenous transcripts are controlled by additional layers of 
regulation for example by histone modifications in the chromatin context or RNA 
Polymerase II CTD phosphorylation, transcription elongation speed and pausing (see 
(Cramer et al., 1999; la Mata et al., 2003; Luco et al., 2011; Moore and Proudfoot, 
2009). Based on the splicing reporter data, further experiments were carried out to 
characterize Hub1’s impact on pre-mRNA splicing of endogenous transcripts.  
First, transcripts were analyzed that are known to be under tight control of the 
splicing machinery, as they can be alternatively spliced upon stimuli or under certain 
cell growth conditions (developmental stages or metastasis) (Li et al., 2006; Lopez, 
1998; Shkreta et al., 2011). For this, total RNA was isolated after cells had been 
transfected with control RNAi or siRNA-oligos targeted against Hub1, hSnu66 or the 
SR protein ASF/SF2 (alternative splicing factor/splicing factor 2; alias: SFRS1). After 
cDNA synthesis via reverse transcription gene-specific primers targeting flanking 
exons in Mcl-1 (myeloid cell leukemia sequence 1 (BCL2-related), exon 1-2), Casp2 
(caspase 2, exon 6-7), ATG4 (autophagy related 4B, cysteine peptidase (exon 12a-
13, UV treatment to induce alternative splicing) and beta-actin (exon 3-4) were used 
to detect alternatively spliced and unspliced transcripts (Figure 23a).  
When control cells were analyzed by RT-PCR using transcripts specific 
primers, only one prominent band corresponding to the maturely spliced mRNA was 
apparent. Interestingly, in Hub1 RNAi samples, additional RT-PCR products of Mcl-1, 
Casp2 and ATG4 were detectable. The molecular sizes of these enlarged PCR 
bands were compared with intronic and exonic sequences of the targeted genes 
showing that the higher migrating band resembled the unspliced pre-mRNA of 
candidate transcripts. Another interesting finding based on the comparison of Hub1 
RNAi-dependent splicing defects with RT-PCR results from hSnu66 or ASF/SF2 
knockdown cells. Although the tri-snRNP protein hSnu66 interacts with Hub1 and 
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they co-localize in nuclear speckles, the impact on accurate pre-mRNA splicing 
diverges in splicing assays. While both, Hub1 and hSnu66 knockdown, affect Mcl-1 
splicing and unspliced intermediates accumulate, defects in Hub1 samples appear 
more severe for Casp2 or ATG4 transcripts than in hSnu66 knockdown cells. Similar 
results were obtained for ASF/SF2, as similar mis-splicing was detected for ATG4 in 
Hub1 and ASF/SF2 samples, but not for Casp2 or Mcl-1. In addition to the splicing 
reporter data, this experiments support Hub1’s role as a crucial factor for proper 
splicing of various endogenous transcripts.  
 
Figure 23: Depletion of Hub1 leads to aberrantly spliced mRNAs and altered splicing patterns  
a) Depletion of Hub1 causes aberrant splicing of endogenous transcripts. After knock down of Hub1, 
hSnu66 or ASF/SF2 cells were harvested and total RNA was isolated. mRNAs of Mcl-1, Casp2 and 
ATG4 were subjected to intron-spanning RT-PCR. b) Detection of aberrant splicing of endogenous 
transcripts with putative weak 5’ splice site after Hub1 knockdown. mRNAs of v-akt murine thymoma 
viral oncogene homolog 1 (Akt), RAD23 homolog A (Rad23A) and Aurora kinase A (AurkA) were 
subjected to intron-spanning RT-PCR (targeted exons indicated on the side). c) Hub1 knockdown 
influences alternative splicing of fibronectin mRNA and efficient splicing in minigene-assays. Genomic 
fragments containing alternatively spliced exons of fibronectin 1 (FN1, exon 31-34 incl. EDA), 
tropomyosin 1 α (TPM, exon 4-7) or Myeloid cell leukemia sequence 1 (BCL2-related) (Mcl-1, exon 1-2) 
expressed as minigenes in U2OS cells after Hub1 or control RNAi. After isolation of total RNA and 
reverse transcription, minigene-specific primers were used for PCR to detect altered splicing patterns 
(schematic exon-intron structure of minigenes depicted alongside). 
 
Co-transcriptional recruitment of splicing factors to regulatory sequence 
elements within the nascent transcript and emerging exon-intron boundaries (splice 
sites) orchestrate the stepwise assembly of the spliceosome. Weak splice sites are 
considered to be recognized poorly by the splicing machinery and thereby require 
auxiliary factors (like SR proteins) to ensure proper and efficient splicing of intronic 
sequences. Thus, endogenous pre-mRNA transcripts with weak splice sites (Ahn et 
al., 2011) were investigated further in Hub1 knockdown experiments. Here, total RNA 
from Hub1 RNAi treated cells was tested for aberrant splicing of transcripts of v-akt 
murine thymoma viral oncogene homolog 1 (Akt), RAD23 homolog A (Rad23A) and 
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Aurora kinase A (AurkA) by intron-spanning RT-PCR (Figure 23b). Indeed, cells 
lacking Hub1 exhibited defective splicing and aberrantly spliced mRNA with retained 
introns accumulated. However, in control RNAi samples exclusively mature 
transcripts of Akt, Rad23A and AurkA were detectable in RT-PCR analysis.  
In parallel to experiments focusing on endogenous transcripts, sophisticated 
minigene assays were established. Instead of artificial transcripts like the intron-
containing GFP ORF in pGint, genomic fragments containing alternatively spliced 
exons of fibronectin 1 (FN1, exon 31-34 incl. EDA alias EIIIA), tropomyosin 1 α 
(TPM, exon 4-7, incl. NM and SK exons) or myeloid cell leukemia sequence 1 (BCL2-
related) (Mcl-1, exon 1-2) were expressed as minigenes as described previously 
(Stoss et al., 1999; White and Muro, 2011; Gooding and Smith, 2008; Bae et al., 
2000). These transcripts have been widely studied to address molecular processes 
like splice site usage, cis-acting regulatory elements and alternative splicing. After 
these genomic fragments were introduced into Hub1 or control RNAi treated U2OS 
cells as minigenes, total RNA was isolated, reversely transcribed and analyzed with 
PCR using minigene-specific primers to detect altered splicing patterns.  
Gene products of fibronectin 1 (FN1) are well characterized and have been 
shown to give rise to various mRNA isoforms due to three alternatively spliced 
regions, namely extra domain A (EDA), extra domain B (EDB) and type III connecting 
segment (V region) (White and Muro, 2011). Alternative splicing of EDA, EDB or V 
region by exon retention or exclusion generates over 20 different isoforms of the 
extracellular matrix protein during developmental stages, tissue injuries or malignant 
transformation of human cells (Magnuson et al., 1991; Muro et al., 1998). Strikingly, 
when exons 31-34 of fibronectin 1 were examined, analysis of the splicing pattern 
elucidated that Hub1 depletion led to skipping of exon EDA and alternative splicing of 
FN1 (Figure 23c). In control cells the FN1 minigene expresses three isoforms to 
almost equal amounts including transcripts containing the EDA exon. The latter 
isoform is largely diminished in Hub1 knockdown cells while the smaller EDA 
negative transcripts appear more abundant, suggesting that Hub1 is necessary for 
correct exon usage and EDA exon retention during alternative splicing of fibronectin.  
 Similar defects could be identified in transcripts encoding for the actin filament 
binding protein tropomyosin 1 α. Here, alternative splicing is utilized to generate 
tissue-specific mRNA isoforms by preferentially retaining the NM (non-muscle) exon 
in non-muscle cells like fibroblasts, while the SK (skeletal) exon is preferred in 
skeletal muscle instead (Lin and Tarn, 2005; Xing and Lee, 2006). Analysis of 
tropomyosin transcripts in Hub1 knockdown cells revealed an aberrant splicing 
pattern compared to control cells (Figure 23c). From total RNA of control cells two 
transcripts were detected in RT-PCR assays, one corresponding to the long isoform, 
which comprises exons 4-5-NM-SK-7 and the other short isoform lacking the NM 
exon, which results in mRNAs containing exon 4-5-SK-7. Hub1-depleted cells 
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showed defective splicing of TPM, with reduced inclusion of the NM exon and 
retention of the intron between exon 5 and the NM exon.  
Another gene tested for Hub1-dependent alternative splicing illustrates how 
switching between different transcript isoforms regulates cellular pathways and 
determines the fate of cells. The human Mcl-1 gene can give rise to three mRNAs 
termed Mcl-1L, Mcl-1S and Mcl-1ES (additional Mcl-1V variant in mouse) (Kim et al., 
2009; Kojima et al., 2010), which are translate into protein isoforms with opposing 
functions. While the large transcript Mcl-1L encodes the anti-apoptotic variant 
comprising the transmembrane and all BCL2-homology (BH) domains 1-4, the 
shorter mRNA isoform Mcl-1S formed by alternative splicing of exon 2 produces the 
pro-apoptotic Mcl-1S protein variant lacking the crucial BH1, BH2 and TM domains. 
The other pro-apoptotic variant, Mcl-1ES, in which alternative splicing of exon 1 
excludes the PEST sequence, encodes a hyperstable protein isoform and acts, like 
Mcl-1S, as a negative regulator of Mcl-1L to induce mitochondrial cell death (Bae et 
al., 2000; Bingle et al., 2000). The Mcl-1 minigene with genomic fragments containing 
alternatively spliced exons 1 and 2 was analyzed by RT-PCR after RNAi treatment. 
Upon Hub1 depletion, cells were defective in faithful splicing of the Mcl-1 transcript 
and mRNAs with retained intron 1-2 accumulated, in contrast to control cells, which 
showed proper splicing of Mcl-1 (Figure 23c). 
In summary, the findings above consolidate and support Hub1 functioning in 
pre-mRNA splicing, as its depletion leads to altered splicing patterns and 
accumulation of aberrantly spliced transcripts from minigenes as well as on 
endogenous expression levels. 
In order to further characterize Hub1-dependent splicing of Akt and AurkA 
mRNAs, the corresponding genomic sequences were introduced into minigene 
constructs and tested in RT-PCR assays after Hub1 knockdown (Figure 24a). The 
examination of critical exon-intron boundaries in Akt (exon 11-12) and AurkA (exon 9-
10) transcripts from minigenes verified the aforementioned splicing defects with 
intron retention in Hub1-depleted cells, which was absent in control cells (Figure 24a, 
upper and middle panel). An additional gene was identified in an exon-specific 
microarray (see chapter 4.16) and characterized in analogous minigene assays: 
Laminin 5 alpha (Lama5). The transmembrane protein laminin 5 contacts integrins 
and components of the extracellular matrix, where it mediates attachment, migration, 
differentiation and organization of cells into tissues (Nguyen and Senior, 2006; 
Spenlé et al., 2013). In genome databases, more than 15 transcript isoforms for the 
Lama5 gene are documented, including an alternatively spliced variant of 5’ exon 63 
and exon 64 (mapped sequence Ensembl ID: AK074307).  
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Figure 24: Hub1 is crucial for accurate splicing of specific splice events in vivo  
a) Aberrant splicing of Akt, AurkA and Lama5 after Hub1 knockdown in RT-PCR based minigene 
assays. Minigenes were co-transfected with Hub1 or control RNAi and splicing patterns were analyzed 
by RT-PCR after total RNA extraction. b) Comparison of splicing specificities dependent on Hub1 and 
splicing factors hSnu66 and Son. Splicing of Hub1-dependent introns and flanking exons in Akt, Mcl-1 
and AurkA mRNAs was analyzed by gene-specific RT-PCR after RNAi against Hub1, hSnu66 or Son in 
U2OS. Primer sets indicate Hub1-sensitive introns in the respective transcripts tested in RNAi 
experiments (red arrow heads), whereas mapping studies with PCR primers located in flanking 
sequences (black arrow head) detected no splicing alterations in neighboring exons/introns. c) Splicing 
proficiency in Hub1 RNAi complementation assays. Stable U2OS cells were transfected with Hub1 or 
control siRNA for subsequent isolation of total RNA. AurkA, Mcl-1, Akt and Tubulin as control were 
subjected to intron-spanning RT-PCR. 
 
After minigene expression of Lama5 gene fragments (containing alternatively spliced 
exons 63 to 65), three transcripts were detectable, corresponding to constitutively 
spliced exons 63-64-65 (448 nt, all three exons), alternatively spliced exons 63+65 
(310 nt, skipping exon 64) and an isoform with retained intron between exon 63-64 
(620 nt, 63-intron-64-65, Figure 24a, lower panel). Lama5 pre-mRNA is spliced in a 
Hub1-dependent manner, as RNAi experiments demonstrated the accumulation of 
transcripts with intron retention when Hub1 was depleted. While the small 
alternatively spliced transcript variant with exons 63+65 was slightly reduced and 
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mRNAs with constitutively spliced exons 63-64-65 were equally expressed, one 
additional intron-containing mRNA became evident. Beside the intron-containing 
mRNA consisting of exon 63-intron-64-65, the unspliced transcript with exon 63-
intron-64-intron-65 and both retained introns accumulated (Figure 24a). 
Aberrant splicing upon Hub1 RNAi affects various transcripts and leads to 
alternatively spliced mRNA isoforms, proposing two possible models for Hub1 
function. Hub1 could act as a constitutive spliceosomal factor, whose depletion could 
interfere unspecifically with general splicing of pre-mRNA. If this was the case, the 
catalytic activity of the spliceosomal machinery should be significantly reduced and 
any intron would be spliced with low efficiency in a sequence-independent manner. 
Alternatively, Hub1 could have a specific function by supporting spliceosomal activity 
and robustness at problematic splicing events to ensure accurate progression 
through the splicing cycle. Then, Hub1 would be crucial for splicing of a number of 
certain particularly sensitive pre-mRNAs or introns and functions in human cells. 
Thus, the previously identified Hub1-dependent transcripts were re-examined 
and tested for intron-retention or mis-splicing, now including exon-intron boundaries 
of the flanking sequences. Several primer pairs were used in various combinations 
covering neighboring exons within the Akt, AurkA and Mcl-1 genes, respectively 
(Figure 24b, primer positions indicated as arrowheads in schematic representation of 
transcripts). If Hub1 depletion would lead to general splicing defects and insufficient 
removal of intronic sequences unspecifically, RT-PCR analysis would detect larger 
transcripts constantly, as additionally retained introns increase PCR product size. 
While in control samples exclusively maturely spliced products were detectable, in all 
cases Hub1 knockdown-induced altered splicing patterns were reproducibly intron-
specific. With PCR primers located in neighboring exons spanning additional flanking 
exons and introns, no further size shift of mRNAs was identified in RT-PCR assays. 
For example, analysis of Akt transcripts confirmed the intron-retention between exon 
11-12 upon Hub1 RNAi and a enlarged PCR product corresponding to the size of 
exon 11-intron-12 was detected. However, when primers were positioned in flanking 
exons like exon 10 and exon 13 spanning the critical exon-intron boundaries, 
transcripts show the same enlargement with no additional sequence elements 
retained in the transcript. This specificity for individual splice events was shown for 
AurkA (exon 9-10) and Mcl-1 (exon 1S-2) pre-mRNAs as well.  
In subsequent RNAi experiments, the specificity of Hub1 for particular splicing 
events was compared to important splicing factors like the tri-snRNP hSnu66 or the 
SR protein Son (Figure 24b, upper left panel immunoblot for knockdown efficiency). 
Son has been reported to bind pre-mRNA directly via its RS- and RB (RNA binding) 
domains, but furthermore facilitates association of other SR proteins with weak splice 
sites (Ahn et al., 2011; Sharma et al., 2011). Interestingly, the aberrant splicing 
pattern in Hub1-depleted cells was not identical to that of hSnu66 or Son. On the one 
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hand, both knockdown of Hub1 and hSnu66 negatively affected splicing of particular 
introns in AurkA and Mcl-1 transcripts, which were not altered upon Son RNAi. On 
the other hand, hSnu66 RNAi affected Akt splicing marginally, while splicing defects 
were prominent after Son and Hub1 knockdown. 
Moreover, characterization of several exons revealed a novel alternatively spliced 
isoform of AurkA, as exon 5 is excluded in the upstream 5’ region when Hub1 is 
depleted, but not in hSnu66 or Son RNA samples (Figure 24b).  
Finally, after the identification of aberrantly spliced transcripts and 
characterization of Hub1-specific splicing events, the question remained, which 
functional surface is necessary on Hub1 to mediate the crucial splicing activity. Thus, 
RNAi complementation in U2OS cells stably expressing siRNA-resistant GFP-Hub1, 
GFP-Hub1 D22A, Hub1-GFP or free GFP was combined with splicing assays, where 
AurkA, Mcl-1 and Akt mRNAs were subjected to intron-spanning RT-PCR (Figure 
24c). When Hub1 was depleted by RNAi in GFP control cells, transcripts of AurkA, 
Mcl-1 and Akt with intron-retention and altered splicing patterns were detected. This 
splicing defect was fully rescued when GFP-Hub1 was expressed and pre-mRNAs 
were efficiently and faithfully processed. In addition, the hSnu66-binding mutant GFP-
Hub1 D22A was also able to restore splicing activity, indicating that physical 
interaction of Hub1 with the tri-snRNP component might contribute, but is not 
essential for this process. In contrast, C-terminally tagged Hub1-GFP failed to 
complement the splicing defects and mis-spliced transcripts accumulated, 
comparable to Hub1 knockdown cells (GFP only).  
 
4.16 Identification of Hub1-dependent alternatively spliced transcripts 
by exon-specific microarray analysis 
During developmental stages and upon certain stimuli like growth factors or cellular 
stress human cells can react by various response pathways. In addition to 
transcriptional regulation, the mRNA repertoire is extended by alternative splicing in 
order to generate different isoforms from the same pre-mRNA. A widely used, 
sophisticated method to identify alternative splicing events is based on exon-specific 
microarray platforms (Cuperlovic-Culf et al., 2006). The Affymetrix Human Exon 1.0 
ST Array combines validated cDNA-based sequences from various mRNA and EST 
databases with predicted gene structures from bioinformatics analyses in genome 
projects like Ensembl, Vega or GENSCAN, allowing the identification of previously 
unknown splice variants. In contrast to 3’ expression analysis, here, probe sets target 
all exons along the entire length of the transcript with at least four probes per exon, 
probing more than one million exons (Gardina et al., 2006).  
This microarray was utilized to unbiasedly characterize global changes in 
alternative splicing in human cells upon Hub1 depletion. Therefore, in three 
independent experiments total RNA was isolated from Hub1 or control RNAi treated 
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U2OS cells 60 h post transfection, when Hub1 depletion was accomplished, but cells 
did not exhibit any signs of cellular stress, nuclear degeneration or apoptosis as 
confirmed by microscopy and flow cytometry. After satisfying the quality control 
criteria, the isolated total RNA was reversely transcribed to synthesize cDNAs, which 
were then fragmented into hybridization-compatible samples and fluorescently 
labeled for hybridization with the microarray. Subsequently, exon-specific probes on 
the microarray chip specifically bound to complementary sequences within the cDNA 
samples and the fluorescent signal was detected and quantified. Sophisticated 
bioinformatics analysis based on the ARH entropy function (Rasche and Herwig, 
2010) compared the individual exon expression levels and quantified the alternative 
splicing patterns in RNA samples from control RNAi treated cells versus Hub1 
knockdown cells. RNA quality control, labeling, microarray hybridization and initial 
microarray analysis was conducted by Atlas Biolabs GmbH (Berlin).  
In Figure 25a representative graphs of three candidate transcripts (Lama5, 
DPP10 and TCEA2) with high confidence hits for splicing alterations upon Hub1 
depletion are depicted. The relative exon expression of each transcript-specific exon 
probe was calculated for control (red line) and Hub1 (“treatment”, blue line) RNAi 
treated samples. The amplitude of difference between each exonic probe of control 
and Hub1 knockdown samples is represented as the splice index. Among the first 
100 high confidence transcripts with altered exon expression the majority of 
transcripts (68%) showed a decrease of exon probe signal in Hub1 samples. In 25% 
of the cases exon probes detected increased levels of targeted RNA sequences in 
Hub1 knockdown cells in comparison to control cells. 3% of the probe set showed 
strong fluctuations or alterations in both directions (4%) within the same transcript. As 
shown previously in minigene assays, the laminin 5 alpha transcript is alternatively 
spliced upon Hub1 knockdown (see Figure 24a). In line with this finding, exon probes 
targeting Lama5 transcripts (probe ID: 987232-9872324; position in exon 63-65) 
reported a strong difference in relative exon expression resulting in high splice index 
values (SI ≥ 8) due to low signals in Hub1 RNAi samples. Similar changes in relative 
exon expression patterns upon Hub1 depletion are exemplified for DPP10 and 
TCEA2 gene products (Figure 25a).  
Based on bioinformatics analysis, genes listed in Figure 25b resemble the top 
50 candidate transcripts exhibiting splicing alterations upon Hub1 depletion in U2OS 
cells, ranked according to their splice index and high confidence score. Interestingly, 
these Hub1-dependent genes appear to be not functionally linked, but rather 
implicated in diverse cellular pathways like G-protein signaling (RGS3), DNA damage 
repair (BRCA1), transcription elongation (TCEA2), cytoskeletal architecture (Lama5, 
Col3A1, EML1) and uncharacterized functions (DPP10, HPS1, HYSL1) (see 
appendix 12.1 for comprehensive microarray data). 
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 In addition to the advanced, in-depth bioinformatics analysis mentioned 
above, the genome-wide exon expression and splice index analysis identified more 
than 3000 altered splice events in total after Hub1 RNAi (Figure 25c). This data 
further corroborated the global impact of Hub1 function on a broad spectrum of 
distinct splicing events and its pivotal role in pre-mRNA processing and alternative 
splicing in human cells. 
Figure 25: Exon-specific microarray revealed global alterations in alternative splicing and mRNA 
expression upon Hub1 depletion 
a) Splice index profile of three candidate transcripts with high confidence hits for splicing alterations 
upon Hub1 depletion (Lama5, DPP10 and TCEA2). Exon-specific probe IDs and their relative positions 
on the targeted transcript are given on the X-axis. The relative exon expression for control samples (red 
line) and Hub1 RNAi samples (“treatment”, blue line) are plotted on the Y-axis (log). The amplitude of 
difference between each exonic probe of control and Hub1 knockdown samples is represented as the 
splice index graph (black line). b) Ranking of top 50 high confidence hits with significant splicing 
alterations upon Hub1 depletion. GeneID and splicing index values of affected transcripts are shown.  
c) Global exon expression and splice index analysis of the exon ST microarray (core) datasets using 
AltAnalyzer software. Basic exon expression profiling and signal processing of control and Hub1 RNAi 
sample datasets from three biological replicates using MiDAS and DABG detection parameters revealed 
over 3226 altered splice events in Hub1-knockdown cells (filtered for DABG and MiDAS p> 0.05 each). 
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d) Alteration in mRNA expression after depletion of Hub1. mRNA expression profiles of Hub1 and 
control RNAi U2OS cells were analyzed by exon-microarray. The heat map shows a two-dimensional 
clustering of top 100 genes with changes in mRNA expression represented by high (red) and low 
(green) intensities, where black indicate no changes in intensities, for 337 transcripts with increased 
levels (≥ 2 fold) and 1172 different mRNAs down-regulated (≤ -2 fold).   
 
 In addition to its primary quantification of probe-specific relative exon 
expression, the microarray yielded further information about global transcriptional 
alterations. When the abundance of gene products expressed in Hub1 knockdown 
cells were compared to control cells, 337 transcripts with increased levels (≥ 2 fold) 
were identified, whereas the majority of transcripts (1172 different mRNAs) was 
down-regulated (≤ -2 fold). Figure 25d summarizes the mRNA expression analysis 
graphically as a heat map showing the quantification of the 100 strongest induced 
and repressed genes, respectively.  
The combination of splicing-specific microarray data and gene expression 
analysis strongly indicates global changes in mature mRNA synthesis upon in vivo 
depletion of Hub1. The decrease in mRNA levels and aberrant splicing of Hub1-
dependent transcripts argue for a crucial role of Hub1 in faithful pre-mRNA 
processing. 
 
4.17 Antagonistic interactions between the transcription inhibitor 
actinomycin D and Hub1 RNAi 
Based on the molecular and cell biological characterization of Hub1 and its impact on 
cell viability in RNAi experiments, it was of interest to identify a chemical compound 
or regulatory proteins that modulate the Hub1-dependent cellular activity or pathway 
and can suppress the Hub1-depletion phenotypes. Two approaches were used to 
address this point: on the one hand, co-depletion of regulatory splicing-associated 
factors by RNAi, and, on the other hand, established inhibitory drugs targeting 
different cellular pathways were tested in Hub1 RNAi experiments. Among others, 
transcription inhibitors (actinomycin D, α-amanitin or DRB (5,6-dichloro-1-beta-D-
ribofuranosylbenzimidazole), caspase inhibitors (Z-VAD-FMK), kinase inhibitors (Clk-
inhibitor TG003, roscovitine, staurosporine, CHK2 inhibitor II) or cell cycle restrictive 
substances (thymdine, hydroxyurea, nocodazole, aphidicolin) were applied. From this 
list, two compounds gave particularly interesting results, the anti-apoptotic pan-
caspase inhibitor Z-VAD-FMK and the transcription inhibitor actinomycin D.  
Blocking the apoptotic cascade by the inhibition of caspases 1, 3, 6, 7, 8 and 
9 (Wood and Shillitoe, 2011; Yang et al., 2003) using the tri-peptide Z-VAD-FMK (N-
benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone) suppressed the induction of cell 
death in Hub1 knockdown cells in caspase cleavage assays as well as microscopy 
and flow-cytometry analyses (data not shown). This further supports the model that 
at late stages of Hub1 knockdown, cells facing profound cellular and mitotic defects 
undergo caspase-dependent cell death (Castedo et al., 2004). Accordingly, when 
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untreated and Z-VAD-FMK-treated Hub1 RNAi cells were examined under the 
microscope, in both samples cells with segmented and disintegrated nuclei were 
detected (as described in section 4.11). However, after caspase inhibition a high 
number of cells exhibiting this fatal loss of genome integrity accumulated in Hub1 
knockdown samples, as the terminal consequence with the induction of apoptotic cell 
death was suppressed by the pan-caspase inhibitor, although the cause of the 
cellular defects upon Hub1 depletion persisted. Thus, Hub1 depleted cells survived, 
despite their severe damage and genomic instability and were not eliminated from 
the population by apoptosis.  
 In contrast to Z-VAD-FMK, which acts on signaling events at late stages of 
Hub1 RNAi-mediated cellular defects, actinomycin D treatment alleviated those Hub1 
depletion phenotypes at earlier stages. Actinomycin D has been described to bind 
DNA directly and thereby inhibit RNA-polymerase II-dependent RNA synthesis by 
blocking transcription elongation (Sobell, 1985; Hollstein, 1974). In the initial 
screening after 48 h of Hub1 knockdown cells were treated with ActD or the vehicle 
DMSO and their cell cycle profile as well as the apoptotic fraction were analyzed by 
flow cytometry (Figure 26a). While both control cell sample profiles with DMSO or 
ActD remained largely unaffected, the DMSO treated Hub1 RNAi sample reproduced 
the characteristic cell cycle arrest at G2/M phase. Surprisingly, the G2/M arrest was 
not triggered in Hub1 knockdown cells, when cells were treated with actinomycin D, 
resulting in a normal inconspicuous cell cycle profile with high G1 and low G2 
populations in spite of Hub1 depletion (for quantification see graph in Figure 26a).  
To further investigate this rescuing effect, later RNAi time points were 
examined after incubation with increasing concentrations of the drug. After prolonged 
incubation the inhibitory activity of actinomycin D showed cytotoxic effects in various 
mammalian cell lines (Bacchetti and Whitmore, 1969; Cassé et al., 1999), thus, a 
dose-dependent increase of the apoptotic sub G1 fraction was emerging in control 
RNAi cells, which was virtually absent in DMSO control samples (Figure 26b and 
quantification in lower panel). 
In vivo depletion of Hub1 alone was sufficient to induce the apoptotic cascade 
after cellular defects and cell cycle arrest, thus the corresponding sub G1 fraction 
was evident after 60 h of Hub1 RNAi and DMSO treatment. Surprisingly, in contrast 
to control cells, where increasing concentrations of ActD were accompanied by an 
increase in apoptotic cell fraction, actinomycin D treatment resulted in a partial 
rescue of the cytotoxicity in Hub1 knockdown cells. Here, incubation with higher 
concentrations of the transcription inhibitor resulted in a decline of the apoptotic sub 
G1 fraction and improvement of G1 and G2 populations (Figure 26b). The 
quantification of the flow cytometry data (Figure 26b, lower panel) illustrates the 
opposing sensitivities of control and Hub1 RNAi cells to actinomycin D treatment 
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Figure 26: The transcription inhibitor actinomycin D alleviates fatal Hub1 depletion phenotypes 
Cell cycle analysis of Hub1 knockdown cells after inhibition of transcription by actinomycin D. a) 48 h 
after Hub1 or control RNAi transfection HeLa cells were incubated with actinomycin D (ActD) or DMSO 
control for 6 h, then fixed and stained for FACS analysis. Cell cycle profiles and corresponding 
quantification graph (below) are shown. b) HeLa cells were transfected with Hub1 or control (lamin A/C) 
siRNA. After 60 h cells were incubated with DMSO, 1.25 μM, 2.5 μM, 5 μM or 10 μM actinomycin D 
(ActD) and 6.25 μg/ml, 12.5 μg/ml, 25 μg/ml μM or 50 μg/ml α-amanitin, respectively, for 6 h, fixed and 
stained for flow cytometry analysis. Cell cycle profiles and corresponding quantifications are shown. c) 
Caspase activation after Hub1 RNAi and drug treatment. Control and Hub1 knockdown cells were 
treated (like in b) and subjected to luminescent reporter assays monitoring caspase cleavage activity. 
 
 Moreover, this rescuing property is specific for ActD in Hub1-knockdown cells 
and not a general feature to transcription inhibitors. In analogous experiments 
conducted with alternative compounds like α-Amanitin (Figure 26b, right panel), 
which interferes with RNA Pol II translocation during RNA synthesis (Bushnell et al., 
2002; Gong et al., 2004) or DRB (data not shown), an inhibitor of the transcription 
associated kinases CDK9 and CDK7 (Yankulov et al., 1995; Zandomeni et al., 1982), 
neither of these drugs showed similar properties and even aggravated the Hub1 
phenotype. 
Using an alternative method to quantify the antagonistic effect of actinomycin 
D treatment, the caspase activity was measured in Hub1 knockdown or control cells 
after drug treatment. In a luminescent assay the proteolytic cleavage of a reporter 
substrate by activated caspases (effector caspase 3 and 7) was measured to monitor 
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the induction of the apoptotic cascade (Figure 26c). In DMSO treated control cells 
caspase cleavage was low, but ActD treatment strongly induced caspase activity, 
hence, apoptosis was induced upon transcription inhibition. Here, the Hub1 RNAi 
treated cells showed the contrary behavior. In line with aforementioned data, Hub1 
depletion alone (DMSO treated sample) already caused a significant induction of 
caspase cleavage and apoptosis. Consistent with the flow cytometry data, 
actinomycin D treatment suppressed caspase activation in Hub1 knockdown cells 
and vice versa. The application of the alternative transcription inhibitor α-Amanitin, 
however, affected both control and Hub1 RNAi cells equally and gave similar results 
in caspase activation assays. 
This data reveals that treatment with the drug actinomycin D can partially antagonize 
Hub1 depletion-mediated cell cycle and apoptosis phenotypes. At the same time, 
Hub1-depleted cells appear to be slightly desensitized to actinomycin D’s cytotoxicity, 
as observed in flow cytometry and caspase cleavage assays. 
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5 Discussion 
Previous work on the ubiquitin-like protein Hub1 has mainly focused on lower 
eukaryotes using model organisms like S. cerevisiae and S. pombe (Luders et al., 
2003; Wilkinson et al., 2004; Yashiroda and Tanaka, 2004; Mishra et al., 2011). Now, 
over 10 years after its discovery, still little is known about Hub1, especially regarding 
higher eukaryotes and mammalian cells. Although Hub1 has been implicated in the 
signal transduction during mitochondrial unfolded protein response, metabolic 
regulatory circuits and lipid metabolism, the cellular and molecular functions of the 
unconventional ubiquitin-like protein Hub1 has remained obscure. This work presents 
the first direct and detailed characterization of Hub1 in human cell lines addressing 
various aspects of interaction studies, functional analysis and in vivo depletion 
experiments.  
 
5.1 Identification of binding factors by yeast two-hybrid link Hub1 to 
splicing-associated complexes 
An unbiased and comprehensive approach to identify protein interaction partners of 
Hub1 was based on the powerful yeast two-hybrid (Y2H) system combined with 
human cDNA libraries. After over 300 clones encoding potential interaction partners 
were isolated from the initial screen, stringent criteria and tests like auto-activation 
after FOA-shuffle, 3-AT resistance, or growth on adenine-lacking (-Ade) media were 
applied to define high confidence hits. Interestingly, the identified candidates 
resembled a heterogeneous group of proteins functioning in endocytosis (adapter 
protein complex AP-2 β subunit 1 α (AP-2β1α), as actin-binding cytoskeleton proteins 
(tropomyosin 2 β (TPM2β), SUMO/ubiquitin-specific peptidases (USPL1), 
serine/threonine-protein kinases (PIM-2), Golgi-associated proteins (Golgin a 5) and 
zinc-finger transcription factors (HIV-EP1) (Figure 1b). Despite extensive in silico 
analysis, a potential canonical Hub1 interaction motif common to all candidate 
proteins could not be recognized by sequence similarity or protein domain structure 
comparison. 
Among these Hub1 binding factors, two splicing-associated factors, namely 
the spliceosomal tri-snRNP protein hSnu66 and the Cdc2/Cdc28-like dual specificity 
protein kinase Clk3, were of particular interest. On the one hand both factors have 
been implicated in pre-mRNA splicing in human cells (Makarova et al., 2001; Duncan 
et al., 1997), on the other hand, these factors have been reported to interact with 
human Hub1 in yeast two-hybrid previously (Wilkinson et al., 2004; Kantham et al., 
2003), and thereby served as an internal positive control affirming validity of the 
screening results. Surprisingly, neither the mode of interaction nor the in vivo 
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relevance of binding to the ubiquitin-like protein was further investigated to elucidate 
the cellular function of Hub1 in these studies. 
Due to the nature of Y2H cDNA libraries that base upon reverse transcription 
of tissue specific mRNAs, the spectrum of expressed transcripts is naturally limited to 
the selected cell types and thereby cannot comprise the whole human proteome. In 
consideration of this fact and the stringent screening criteria applied, it is likely that 
there are more Hub1 interaction partners remaining to be characterized by alternative 
techniques.  
Although the yeast two-hybrid system has its disadvantages, as heterologous 
overexpression of human proteins in yeast does not ensure proper folding and 
functionality of all prey AD fusion proteins and auxiliary factors like required 
chaperones or posttranslational modifications can be missing, this unbiased 
approach provided an first important hint for the identification of interaction partners.  
Despite Hub1’s high conservation from yeast to human, when the identified 
candidates were tested with HUB1 orthologs from S. cerevisiae, S. pombe and H. 
sapiens in Y2H interaction studies, the spliceosomal tri-snRNP protein hSnu66 
appeared to be the only common binding partner of all Hub1 variants (Figure 1c). 
This finding suggests that the association of Snu66 with Hub1 evolved early in 
eukaryotic evolution. Thus, Snu66 might be a primordial binding partner of Hub1 with 
strong implications in pre-mRNA processing.  
In contrast, bioinformatics analysis could not clearly identify homologous 
proteins of the other novel Y2H binders in S. cerevisiae, which might explain why 
neither ScHub1 nor SpHub1 have acquired protein properties necessary for these 
interactions. However, in S. pombe pre-mRNA splicing is facilitated by auxiliary 
splicing factors like hnRNP-like proteins (Stutz et al., 2000), SR proteins (Srp2p 
(Webb et al., 2005)) and their respective kinases, Cdc2/Cdc28-like protein kinase 
Kic1 and SR protein kinase 1 homolog Dsk1 (Tang et al., 2003; 1998). Kic1 shows 
high similarity to the conserved class of LAMMER kinases Clk1-Clk4 of which human 
Clk3 was isolated as a Hub1 interactor in the Y2H screen. Despite the fact that 
fission yeast has developed regulatory RNA sequence elements for trans-acting 
factors like SR proteins that have not been identified in S. cerevisiae, both HUB1 
orthologs ScHub1 and, in particular, SpHub1 failed to bind the human Clk3 in yeast 
two-hybrid.  
Like transcription, pre-mRNA splicing is an essential cellular process to 
ensure faithful processing, maturation and proper translation of the transcript to give 
rise to functional proteins. On the other side the ubiquitin-proteasome-system 
facilitates the efficient removal of abnormal, defective or undesired proteins by 
targeting doomed substrates for proteolysis. The covalent attachment of ubiquitin to 
proteins by an enzymatic cascade specifically marks proteins for degradation by the 
proteasome (Ciechanover, 2005; Peters, 1994). Besides serving as degradation 
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signals for proteolysis, ubiquitin and ubiquitin-like proteins were shown to play pivotal 
roles in virtually all cellular processes e.g. endosomal trafficking, autophagy, signal 
transduction, DNA replication and repair, transcription, cell cycle and cytokinesis 
(Grillari et al., 2010; van der Veen and Ploegh, 2012). Surprisingly, pre-mRNA 
splicing accomplished by its macromolecular machine, the spliceosome, has been 
widely excluded from this list.  
Here, initial results demonstrating an interaction of the ubiquitin-like protein 
Hub1 with a core-spliceosomal protein hSnu66, raised several important questions. 
Firstly, does Hub1 bind hSnu66 directly and what is the molecular mode of 
interaction? Secondly, which cellular pathways is Hub1 implicated in and does this 
association with a spliceosomal factor accord with a potential function of Hub1 in 
human pre-mRNA splicing? And thirdly, the fundamental question, that had to be 
addressed, does Hub1 fulfill an essential role in human cells and how do cells 
respond to the inactivation of Hub1? 
 
5.2 Hub1 binding is mediated via a conserved Hub1 interaction 
domain in hSnu66 
Translating the findings from the heterologous yeast two-hybrid to the mammalian 
system, co-immunoprecipitation experiments with transiently transfected human cells 
validated the association of Hub1 with hSnu66 in vivo. The immunoprecipitation of 
epitope-tagged hSnu66 co-purified with Hub1 and vice versa (Figure 2).  
In initial studies the Hub1 binding factor hSnu66 was characterized as a 
crucial constituent of the spliceosomal tri-snRNP complex (Makarova et al., 2001). 
Immunodepletion of hSnu66 from human nuclear extracts inhibited subsequent 
mRNA splicing reactions, and this activity could be re-established by supplementing 
the depleted extract with recombinant hSnu66 protein, which underscores its 
essential function in pre-mRNA splicing in vitro. Moreover, hSnu66 plays a 
particularly interesting role, as it is not part of pre-existing U5 or U4/U6 snRNP sub-
complexes, but rather associates late during tri-snRNP assembly. These findings are 
supported by interaction and mapping studies analyzing the U4/U6.U5 tri-snRNP 
framework (Liu et al., 2006). Here, hSnu66 was shown to bind to the core 
components like the U4/U6 protein PRPF3, the U4/U6 and U5 bridging factor PRPF6, 
and central DExH/D-box helicase hBrr2, but not U5 key protein PRPF8. However, the 
important questions, how binding to these factors is mediated and which domains 
within hSnu66 are crucial for these interactions were not addressed. When 
biochemical analysis and purification of spliceosomal complexes at distinct stages of 
splicing catalysis were combined with sophisticated mass spectrometry approaches, 
hSnu66 was shown to be incorporated into the tri-snRNP, in pre-catalytic B 
complexes and activated spliceosomes (Bact complex) of human nuclear splicing 
extracts (Makarov et al., 2002; Bessonov et al., 2010; Agafonov et al., 2011). hSnu66 
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is thought to be an important factor mediating protein-protein interactions for the 
recruitment of the tri-snRNP to join the pre-spliceosomal complex A, when U1 and U2 
snRNPs are already loaded on pre-mRNA, to stably form the pre-catalytic complex B. 
In addition to its splicing-associated function, hSnu66 has been discussed to act as a 
transcription activator of hypoxia-responsive genes, namely erythropoietin (EPO) and 
vascular endothelial growth factor (VEGF) (Gupta et al., 2000). In fact, hSnu66 might 
also function as a regulatory switch between hypoxia-induced factors (HIF1α and 
HIF2α) upon hypoxia (Koh et al., 2008; 2011), but the molecular mechanism of this 
regulatory circuit and if these effects are linked to mRNA splicing remains unclear. 
Notably, among other tri-snRNP factors like PRPF3, PRPF8 or PRPF31 hSnu66 is 
considered as a disease-relevant gene during hypoxia-induced retinal degeneration 
in autosomal dominant retinitis pigmentosa patients (Schmidt-Kastner et al., 2008). 
Furthermore, hSnu66 (alias SNRNP110 or SART1 (squamous cell carcinoma antigen 
recognized by T cells)) is implicated in various aspects of tumorigenesis as it is 
significantly up-regulated in various cancer tissues (Takaishi et al., 2008; Matsumoto 
et al., 1998; Kawamoto et al., 1999) and has been identified as an autoimmune 
epitope which is recognized by tumor-specific cytotoxic T lymphocytes (Kikuchi et al., 
1999; Yoshida and Tanaka, 2004).  
Structure prediction and bioinformatics analysis have elucidated that hSnu66 
is an intrinsically unstructured protein with low complexity regions and belongs to the 
group of highly disordered proteins in the spliceosomal proteome (Korneta and 
Bujnicki, 2012). In fact, compared to other ribonucleoprotein-based “molecular 
machines” the spliceosomal complex is comprised of more intrinsically unstructured 
and disordered proteins than for example the ribosome. Due to complex RNA-RNA, 
protein-RNA and protein-protein interaction networks and major rearrangements 
during the transesterification steps, structural flexibility of spliceosomal factors for 
different conformational stages is necessary. Thus, SR-related proteins like hSnu66 
involved in mRNA recognition, intron/exon definition and spliceosomal assembly tend 
to be more disordered than splicing factors that carry out the splicing catalysis 
(Korneta et al., 2012). Furthermore, the formation of intricate protein-RNA complexes 
like snRNPs is facilitated and coordinated by molecular chaperones to prevent 
premature assembly or aggregation. For example, the specialized chaperone plCln 
orchestrates the Sm ring formation on snRNA, while other auxiliary factors like Aar2 
support correct incorporation of large multidomain proteins including PRPF8 into 
functional U5 and tri-snRNPs, respectively (Chari et al., 2008; Weber et al., 2011; 
Sahi et al., 2010). 
However, hSnu66 contains several short motifs, which underscore its nucleic 
acid-directed function, as the putative leucine zipper, the engrailed homology domain 
1 and the nuclear localization signal can mediate direct contact with DNA, whereas 
its N-terminal RS-domain is involved in RNA related processes. Both, LZ and EH1 
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domains, have been identified and characterized as DNA binding domains in 
transcriptional regulators where they can act alone or in concert with co-activators or 
repressors like the mammalian Groucho to control gene expression (Kutay and 
Güttinger, 2005; Struhl, 1989; Goldstein et al., 2005; Copley, 2005; Makarova et al., 
2001). With respect to its aforementioned putative role in transcription of e.g. 
hypoxia-induced genes, an additional role for hSnu66 in transcriptional regulation 
cannot be ruled out, but both aspects require further investigation.  
The N-terminus of hSnu66 reveals another interesting domain, the arginine-
serine rich domain. In contrast to yeast ScSnu66, the human ortholog hSnu66 gained 
this additional domain that is widely distributed among splicing factors. The over 240 
RS-domain-containing proteins are interwoven with diverse functions during mRNA 
processing like splicing, mRNA export, regulating kinase and phosphatase activity, 
translation, transcription, and RNA Polymerase CTD binding (Tarn and Steitz, 1994; 
Huang et al., 2004; Stojdl and Bell, 1999; Sanford et al., 2004; McCracken et al., 
1997). Notably, arginine-serine rich domains can stimulate direct binding to mRNA, 
e.g. at regulatory exonic enhancer sequences (Hertel and Graveley, 2005; Shen et 
al., 2004), but can serve as platforms for protein-protein interactions as well 
(Graveley, 2004; Kohtz et al., 1994; Wu and Maniatis, 1993). Interestingly, several 
RS-domains do not only anchor the SR protein to certain RNA sequences or binding 
partners, they also appear to have intrinsic splicing-stimulatory activities. Isolated 
RS-domains are sufficient to activate splicing in HeLa cell nuclear extracts if they are 
artificially tethered to pre-mRNAs that contain splicing enhancer sequences (Shen 
and Green, 2006; Philipps et al., 2003). In fact, RS-domain proteins play important 
roles during early steps of spliceosome assembly and orchestrate the communication 
between 5’ and 3’ splice site during early spliceosome assembly (Fu, 1995; Ram and 
Ast, 2007). Although the snRNA of the U1 snRNP is able to base-pair with 5’ splice 
sites of pre-mRNA exons, a stable association is only established by protein-protein 
and protein-RNA contacts between RS proteins like ASF/SF2 and the SR-related 
factor U1-70k (Kohtz et al., 1994). Furthermore, the inactivation of nuclear splicing 
extracts by depleting the U1 snRNP can be complemented by the addition of purified 
SR proteins that restore splicing activity (Stark et al., 1998; Crispino et al., 1994; Tarn 
and Steitz, 1994).  
Surprisingly, although hSnu66 associates with central tri-snRNP proteins and 
is implicated in central steps of mRNA splicing, little is known about the molecular 
mechanism of hSnu66 and its function is poorly understood. The interaction with the 
ubiquitin-like protein Hub1 is an intriguing feature of hSnu66. In order to identify 
which domain or motif is crucial for Hub1-hSnu66 interaction, mapping studies with 
several hSnu66 truncations were performed. Surprisingly, not the central LZ or EH1 
domains but the hSnu66 N-terminal fragment (AA1-185) comprising the RS-domain 
and the highly conserved stretch of 18 AA (AA111-139) was able to bind and co-
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purify with Hub1. Although RS-domains are well-known protein interaction module, 
further dissection of the N-terminus revealed that a short, highly conserved stretch 
within hSnu66 was already sufficient and necessary for the interaction with Hub1 
(Figure 3b). Despite the clean and precise mapping of this interaction interface, co-
immunoprecipitations of overexpressed fusion proteins can be bridged by co-
purifying factors or chaperones. Therefore, direct binding was further confirmed by 
GST pull down assays with recombinant Hub1 and the isolated binding motif, HIND, 
as a GST fusion (Figure 3c).  
Interestingly, this HIND domain is highly conserved among hSnu66 orthologs 
from yeast to humans. In Snu66 of S. cerevisiae and some other Saccharomycotina, 
two HINDs are positioned in tandem at the very N-terminus, but they lack the RS-
domain, which is a common domain among all vertebrate Snu66 orthologs (Mishra et 
al., 2011). The Hub1 interaction domain is an intriguing module; while 
Saccharomycotina have evolved the tandem HIND, higher eukaryotes up to 
vertebrates express single HIND versions of Snu66. However, plants like Arabidopsis 
thaliana lack the Hub1 interaction domain in AtSnu66, but this is compensated by the 
translocation of the HIND to another tri-snRNP protein, PRP38. Surprisingly, in the 
protozoan parasite Plasmodium falciparum, both tri-snRNP proteins Snu66 and 
PRP38 contain HIND sequences, which bind Hub1 (Mishra et al., 2011). This 
phenomenon might be due to the complex evolutionary origin of apicomplexa with 
characteristics of protists and features of photosynthetic algae (Gould, 2012).  
The functionality of these “unusual” HINDs in AtPRP38, PfPrp38 and PfSnu66 
was verified by GST pull down assays and yeast two-hybrid interaction studies (data 
not shown, (Mishra et al., 2011)). Even when Hub1 activity was constrained by 
linearly fusing it to various tri-snRNP proteins like PRP38, Snu66 or PRP8, artificial 
tethering of Hub1 to the now fully “Hub1-modified” spliceosome was able to 
complement the SRC1 alternative splicing defect in S. cerevisiae hub1Δ strains. This 
phenomenon suggests that Hub1 binding is not crucial for its respective direct 
binding partner, but rather for the functional complex within the spliceosome.  
Due to the unique features of Hub1 as an unusual ubiquitin-like protein 
implicated in interactions with spliceosomal core components, the crystal structure of 
human Hub1 in complex with the hSnu66 HIND was solved in order to obtain 
molecular insights into this mode of binding. During this project, the human Hub1-
HIND complex structure was resolved in parallel with its yeast homolog (Mishra et al., 
2011), which allowed a direct comparison of conserved but also unique features of 
this interaction interface. The obtained structure with a resolution of 2 Å highlights 
human Hub1 sharing the characteristic β-grasp fold similar to ubiquitin and ubiquitin-
like proteins with their typical ββαβαβ secondary structure pattern, as described 
previously (McNally et al., 2003) (Figure 4a).  
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In addition, the HIND itself exhibits an interesting feature, as the short 18 AA 
peptide has the intrinsic ability to form an α-helical secondary structure in solution 
(Mishra et al., 2011). The interaction interface between the human HIND and Hub1 is 
mediated via a salt bridge between R127 of hSnu66 HIND and D22 of Hub1 
accompanied by several hydrophobic contacts formed by aliphatic residues. This 
structure clearly reveals the nature of the non-covalent mode of binding and 
elucidates crucial residues responsible for a stable interaction between human Hub1 
and Snu66. In both Snu66-Hub1 interfaces the binding is strengthened by the central 
salt bridge and supported by accompanying hydrophobic contacts. The structural 
comparison of human and yeast Hub1-HIND complexes emphasizes the similarity of 
the two superimposable structures indicating the high evolutionary conservation of 
the complex at molecular level (Figure 4b).  
Compared to non-covalent binding interfaces of ubiquitin and ubiquitin-like 
proteins, the Hub1-HIND structure highlights an unique mode of interaction and a 
novel binding paradigm. Several ubiquitin binding domains (UBDs) have been 
identified and crystalized in complex with the ubiquitin protein (Dikic et al., 2009). The 
UBDs can be grouped according to their structural binding properties and come in 
different flavors; domains like the UBA (ubiquitin associated domain), Cue (named 
after Cue2) and various types of ubiquitin interaction motifs (UIMs like double sided 
UIM (DUIM) or inverted UIM ubiquitin interaction motifs MIU) utilize single or multiple 
α-helices to generate an interaction platform for ubiquitin binding. Another module for 
interaction is formed by zinc finger domains like the nuclear protein localization 4 zink 
finger (NZF) or zinc finger ubiquitin binding protein A20 (ZnF A20). Furthermore, the 
pleckstrin-homology fold is a common feature of GLUE (GRAM-like ubiquitin binding) 
and PRU (pleckstrin-like receptor for ubiquitin) UBDs that are found in EAP45 and 
RPN13, respectively. Two other domains (UBC and UEV) mimic the ubiquitin 
interaction interface of E2 conjugating enzymes to mediate binding by but lacking 
catalytic activity of the respective enzymes. Finally, beside these classical UBDs 
further variously shaped ubiquitin-interaction modules like the Jab/MPN domain in 
PRPF8 were identified (Husnjak and Dikic, 2012). The vast majority of UBDs 
associate with ubiquitin via the hydrophobic area around I44 supported by L8 and 
V70 on sheets β3β4 (Dikic et al., 2009). In contrast, the Hub1-HIND interaction 
surface is located on the opposing side to the canonical UBD patch formed by helix 
α1 and sheets β1β2 (Mishra et al., 2011). Both ubiquitin and Hub1 adapt their 
conformation and undergo an induced fit upon interaction with their respective 
interaction domains, but their main-chain fold remains unchanged (Lange et al., 
2008; Wlodarski and Zagrovic, 2009). Moreover, the Hub1-HIND complex also clearly 
differs from the non-covalent interaction of other ubiquitin-like modifiers like SUMO 
with its SIM (SUMO interaction motif) (Song et al., 2005; Hecker et al., 2006) and the 
Atg8 homolog LC3 with its interaction region (LIR) (Noda et al., 2010).  
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Despite the detailed information obtained in binding studies and the crystal 
determination, the structure only includes the isolated HIND peptide while flexible 
flanking regions of hSnu66 are missing. Therefore, it remains unclear how Hub1 is 
imbedded into lager complexes e.g. with Snu66 in the spliceosomal context. 
Heteronuclear single quantum coherence (HSQC) data of recombinant yeast 
ScSnu66 affirmed the largely unstructured nature of the full-length protein. 
Remarkably, upon addition of its binding partner Hub1, the spectrum of the N-
terminal region containing the two HINDs changes drastically, showing that Hub1 
binding induces folding of the otherwise unstructured protein (Mishra et al., 2011). 
During the different steps of splicing the spliceosome undergoes extensive 
rearrangements, in which RNA and protein networks are disrupted, while new 
physical interactions are established leading to different conformations of the 
spliceosome. Considering the Hub1-HIND structure and folding experiments in vitro, 
it is likely that in distinct spliceosomal complexes Snu66 is engaged in different 
conformations converting between the Hub1-bound and -unbound state. It would be 
interesting to investigate at which stage and in which complex Hub1 interacts with 
Snu66 and if this binding might act as a molecular switch between two 
conformations. 
Besides the highly conserved properties, human Hub1 exhibits an additional 
particularly interesting surface formed by the loop on α2-β3 with two unusually 
exposed hydrophobic residues, W47 and Y48. Although this aromatic patch is highly 
conserved in all metazoan orthologs, it is not present in yeast ScHub1. This particular 
patch is not common among ubiquitin or other ubiquitin-like proteins as judged from 
structure and sequence comparisons. Due to Hub1’s unique properties as shown for 
Snu66 binding, this aromatic patch might be involved in the formation of an additional 
interaction interface with an hitherto unidentified factor, thereby underscoring the 
special position of Hub1 among ubiquitin-like proteins.  
The data obtained from structural and interaction studies allowed molecular 
insights into the mode of interaction between Hub1 and hSnu66. After crucial amino 
acid residues important for the binding were identified, they were characterized by 
mutational analysis in further experiments. 
As the salt bridge between R11 of HIND (R127 in hSnu66) and D22 of Hub1 
strengthens and stabilizes the interaction, point mutations were inserted at these 
particular residues to abrogate the interaction. Indeed, single alanine substitutions in 
Hub1 or hSnu66 that interfered with the formation of the salt bridge abolished the 
formation of a stable Hub1-HIND complex as demonstrated in different co-
immunoprecipitation and protein interaction experiments under various conditions. 
Furthermore, these point mutations including the hSnu66 mutant with deleted HIND 
(ΔHIND) were also tested in yeast two-hybrid studies as the initial findings had been 
obtained from the mammalian Y2H screen. Here, exclusively Hub1 WT and hSnu66 
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WT showed physical interaction, whereas both mutations in hSnu66 (R127A and 
ΔHIND) and Hub1 (D22A) abrogated binding, confirming the abovementioned results 
(Figure 5c). Given the fact that the Hub1-hSnu66 interaction is highly conserved and 
orthologs of different species cross-interact, endogenous ScSnu66, which is present 
in the Y2H parental strain, could have bridged interactions from the screen. To rule 
out this possibility the corresponding Y2H constructs were introduced into Δsnu66 
knock-out strains and interaction studies were repeated. Also, in this Δsnu66 strain 
background all interactions of identified Y2H candidates with Hub1 were confirmed 
and supported the data. However, in addition to the D22 surface on Hub1 mediating 
the interaction with hSnu66, another region on Hub1, namely the C-terminal surface 
around R9, functions as a crucial interface for binding to the SR protein kinase Clk3 
and endocytosis adapter AP2β (Figure 5d). Interestingly, both residues (D22 and R9) 
are not critical for the Y2H interaction with USPL1 (SUMO/ubiquitin-specific 
peptidase-like 1), a factor which can bind and cleave SUMO species (SUMO1 and 
SUMO2/3) in human cells, but for its essential function the catalytic activity is 
dispensable (Schulz et al., 2012). The molecular function of USPL1 is yet unknown, 
but it is likely that it rather recognizes the compact ubiquitin-like fold of Hub1 than 
single specific residues in the heterologous system. Considering the aromatic patch 
formed by W47 and Y48, the HIND surface D22, and the exposed residue R9, Hub1 
utilizes at least three different crucial surfaces located on opposing sides of the 
protein. This allows Hub1 to act as a multifaceted binding module with fundamentally 
different interaction properties, reflecting an intriguing feature of the small ubiquitin-
like protein. Further investigation will be necessary to fully characterize potential 
interaction interfaces and their respective binding domains. 
 
5.3 Hub1 and hSnu66 reside in nuclear splicing speckles  
In order to allow metabolic and catabolic processes, expression and replication of 
genetic information, and complex biochemical reactions, eukaryotic cells are 
compartmentalized into specialized organelles and membrane-bound compartments. 
In particular, the nucleus is highly organized into chromosome territories, several 
nuclear bodies and subnuclear domains, which coordinate gene expression, RNA 
processing and export, signaling cascades and various cellular functions (Lanctôt et 
al., 2007). In addition to the genetic information densely packed as chromatin, the 
nuclear space is subdivided into so-called nuclear bodies like the nucleolus, 
promyelocytic leukemia nuclear bodies (PML bodies), Cajal bodies (or coiled bodies, 
nuclear splicing speckles (or interchromatin granule clusters or SC35 domains) and 
several other poorly characterized domains like perinucleolar caps, paraspeckles and 
clastosomes (Lamond and Earnshaw, 1998). Nuclear bodies can vary in shape and 
number depending on cell type, cell cycle stage and stimuli, as they fulfill diverse 
functions in the cell. For example, beside rDNA transcription, rRNA processing as 
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well as pre-assembly of ribosomal subunits the nucleolus plays an important role in 
cell cycle regulation by the sequestration of crucial key players like the Cdc14 
phosphatase (Visintin and Amon, 2000). PML bodies respond to various stimuli 
including oxidative stress, viral infection and DNA damage and are implicated in 
transcriptional regulation and cell cycle control (Ruggero et al., 2000). Protein 
complexes containing small nuclear RNAs (snRNA) or small nucleolar RNAs 
(snoRNAs), are modified and assembled into snRNPs and snoRNPs, respectively, in 
Cajal bodies. After their maturation, snRNPs cycle from Cajal bodies to nuclear 
splicing speckles, where they are engaged in splicing-competent complexes and 
return after participating in splicing catalysis for reassembly into functional complexes 
(Fischer et al., 1997; Cioce and Lamond, 2005). Nuclear splicing speckles are 
believed to be important for pre-mRNA splicing factor maturation and modification, as 
well as for complex formation and storage (Lamond and Spector, 2003). They are 
highly dynamic structures from which snRNPs and splicing factors like SR proteins 
shuttle to active sites of splicing (Wei et al., 1999; Misteli et al., 1997). In the current 
model this shuttling of splicing proteins is orchestrated by kinases and phosphatases 
that regulate the phosphorylation status of their substrates. In particular, members of 
the SR protein family and their regulatory counterparts, hnRNPs, change their 
nuclear distribution and activity upon phosphorylation by Cdc2/Cdc28-like protein 
kinases CLK1-4, SR protein kinases SRPK1/SRPK2 and AKT kinase, respectively 
(Colwill et al., 1996; Stojdl and Bell, 1999; Blaustein et al., 2005). Splicing factors like 
ASF/SF2 (SRSF1) and SC35 (SRSF2) are established constituents of nuclear 
speckles, but also inactive RNA Pol II, poly-adenylated mRNA and long non-coding 
RNAs like MALAT1 have been identified in these structures (Tripathi et al., 2012; 
2010; Caceres et al., 1998; Xie et al., 2006).  
The physical interaction of Hub1 with spliceosomal components like hSnu66 
and SR protein kinase Clk3 strongly indicated a conserved role of Hub1 in pre-mRNA 
splicing. Considering this link of Hub1 to pre-mRNA processing localization studies 
were performed to underscore its functional relationship to splicing-associated 
nuclear domains like Cajal bodies or nuclear speckles. Indeed, immunofluorescence 
staining elucidated a distinct speckle-like distribution of Hub1 within the nucleus 
(Figure 6). Here, it co-localizes with splicing factors SC35, U1A and Y12, which serve 
as well-established marker proteins for nuclear splicing speckles affirming Hub1’s 
functional and spatial association with the splicing machinery. Furthermore, Hub1 
has been recently described to associate with coilin in Cajal bodies, where 
spliceosomal subcomplexes assemble and mature into functional tri-snRNPs (Švéda 
et al., 2013). Importantly, Hub1’s interaction partner hSnu66 is found in nuclear 
speckles as well, co-localizing with SC35 and other tri-snRNP factors like PRPF4, 
which supports the physical interaction data and indicates the functional link to pre-
mRNA splicing (Figure 6b).  
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In co-expression experiments, hSnu66 actively recruited Hub1 to nuclear 
splicing speckles in an HIND dependent manner, which led to an accumulation of 
hSnu66 and Hub1 in these subnuclear domains (Figure 8a). While interfering with the 
Hub1-hSnu66 interaction by using Hub1 D22A or hSnu66ΔHIND mutants had no 
negative impact on the nuclear distribution of the tri-snRNP protein, the accumulation 
of Hub1 in splicing speckles was diminished. Beside the Hub1 interaction domain, 
mapping studies with hSnu66 revealed additional domains involved in tri-snRNP 
binding, nuclear localization and nuclear speckle targeting (Figure 10). The central 
domain comprises the interaction interface for the association with PRPF6 and 
nuclear localization signals (Figure 10b-d). Notably, the N-terminus of hSnu66 
containing the RS-domain and the HIND harbors an additional targeting signal and is 
proficient for nuclear speckle localization. This fragment efficiently binds Hub1 in vivo 
(Figure 11c) and is sufficient to recruit Hub1 to splicing speckles in a RS-domain-
dependent manner (Figure 11a). RS-domains are widely common features of 
splicing-associated factors often combined with RNA recognition motifs to mediate 
protein–RNA and protein–protein interactions (Shen et al., 2004; Manley and Tacke, 
1996; Graveley, 2004; Hertel and Graveley, 2005). Furthermore, nuclear import and 
targeting to nuclear splicing speckles can be enforced by RS-domains as they are 
recognized by specific nuclear import factors, so called SR transportins, in a 
phosphorylation-dependent manner (Allemand et al., 2001; Kataoka et al., 1999). 
Further experiments dissected the effect of Hub1 binding and the contribution of the 
RS-domain to the localization of the N-terminal fragment of hSnu66. While full-length 
hSnu66 and the isolated N-terminus are efficiently recruited to splicing speckles 
together with Hub1 (Figure 11b), the RS-domain is sufficient for targeting to nuclear 
speckles, as shown in experiments with the Hub1 binding-deficient mutant (N-
terminal RA). Interestingly, the crucial role of Hub1 in nuclear retention of the hSnu66 
fragment became evident, when the nuclear/cytoplasmic shuttling was enforced by 
the attachment of a nuclear export signal from the export receptor CRM1 (Figure 
11b). Hub1 binding allows hSnu66’s N-terminus to be incorporated into nuclear 
speckles and spliceosomal subcomplexes, while the NES-HIND RA mutant fragment 
lacking this Hub1-dependent integration is efficiently exported and depleted from the 
nuclear compartment. In summary, the data revealed an interesting interplay 
between Hub1 and hSnu66; hSnu66 actively recruits Hub1 to nuclear speckles, as it 
is efficiently imported into the nucleus via its RS-domain and NLS. As the central 
region in hSnu66 mediates the association with tri-snRNP factors, while the RS-
domain likely serves as an additional interaction platform, the Hub1 interaction 
domain directly binds and directs Hub1 to splicing complexes piggy-back.  
Interestingly, the interaction with hSnu66 contributes to Hub1 targeting to 
nuclear speckles, but is not essential as the binding mutant Hub1 D22A still localizes 
to splicing speckles and overlaps with SC35 pattern exhibiting no significant 
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difference to Hub1 WT (Figure 7a). Although both Hub1 WT and Hub1 D22A show a 
similar nuclear localization in fixed, pre-extracted immunofluorescence staining, the 
kinetics of targeting and shuttling between these structures might be significantly 
different for the two proteins. In order to address this point FRAP (fluorescence 
recovery after photobleaching) experiments would be an excellent method to gain 
further insights into Hub1 dynamics (Ishikawa-Ankerhold et al., 2012). Here, the GFP 
moiety of the respective Hub1 fusion protein is bleached in vivo by laser pulses 
around distinct nuclear speckle areas and the time for fluorescence recovery 
correlates with the mobility and dynamics of the Hub1 protein. In a similar approach, 
shuttling of WT hSnu66 and the Hub1 binding-deficient mutant hSnu66ΔHIND 
between active sites and nuclear speckles could be compared to further examine the 
contribution of the Hub1–HIND interaction in vivo.  
Another important issue deals with the interplay between Hub1 and its binding 
partner hSnu66. As ubiquitin-like proteins are known to modulate the activity, 
localization or physical interactions of their substrates, co-purification studies with 
hSnu66 WT and hSnu66ΔHIND were conducted to determine Hub1-dependent 
changes in protein complex composition upon Hub1 binding (Figure 9). As a 
constituent of the tri-snRNP complex the association of hSnu66 with central 
components of the U4/U6 (PRPF3, PRPF4) and the U5 (PRPF8, PRPF6) was 
monitored. Hub1 binding is not essential for the incorporation of hSnu66 into the tri-
snRNP, as no significant changes in co-purification experiments were observed for 
Hub1-deficent mutants (hSnu66ΔHIND or hSnu66 R127A). In addition to the directed 
tri-snRNP complex analysis, mass spectrometry was used as a proteomic approach 
to identify alterations in co-purifying protein complexes with WT and Hub1-binding 
deficient hSnu66 (Figure 9). A broad spectrum of splicing factors as well as proteins 
involved in mRNA processing and export were detected specifically in samples with 
immunoprecipitated hSnu66 and hSnu66ΔHIND. In addition to the already 
characterized hSnu66-associated tri-snRNP factors PRPF6 and PRPF8, 
spliceosomal proteins like CDC5L and PRP19 of the NTC (PRP19 complex), DEAD 
box helicases (DDX) and SR proteins like ASF/SF2, SFRS3 and SRSF5 as well as 
their respective kinases SRPK1 and GSK3 were significantly enriched in co-
immunoprecipitation experiments. Moreover, as a substantial fraction of hSnu66 
localizes to both nuclear speckles and the nucleolus (Figure 6b), nucleolar proteins 
including NPM3, UBF1 and NOP52 were identified in hSnu66 purifications. This dual 
localization has been reported for other splicing factors as well, e.g. the DEAH box 
ATPase Prp43 (Leeds et al., 2005; Van Koningsbruggen et al., 2004) and could 
reflect additional functions of RNA binding factors like hSnu66 in rRNA metabolism, 
as suggested previously (Li et al., 2009). Furthermore, it was shown that snRNPs 
and Sm proteins pass the nucleolus and Cajal bodies before reaching their 
destination, the nuclear speckles (Sleeman et al., 2001; Sleeman and Lamond, 
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1999). Thus, the dual localization might represent to snapshots during hSnu66 
nuclear speckle targeting and incorporation into functional snRNP complexes. 
The qualitative comparison of co-immunoprecipitation experiments with WT 
and Hub1 binding-deficient hSnu66 by mass spectrometry revealed only mild 
differences in the abundance of multiple co-purified and interacting proteins. This 
finding is in line with recent data in which the interactomes of yeast ScSnu66 in WT 
and HUB1-deletion stains (hub1Δ) were analyzed and compared by quantitative 
mass spectrometry (Mishra et al., 2011). Here, the composition of ScSnu66 
interactors was largely unaltered, but components of the U2 snRNP and the SF3 
complex were overrepresented in the absence of Hub1. As human hSnu66 provides 
multiple interaction interfaces (RS-domain, HIND and central PRPF6 association 
domain) it is possible that loss of Hub1 binding can be compensated via alternative 
modes of recruitment and binding modules (Figure 8,10,11). However, for 
quantitative analysis a more sophisticated approach like SILAC (stable isotope 
labeling by amino acids in cell culture) would be necessary, which would give a 
detailed and robust readout with high resolution and sensitivity compared to 
conventional mass spectrometry.  
Although the data presented here allows a detailed characterization and 
molecular insights into a unique non-covalent mode of interaction between an 
ubiquitin-like protein and an important tri-snRNP splicing factor, the spatial and 
temporal framework for Hub1-HIND complex formation requires further investigation. 
Additional layers of regulation like posttranslational modification might influence the 
interaction network of Hub1 and hSnu66, as phosphorylation is the main regulatory 
element within the splicing machinery. While SR-kinases control the recruitment of 
RNA binding factors to pre-mRNA, phosphorylation is also essential for splicing 
catalysis itself, as PRP28 needs to be modified in order to allow the incorporation of 
the tri-snRNP and the formation of the pre-catalytic spliceosome (C complex) 
(Mathew et al., 2008). Recently, additional posttranslational modifications like 
acetylation and notably, ubiquitylation have come into focus (Kuhn et al., 2009; 
Bellare et al., 2006). The spliceosome core component PRPF8 was shown to be 
modified by ubiquitin, which is important for the regulation of the helicase activity of 
Brr2 unwinding the U4/U6 snRNAs in vitro (Bellare et al., 2008). Interestingly, when 
hSnu66 was tested for posttranslational modifications by denaturing 
immunoprecipitations and mass spectrometry, over 16 phosphorylation sites on 
serine and threonine residues in hSnu66 were identified (data not shown). Two of 
them are in close proximity of the Hub1 interaction domain at position S111 and S117 
(HIND: AA 116-135). Furthermore, directed assays elucidated that hSnu66 is also 
multiply modified by the ubiquitin-like protein SUMO. This data was supported by 
large scale quantitative mass spectrometry analyses in which K94, K141, K709 were 
identified as SUMOylated lysines in hSnu66 (Vertegaal et al., 2006). Thus, the short 
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stretch in hSnu66 (AA 111-141) might constitute a regulatory hotspot that is modified 
by SUMO, phosphorylated and embeds the HIND for Hub1 binding. To address this 
point amino acid substitutions that mimic or abrogate posttranslational modifications 
of the targeted residues can be introduced in hSnu66 and the effect on Hub1-binding 
kinetics and affinities can be measured.  
Considering phosphorylation and SUMOylation as quick and reversible 
posttranslational modifications involved in multifaceted regulatory cellular processes, 
covalent attachment of SUMO and phosphate moieties to crucial residues in flanking 
sequences of the HIND might modulate Hub1 binding to hSnu66. These data suggest 
a model, in which posttranslational modifications serve as a cellular control 
mechanism to prevent undesired Hub1-binding to hSnu66 in order to spatially or 
temporally restrict this interaction to a particular process. A plausible explanation 
would be that this regulation is necessary to ensure correct tri-snRNP formation and 
licensing as hSnu66 is recruited late during assembly. To avoid premature 
association of Hub1, hSnu66 is kept in a HIND inactive state by phosphorylation or 
SUMOylation and Hub1-binding is blocked until the U4/U6.U5 tri-snRNP is properly 
assembled. Only when hSnu66 is incorporated into a functional tri-snRNP complex, 
the HIND becomes accessible and Hub1 binding is permitted to facilitate progression 
in the splicing cycle. 
In line with the immunofluorescence data showing that Hub1 and hSnu66 co-
localize in nuclear speckles in the context of pre-mRNA splicing complexes, several 
proteomic studies dissecting the composition of spliceosomal subcomplexes at 
different steps during the splicing cycle independently identified hSnu66 and Hub1. 
While Hub1 was found in human B and Bact complexes, hSnu66 was detected in the 
isolated tri-snRNP as well as in B, Bact and C spliceosomal complexes (Herold et al., 
2009; Bessonov et al., 2010; 2008; Deckert et al., 2006; Agafonov et al., 2011; Jurica 
et al., 2002).  
Taking advantage of the different variants of Hub1 and hSnu66 characterized 
in this work, further experiments with in vitro splicing assays and interaction studies 
might elucidate the functional role of Hub1 and hSnu66 in splicing. For example, as 
the splicing reaction can be reconstituted in vitro the different functional spliceosomal 
complexes can be arrested at particular steps of the transesterification reaction. It 
would be interesting to isolate Hub1 or hSnu66 from spliceosomes at various stages, 
deplete these factors from splicing extracts and to perform complementation assays 
with the recombinant proteins and their mutant variants. Due to the multifaceted 
nature of protein-protein, RNA-protein and RNA-RNA interactions within splicing 
complexes, crosslinking and co-immunoprecipitation experiments with splicing 
extracts would be feasible approaches to further characterize the molecular function 
of Hub1.  
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While hSnu66 is efficiently imported into the nucleus and exclusively recruited 
to nuclear subdomains, additional functions of Hub1 outside the nuclear envelope 
can not be excluded as live cell imaging and cellular sub-fractionation experiments 
detected notable cytoplasmic pools of Hub1 (Figure 7b, 11b). In contrast to the 
hSnu66 binding-deficient mutant Hub1 D22A the C-terminally tagged variant of Hub1 
(Hub1-GFP or Hub1FLAG) was not retained in nuclear substructures after pre-
extraction (Figure 7a), even though it was properly folded and functional in hSnu66 
interaction (see Figure 5b). Thus, the C-terminal surface, which is compromised of 
bulky or charged extensions, appears to be a crucial interface on Hub1 important for 
proper recruitment and incorporation into splicing-associated protein complexes 
within nuclear speckles. 
 
5.4 Conserved and evolved protein features of Hub1  
Although Hub1 is highly conserved from yeast to human, little was known about its 
molecular function. Initial work in lower eukaryotes S. cerevisiae and S. pombe 
addressed the ubiquitin-like nature of Hub1 and its impact on cell growth. 
Interestingly, while S. cerevisiae cells with a deletion of HUB1 (hub1Δ) are viable and 
exhibit no discernable growth defects (Mishra et al., 2011; Luders et al., 2003), 
hub1Δ in S. pombe is lethal (Yashiroda and Tanaka, 2004; Wilkinson et al., 2004). 
However, in S. cerevisiae hub1Δ shows negative genetic interactions with mutant 
alleles of several splicing factors like prp17Δ, snu17Δ and prp8*, which expresses a 
partially defective variant of the core-spliceosomal protein Prp8 (Mishra et al., 2011). 
This provides further evidence for Hub1 functioning in pre-mRNA splicing. With these 
two strain backgrounds, S. cerevisiae and S. pombe hub1Δ,  different variants of 
Hub1 were tested for functionality in complementation cell growth assays. 
Importantly, although each Hub1 variant could complement the growth defects in the 
respective yeast strain under normal conditions, rescue assays revealed significant 
differences between yeast and human Hub1 at restrictive temperatures (Figure 12). 
When hub1Δ S. pombe cells were supplemented with constructs expressing HUB1 
orthologs from S. cerevisiae, S. pombe and H. sapiens, only the human and fission 
yeast HUB1 fully complemented the lethality at higher temperature, while S. 
cerevisiae Hub1 exhibited clear growth defects. Vice versa, the human Hub1-
encoding gene could not fully rescue the synthetic lethality of the double mutant 
hub1Δ prp8* in S. cerevisiae, while ScHUB1 and SpHUB1 facilitated growth at 
restrictive temperatures.  
Based on recent data elucidating an important role of Hub1 in splice-site 
usage and alternative splicing in yeast (Mishra et al., 2011), an alternative 
complementation readout highlights the functional differences between the different 
HUB1 orthologs. Alternative splicing of the SRC1 gene product in S. cerevisiae 
depends on Hub1 for proper splicing of the overlapping non-canonical 5’ splice sites 
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giving rise to two mRNA isoforms, SRC1-L (long isoform) and SRC1-S (short 
isoform). While both yeast variants of Hub1 were able to rescue the splicing defect in 
hub1Δ strains, human Hub1 failed to fully restore alternative splicing of SRC1.  
These distinct activities of Hub1 in complementation assays might be 
explained by the fundamental differences of pre-mRNA splicing in various species. 
Only three percent of the genes in the S. cerevisiae genome carry introns with only 
six ORFs containing two introns (Barrass and Beggs, 2003). In contrast, splicing of 
pre-mRNA with multiple introns is much more prevalent in fission yeast with 43 % of 
its genes comprising intronic sequences (Wood et al., 2002). These differences in 
splicing prevalence and regulation in splice site recognition and selection (as 
discussed in 5.1) might reflect the impact of HUB1-deletions in the respective yeast 
species and correlate with the implication of Hub1 in pre-mRNA splicing.  
In S. cerevisiae Hub1 enables the spliceosome to process transcripts with 
non-canonical splice sites to ensure proper and faithful splicing even at suboptimal 
sequences like the overlapping splice sites in SRC1. As the number of critical Hub1-
dependent splice sites is limited, deletion of the ubiquitin-like protein (hub1Δ) does 
not challenge cells under normal growth conditions, because difficult splice sites in 
non-essential transcripts might still be processed by the spliceosome even in the 
absence of Hub1, albeit with very low efficiency. If the spliceosome is compromised 
in activity (for example by mutations in core-splicing factors like Prp8) non-canonical 
splice sites constitute serious obstacles for the dynamic splicing machinery. Here, 
Hub1 might mediate conformational rearrangements, which allow higher flexibility of 
the spliceosome to tolerate and to process critical splice sites in order to ensure 
efficient and faithful pre-mRNA splicing. The accurate transition between the different 
spliceosomal complexes is under tight control of DExH/D-box helicase like hPrp28 
and hBrr2. Moreover, as non-canonical splice sites are recognized poorly and 
challenge spliceosomal assembly, Hub1 might serve in spliceosomal quality control 
to facilitate the correct incorporation and activation of spliceosomal subcomplexes by 
DExH/D-box helicases. 
Due to the low complexity of pre-mRNA splicing in S. cerevisiae, this model for 
the molecular function of Hub1 in the spliceosome might reflect the original activity of 
the ubiquitin-like protein in the spliceosome very early in evolution. In higher 
eukaryotes, where alternative splicing is utilized to expand the cellular repertoire of 
gene products, several additional surveillance mechanisms were established to 
facilitate correct pre-mRNA processing and high fidelity by the spliceosome. In order 
to cope with a higher complexity on sequence level and splice variants due to 
variations at splice sites, auxiliary RNA binding factors (SR proteins and hnRNPs) are 
recruited to cis-regulatory elements on pre-mRNAs to mediate loading of the splicing 
machinery at the correct splice site for efficient exon recognition and proper splicing. 
Although initial steps like splice site recognition and recruitment of the 
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prespliceosomal complex A with U1 and U2 snRNPs are more sophisticated in higher 
eukaryotes, the spliceosomal core machinery catalyzing the transesterification 
splicing reaction is largely identical from yeast to man. Thus, the function of Hub1 
might have become particularly important at the interface between the “evolved” 
splice site recognition with prespliceosomal complex assembly and processing of 
suboptimal splice sites by the conserved core spliceosome. Despite the high 
conservation, in higher eukaryotes Hub1 might have gained an additional or more 
prevalent function in pre-mRNA splicing, which is conveyed by a distinct, intrinsic 
feature of the ubiquitin-like protein, but is absent in S. cerevisiae.  
 
5.5 Different surfaces on Hub1 facilitate distinct interactions 
Even though Hub1 is structurally very similar to ubiquitin, the mode of interaction is 
very different. Encompassing solely the ubiquitin-fold and lacking any N- or C-
terminal extensions, Hub1 is only able to function through non-covalent interactions 
with other proteins.  
Based on the structural data and hSnu66 interaction studies, the question of 
which surface on Hub1 is crucial for its essential activity, was addressed. For this 
approach, various Hub1 point mutations, changing conspicuous residues in different 
patches on the Hub1 protein were generated and tested in RNAi complementation 
and immunoprecipitation assays.  
Firstly, the siRNA-resistant cDNA expressing a Hub1 variant deficient in 
Snu66 interaction (D22A) rescued viability only partially, indicating that specific 
binding of Hub1 to the spliceosomal protein hSnu66 contributes, but is not essential 
in humans cells under standard growth conditions. These data were further 
supported by analogous complementation experiments in S. pombe, where Hub1 
D22A restored viability in hub1Δ stains (Mishra et al., 2011). Notably, further analysis 
of mutations interfering with hSnu66 binding (Hub1 D22A) or Clk3 kinase interaction 
(Hub1 R9A) individually or in combination (Hub1 RDAA) did not further attenuate the 
rescue capacity. Thus, the interplay of Hub1 with tri-snRNP protein hSnu66 or SR-
kinase Clk3 might contribute to the Hub1 mediated activity in pre-mRNA processing, 
but additional factors utilize alternative surfaces on Hub1 to execute its essential 
function.  
Intriguingly, RNAi complementation experiments revealed the importance of 
Hub1’s C-terminus as variants carrying C-terminal extensions, like charged or bulky 
epitope tags, were not able to rescue the lethal depletion phenotype. These 
extensions did not negatively affect Hub1 hSnu66 interaction, protein stability or 
folding, but rather interfered with physical interactions, which might be mediated via 
this surface. Notably, introducing mutations into very C-terminal residues of Hub1 or 
truncating the terminal amino acids (ΔYYQ/YYL), did not significantly alter the activity 
of Hub1 (Luders et al., 2003; Mishra et al., 2011). In addition to the characterization 
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in RNAi complementation experiments, the relevance of this C-terminal interface 
became more evident in localization studies in human cells (Figure 21). While Hub1 
WT and the Snu66 binding deficient mutant Hub1 D22A resided in nuclear speckles, 
the C-terminally tagged Hub1-GFP failed to be incorporated into respective nuclear 
substructures and was washed out of the nucleus. Due to the compact ubiquitin-fold 
of Hub1 with the typical protruding C-terminus of UBLs missing, this site might have 
gained particular importance for Hub1 as a non-conventional ubiquitin-like protein.  
Analogous to the complementation experiments performed in yeast, RNAi 
rescue assays reintroducing different Hub1 orthologs into human tissue culture cells 
were conducted (Figure 16b). Here, human and fission yeast Hub1 were able to 
restore viability after Hub1 knockdown, while S. cerevisiae Hub1 failed to 
complement the lethal RNAi phenotype despite equal protein expression levels. This 
supports the model that Hub1 from mammals and S. pombe owns crucial protein 
properties that are missing in the ScHub1 variant. 
This finding drew the attention to particular surfaces, which are conserved 
from fission yeast to mammalian Hub1, but differ from S. cerevisiae Hub1. The most 
significant structural difference was identified in the loop on α2-β3 in human Hub1, 
with exposed hydrophobic residues W47, Y48 and F51, which are conserved in all 
metazoan orthologs.  
Due to the unusually exposed orientation of the tryptophan and tyrosine, 
these residues might create an additional binding site opposing the HIND surface. 
Initial experiments showed that single mutations in Hub1 (WYFGGL) did not 
significantly affect the rescue capacity, but in combination with mutations in the Clk3 
of hSnu66 binding sites (Hub1 R9AWYGG and RDAAWYFGGL), these Hub1 
variants were less potent in restoring viability after RNAi, despite similar expression 
levels.  
Most hydrophobic amino acids are buried within the protein tertiary structure during 
protein folding for stabilization, while hydrophilic residues are oriented to the solvent 
(Dyson et al., 2006). Alternatively, exposed hydrophobic amino acids like tryptophan 
and tyrosine were reported to be crucial for the formation of various interaction 
interfaces for multimerization or ligand binding (Moreira et al., 2007). For example, 
RNA binding proteins harboring RNA recognition motifs (RRM) utilize tryptophan, 
phenylalanine and tyrosine residues in their four β-sheets to recruit and coordinate 
binding to RNA species (Cléry et al., 2008).  
Hub1 exhibits remarkable features, as it utilizes several residues and surfaces 
for various interactions. Beside the Hub1-HIND surface mediated via D22 and the 
Clk3 interaction via R9, the C-terminal surface and the hydrophobic patch with W47, 
Y48 and F51 resemble binding sites, which might act synergistically to accomplish 
Hub1’s essential function in human cells. 
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5.6 In vivo depletion of Hub1 causes cell cycle defects and apoptotic 
cell death  
Human cells arrest in distinct cell cycle phases upon checkpoint activation as a 
cellular response to stress or toxic insults e.g. accumulation of aberrant synthesis 
products or DNA damage. After the transfection with Hub1 RNAi all tissue culture cell 
lines tested (U2OS, HCT116, HeLa) exhibited strong cell cycle progression delays, 
accompanied by defects in mitotic cell division, including aberrant metaphase plate 
formation and chromosome missegregation. Further cell cycle synchronization and 
release assays elucidated that Hub1 RNAi cells, but not cells treated with a control 
siRNA, exhibited G2/M cell cycle progression defects after S-phase release. Flow 
cytometry analysis revealed that Hub1 siRNA treatment initially (after 48 hours) 
caused defects in G2/M cell cycle progression, and later (72 hours) culminated in a 
rise of sub G1 fractions, indicative of cells undergoing apoptosis (Figure 14-16).  
Cell lines with compromised checkpoints, for example HeLa, with inactive p53 
pathway (Hoppe-Seyler and Butz, 1993) are prone to overcome G2/M arrests, a 
process called mitotic slippage, frequently observed in DNA replication checkpoint 
mutants (Di Leonardo et al., 1997; Riffell et al., 2009). Due to the checkpoint 
override, cells face unfaithful chromosome segregation and undergo aberrant mitosis, 
resulting in abnormally fragmented nuclei and subsequent induction of apoptosis 
reflecting hallmarks of mitotic catastrophe (Castedo et al., 2004), as observed in 
Hub1 RNAi treated cells. As the accumulation of aberrantly spliced transcripts 
causes multifaceted cellular stresses and misregulation of various cellular pathways 
(Venables, 2004), Hub1 appears to be a pivotal factor to facilitate efficient and faithful 
splicing which is crucial for maintaining cellular homeostasis.  
In line with the obtained Hub1 RNAi data, recent high throughput siRNA 
screenings (Neumann et al., 2006) underscored the importance of core splicing 
components like tri-snRNP proteins PRPF8, hBrr2, PRPF6 and associated non-
snRNP proteins like components of the PRP19 complex (NTC) for proper cell cycle 
progression and faithful mitosis. Interestingly, only one fifth of the 150 core 
spliceosomal factors analyzed exhibited mitotic defects in this RNAi based approach 
(Neumann et al., 2010; Hofmann et al., 2010), while Hub1 appears to be an 
additional potent candidate for this list.  
Similar to Hub1, inactivation of important splicing factors like SR proteins 
SC35 and ASF/SF2 causes genome instability and cell cycle defects, which entail 
proto-oncogenic potential in vertebrate cells (Karni et al., 2007; Li and Manley, 2005; 
Xiao et al., 2007). Furthermore, it was shown that efficient splicing of pre-mRNA and 
its incorporation into mRNP complexes is important to maintain genome stability (Li 
and Manley, 2006). In eukaryotes, co-transcriptional processing couples mRNA 
synthesis directly to splicing and mRNA export. If mRNA processing is impaired 
during transcription by chemical inhibition (Gan et al., 2011), depletion of crucial 
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splicing factors by RNAi (Li et al., 2007; Li and Manley, 2005; Stirling et al., 2012) or 
mutant alleles of genes involved in mRNA export (THO/THREX (Huertas and 
Aguilera, 2003)), the nascent transcript stalls and accumulates at DNA. Similarly 
stalled RNA polymerase that faces obstacles blocking transcription elongation like 
DNA damage, replication forks or hypernegative supercoiled DNA can lead to free 
nascent pre-mRNA. As a result, the naked RNA strand emerging from RNA 
polymerase, which is not incorporated into functional mRNP, can form undesired 
RNA:DNA hybrid structures, so called R-loops (Aguilera and García-Muse, 2012). If 
the hybridizes stretches are not resolved by RNase H-like enzymes, these structures 
can cause substantial DNA damage and give rise to mutations, recombination or 
chromosomal rearrangements. 
In addition to the cell cycle arrests and mitotic defects, in vivo depletion of 
Hub1 triggers the DNA damage response pathway and the activation of several key 
effector proteins (Figure 17). Hub1 knockdown leads to stabilization and activation of 
p53, transcriptional up-regulation of p21 and phosphorylation of histone 2A at S139 
(γH2AX). Interestingly, cells treated with Hub1 siRNA exhibit reduced proteins levels 
of the nucleotide excision repair factor xeroderma pigmentosum group C (XPC), 
whose activity is regulated via ubiquitylation and degradation upon UV-irradiation to 
facilitate efficient DNA repair in concert with hRad23B (Wang, 2005; Sugasawa et al., 
2005). However, at the moment it is unclear what the cause and type of DNA 
damage is that accumulates in Hub1-depleted cells and how Hub1 might affect DNA 
damage signaling and stability of crucial factors. Whether Hub1 functions like RNA 
processing factors that play crucial roles during DNA damage repair directly, e.g. 
hnRNPU-like proteins (hnRNPUL1/2) which contribute to DNA-end resection (Polo et 
al., 2012; Beli et al., 2012; Pont et al., 2012) will require further research. 
Altogether, this data clearly indicates that the ubiquitin-like protein Hub1 is a crucial 
factor to ensure genome integrity.  
 
5.7 Hub1 RNAi leads to aberrant splicing and mRNA retention 
Active splicing is a highly dynamic process in which spliceosomal subcomplexes are 
constantly recruited to regulatory sequences within the nascent pre-mRNA emerging 
from the RNA polymerase to perform the splice cycle (chapter 2.5). Furthermore, co-
transcriptional recruitment of the splicing machinery and active splicing are required 
for efficient mRNA export (Riedl and Shi, 2004; Reed and Hurt, 2002). The phospho-
protein SC35 is a well-established nuclear speckle marker that illustrates the shuttling 
of splicing factors between splicing foci and sites of active transcription. SC35 was 
shown to associate with pre-mRNA sequences as well as to directly contact RNA Pol 
II’s CTD (Riffell et al., 2009; Lin et al., 2008; Di Leonardo et al., 1997).  
To address the effect of Hub1 knockdown on pre-mRNA splicing, central 
splicing and RNA processing factors were investigated in a time window, in which 
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Hub1 protein levels were already significantly reduced, but cells did not show any 
signs of severe stress nor degeneration like nuclear disintegration. Whereas control 
cells showed normal distinct SC35 domains with many small foci distributed within 
the interchromatin space, Hub1 knockdown cells exhibited an aberrant SC35 pattern 
with high enrichment in enlarged nuclear speckles, while small foci diminished. 
These changes in nuclear distribution were not restricted to SC35, as this effect of 
Hub1 depletion was also observed for various other splicing-associated factors like 
U1A, hnRNP1 or trimethylguanosine-capped snRNPs (Figure 20). 
Direct evidence of Hub1 RNAi-dependent defects in pre-mRNA processing 
was obtained when endogenous poly-adenylated mRNA was visualized by FISH. In 
line with aberrant splicing factor distribution, depletion of Hub1 caused nuclear 
retention of polyadenylated mRNA in enlarged speckles, while the cytoplasmic 
fraction was significantly reduced, indicating impaired processing and nuclear 
shuttling as described previously (Kaida et al., 2007; Dias et al., 2010). The observed 
RNA accumulation was weaker compared to cells in which crucial mRNA export 
factors had been depleted (Yamazaki et al., 2010), indicating that Hub1 activity is 
crucial for early mRNA processing steps rather than facilitating mRNA export further 
downstream.  
However, the characterized Hub1 knockdown phenotypes were highly similar 
to those observed in cells in which splicing was repressed by the splicing inhibitor 
Spliceostatin A, repressing oligonucleotides, or RNAi (Kaida et al., 2007; O'Keefe et 
al., 1994; Tanackovic and Krämer, 2005). These data further underscore that Hub1 is 
a crucial factor for pre-mRNA splicing and processing in vivo.  
 
5.8 Human Hub1 is crucial for specific splicing events 
The strong phenotypes associated with Hub1 depletion in human cells suggest that 
human Hub1 plays a much more fundamental cellular role than its S. cerevisiae 
counterpart. Reasonable models are that Hub1 is crucial in human cells either for 
general splicing, or for splicing of a number of certain, particularly sensitive pre-
mRNAs or introns.  
To address splicing competence of Hub1-depleted human cells, firstly splicing 
of artificial splicing reporters was analyzed. Minigenes are frequently used tools to 
characterize and manipulate various aspects of pre-mRNA splicing e.g. strength of 
particular splice sites, branch point or pyrimidine tract sequences (Gaildrat et al., 
2010; Cooper, 2005; Stoss et al., 1999; Singh and Cooper, 2006). Furthermore, 
transcript specific cis- and trans- active regulatory elements like splice site enhancer 
or silencer sequences and their respective RNA binding proteins can be examined in 
detail (Wang and Burge, 2008; Lopez, 1998). Notably, specifically in Hub1 siRNA 
treated cells, splicing of the GFP minigene pre-mRNA was defective and unspliced 
transcripts accumulated, proving that Hub1 indeed is crucial for pre-mRNA splicing in 
Discussion 
 99 
human cells (Figure 22). However, in this setup variations at the 5’ splice sites did not 
significantly affect Hub1-dependent splicing defects even when highly divergent 
sequences were introduced into the respective gene products. This might be 
explained by the fact that the artificial pGint / pRint minigene transcripts are 
constitutively highly expressed and comprised of a single, relatively short intron 
lacking cis-regulatory elements. Thus, to address the physiological role of Hub1 in 
pre-mRNA splicing, endogenous transcripts and alternative splicing model substrates 
were examined.  
Several layers of regulation have been identified to affect splicing efficiency 
and alternative splicing in human cells. Chromatin structure, histone modification and 
promoter strength modulate recruitment of splicing factors and RNA pol II associated 
factors which can then lead to significant changes in splice site recognition and 
usage (Luco et al., 2010; Cramer et al., 1999; Luco et al., 2011). By transplanting 
genomic fragments containing alternatively spliced exons into mammalian expression 
plasmids, some of these regulatory effects can be omitted to address Hub1’s splicing 
specificity. For this, gene products were examined that are known to be regulated by 
alternative splicing at different developmental stages, tissue-specific programs or 
upon exogenous stimuli. Fibronection 1 (FN1, (Muro et al., 1998)), tropomyosin 1α 
(TPM, (Graham et al., 1992)) or myeloid cell leukemia sequence 1 (MCL1, (Bae et 
al., 2000)) served as model transcripts in U2OS cells after RNAi treatment (Figure 
23c). The RT-PCR analyses elucidated that Hub1 is crucial for correct splice site 
usage and faithful pre-mRNA splicing of distinct splice sites as Hub1 depletion 
resulted in different forms of alternative and constitutive splicing defects in various 
transcripts. In case of FN1, Hub1 knockdown caused exon (ED-A) skipping, whereas 
intron retention coupled to moderately lower steady-state mRNA levels was observed 
for TPM and Mcl-1. Furthermore, these data demonstrate that individual sequences 
like ED-A, TPM intron 4-5 and Mcl-1 intron 1-2 are particularly sensitive to Hub1 
depletion, while other flanking sequences within the same transcript show no 
alterations, indicating that Hub1 is not a general splicing factor, but promotes specific 
splice events.  
The model that Hub1 enables the spliceosome to process certain unprivileged 
transcripts to ensure efficient and faithful splicing was further strengthened, when 
endogenous Hub1-dependent transcripts were identified. Splicing of various 
endogenous pre-mRNAs (Mcl-1, Akt, Casp2, AurkA etc.) was affected in Hub1-
depleted cells, as shown in a candidate-based RT-PCR screen. Apparently, Hub1 
activity owns sequence specificity, as splicing defects were restricted to distinct 
splice sites in certain transcripts, while other gene-products tested simultaneously 
were processed normally, arguing that Hub1 is not essential for splicing per se, but 
needed for efficient splicing events via specific splice sites. 
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In addition to direct candidate approaches comprehensive exon-specific RNA 
microarray profiling was performed to detect global changes in alternative splicing in 
human cells upon Hub1 depletion (Figure 25). The unbiased microarray analysis 
elucidated broad alterations in mRNA exon patterns for multiple transcripts with a 
majority (ca. 68%) exhibiting exon exclusion specifically in Hub1 knockdown cells. 
Furthermore, the splicing array data clearly demonstrates, with single exon 
resolution, that Hub1 depletion affects alternative splicing of individual exons, while 
flanking sequences within the same transcript show no alterations. This might be 
explained by splice site usage defects in cells with spliceosomes lacking Hub1. Here, 
the Hub1-deprived splicing machinery fails to efficiently recognize and define the 
exon boundaries, which hinders spliceosomal assembly. As co-transcriptional 
splicing is a highly dynamic process, neighboring flanking exons with strong splice 
sites and/or splicing enhancer sequences could be favored over Hub1 sensitive 
exons, which are subsequently excluded from the transcript. Splice site usage and 
thus alternative splicing is determined by the interplay of multiple factors including 
SR, hnRNP and other spliceosomal proteins as well as RNA pol II activity and 
histone modifications (Mabon and Misteli, 2005; la Mata et al., 2003). However, this 
data demonstrates that Hub1 is an additional determining factor for alternative pre-
mRNA splicing in human cells. 
Although these data further extend the view on transcripts, which are spliced 
in a Hub1-dependent manner, the growing list of Hub1 substrates is most likely not 
complete due to several technical challenges. Although the Affymetrix human exon 
array comprises specific probes for validated cDNA-based sequences as well as 
predicted and previously unknown splice variants, alternative splicing events like 
intron-retention and proximal cryptic splice site recognition cannot be resolved by this 
technique. To address this question, comparative RNA sequencing would be a 
powerful method and might give in depth insights into Hub1-dependent splicing 
reactions. Additionally, in Hub1 knockdown cells a certain fraction of aberrantly and 
alternatively spliced transcripts are subjected to rapid mRNA decay, as Hub1-
dependent splicing defects most likely interfere with mRNA maturation and give rise 
to pre-mature stop codons, the bona fide nonsense-mediated decay (NMD) 
substrates (Kervestin and Jacobson, 2012). This is supported by the observed 
substantial down regulation of mRNAs upon Hub1 knockdown on transcription level 
detected in microarray expression data sets.  
Interestingly, a considerable number of Hub1-dependent splice substrates 
were previously characterized as transcripts containing weak splice sites (Akt, 
FANCG, Rad23) (Ahn et al., 2011). While strong splice sites are efficiently 
recognized and spliced by the spliceosome, proper splicing of pre-mRNAs with weak 
splice sites challenge the spliceosomal assembly and require auxiliary factors like the 
RS-domain protein Son. Son was reported to facilitate recruitment and stable 
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association of U1-70K, U2AF65 and SC35 at weak splice sites and is thereby crucial 
for accurate and efficient splicing of certain pre-mRNAs (Ahn et al., 2011; Sharma et 
al., 2011). To further dissect if Hub1 affects splicing of weak splice sites similar to 
Son or the spliceosomal core with hSnu66, Hub1 RNAi induced aberrant splicing was 
compared to splicing defects in cells in which the tri-snRNP protein hSnu66 or the SR 
protein Son were knocked down. Whereas Hub1 and Son are important factors for 
efficient Akt pre-mRNA splicing, Hub1 and hSnu66 (but apparently not Son) 
facilitated splicing of Mcl-1 and AurkA. These data suggest that Hub1 might act at the 
crossroads between the early steps during spliceosome assembly and spliceosomal 
core, as Hub1 knockdown phenotypes combine characteristics of both crucial 
branches for splicing activity. In line with the hSnu66-independent activities of Hub1 
identified in knockdown complementation assays, RNAi rescue experiments showed 
that the hSnu66 binding-deficient Hub1 D22A variant was able to complemented the 
splicing defects, while the C-terminally extended version of Hub1 failed to support 
splicing. This finding reinforces the model in which direct binding of Hub1 to hSnu66 
via the HIND element is not essential for Hub1-dependent splicing, even though, the 
additional surface opposing the Hub-HIND interface on Hub1 mediates its crucial 
activity in human cells.  
Since the splice sites of the investigated introns that are sensitive to Hub1 
show no obvious sequence similarity, Hub1 may act as a splicing qualifying factor for 
splicing events that are unprivileged for different reasons. Further studies will be 
necessary to characterize, which crucial sequence features mediate Hub1-dependent 
splicing e.g. pre-mRNA folding constrains (secondary structures), cis-acting splicing 
enhancers or silencers, or presence of RNA binding proteins (Matlin et al., 2005; 
Wang and Burge, 2008; Hiller et al., 2007). However, in striking contrast to canonical 
regulators of alternative splicing that directly target pre-mRNAs by binding to 
regulatory sites using their sequence-specific RNA recognition motifs, Hub1 appears 
to stimulate unprivileged splicing events through modifying the splicing machinery 
rather than targeting specific RNA substrates. 
 
5.9 Hub1 knockdown desensitizes cells to actinomycin D 
Aberrant mRNA splicing is a common characteristic of many cancers (Fackenthal 
and Godley, 2008; Venables, 2004), as it causes cellular stresses and mis-regulation 
of various cellular pathways underlining that efficient and faithful splicing is crucial for 
cellular homeostasis. In eukaryotic cells, Hub1 plays a central role to ensure efficient 
and faithful splicing of suboptimal splice substrates, as its inactivation leads to 
extensive splicing defects entailing abnormal mitosis and, finally, apoptosis. Several 
RNAis and chemical compounds were tested to identify growth conditions under 
which the Hub1-dependent cellular activity becomes particularly important or to find 
drugs that modulate cellular pathways to suppress the Hub1 depletion phenotypes. 
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To this end, transcription inhibitors like actinomycin D (ActD), α amanitin and 5,6-
dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), were included in this study, 
which affect RNA polymerase activity and reduce mRNA synthesis by different 
modes of action (Bensaude, 2011).  
Intriguingly, actinomycin D was able to partially rescue the Hub1 RNAi 
phenotype (Figure 26). At early time points after siRNA transfection, ActD treatment 
affected control RNAi cells only marginally, while the observed G2/M arrest in Hub1 
knockdown cells was already significantly decreased after incubation with ActD. At 
later stages of knockdown, when control cells were treated with increasing drug 
concentrations, the fraction of apoptotic cells increased accordingly due to the 
cytotoxic effect of transcription inhibition by ActD. Notably, although Hub1 knockdown 
is fatal for human cells, after incubation with actinomycin D HeLa cells did not show a 
synergistic effect at increasing drug concentrations, but rather exhibited an improved 
cell cycle distribution ratio for G1 and G2/M populations, while the apoptotic fraction 
decreased.  
As alternative transcription inhibitors like α amanitin or DRB, did not show 
similar antagonistic effects with Hub1 knockdown, this effect was specific for Hub1-
depletion combined with ActD. This might be explained by the different modes of 
action of these drugs on RNA Pol II during RNA synthesis. 
Actinomycin D belongs to the family of natural polypeptide antibiotics 
produced by Actinobacteria of the genus Streptomyces. It binds ssDNA with high 
affinity and intercalates preferentially into GC rich regions (Hollstein, 1974; Sobell, 
1985). Thereby, ActD specifically inhibits transcription elongation by RNA pol II (but 
also RNA Pol I and III) and most significantly affects synthesis of long mRNAs and 
rRNAs (Perry and Kelley, 1970). At high cellular concentrations actinomycin D can 
interfere with DNA synthesis and cause DNA doubles strand breaks (Mischo et al., 
2005). 
In contrast, the cyclic peptide mushroom toxin,  α-Amanitin, specifically binds 
to the catalytic center of RNA pol II where it blocks the incorporation of NTPs and 
RNA synthesis as an irreversible inhibitor (Bushnell et al., 2002; Lindell et al., 1970). 
The nucleoside analog DRB interferes with RNA pol II elongation by inhibiting its 
transcription promoting kinase complexes CDK9 / cyclin T of pTEFb and CDK7 of 
TFIIH (Yankulov et al., 1995; Zandomeni et al., 1982; Marshall et al., 1996). The 
CDK9/7 activities are crucial to overcome repression of transcription by negative 
transcription elongation factors (N-TEFs) in order to allow the transition to productive 
mRNA synthesis (Price, 2000).  
While transcriptional inhibition by ActD in combination with Hub1 knockdown 
mitigated Hub1 depletion-dependent apoptosis and, in turn, drug-dependent toxicity, 
neither α-Amanitin nor DRB treatment exhibited similar properties, but rather 
aggravated the Hub1 phenotype. Considering the crucial role of Hub1 in pre-mRNA 
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splicing, reducing the transcription rate and thereby splicing dynamics by actinomycin 
D could be beneficial for human cells when the splicing machinery lacks Hub1 as in 
RNAi experiments. In addition to the inhibition of transcription, actinomycin D affects 
pre-mRNA processing and increases mRNA stability (Clement et al., 1999). 
Furthermore, actinomycin D treatment has been shown to alter alternative splicing 
patterns for example of Mdm2 (Lents et al., 2008).  
While under standard growth conditions with high transcription rates and 
spliceosomal dynamics Hub1 depletion results in extensive splicing defects, nuclear 
RNA retention and aberrant gene-products, additive actinomycin D treatment might 
positively affect RNA metabolism. As long transcripts are particularly sensitive to 
ActD and might contain multiple Hub1-dependent splice events, slowed down 
transcription elongation rates might allow the spliceosome to process and splice 
nascent pre-mRNA correctly even under Hub1-deprived conditions upon actinomycin 
D treatment. Although additional functions of Hub1 that affect transcription directly 
cannot be ruled out at the moment, this phenomenon might be valuable to gain 
further insights into the close link between chromatin, transcription and mRNA 
splicing and their regulatory feedback loops. 
 
5.10 The Hub1-dependent splicing model  
The efficient and correct splicing of nascent transcripts is an essential regulatory 
element of posttranscriptional eukaryotic gene expression. This intricate process is 
accomplished by the coordinated assembly and orchestrated transition of multifarious 
RNA-protein complexes, which constitute the catalytically active spliceosome. Based 
on the characterization of human Hub1 presented in this thesis and considering 
respective work in yeast, a comprehensive model for the molecular function of the 
ubiquitin-like protein Hub1 in pre-mRNA splicing is proposed (Figure 27). 
The splicing pathway includes several control mechanisms to verify 
spliceosomal complex formation at distinct transition steps to either promote correctly 
assembled spliceosomes or reject aberrantly composed complexes from further 
progression (Koodathingal and Staley, 2013). In order to guarantee the low error rate 
in pre-mRNA splicing (Fox-Walsh and Hertel, 2009), a group of DEXD/ H-box 
ATPases including Prp5, Prp16, Prp22, and Prp43 serve as proofreading enzymes, 
which discard splicing intermediates after spliceosomal stalling as a result of aberrant 
spliceosome assembly and suboptimal splice substrates, respectively (Egecioglu and 
Chanfreau, 2011). At early stages the correct engagement of the U2 snRNP at the 
branch point sequence is inspected by Prp5 (Xu and Query, 2007). In later steps, 
after the formation of the catalytically active B* complex, suboptimal splice substrates 
are detected and rejected by the DEXD/H-box ATPase Prp16 before 5’ss cleavage 
(Mayas et al., 2006). The second transesterification step is monitored by Prp22, 
which certifies the proper complex formation at the 3’ss for correct exon ligation 
Discussion 
 104 
(Koodathingal et al., 2010). While proofreading enzymes promote the splice cycle 
progression of accurate splicing intermediates, defective spliceosomes and 
suboptimal splice substrates are finally discarded and disassembled by DEAH-box 
proteins like Prp43 (Mayas et al., 2010).  
Importantly, the fundamental concept of spliceosomal quality control is based 
on the highly dynamic nature of global RNA/protein network rearrangement during 
spliceosomal complex assembly and is manifested in the “kinetic proofreading 
model” (Hopfield, 1974). In this model, two antagonistic activities or pathways 
compete for directionality, in which the equilibrium shifts depending on biochemical 
reaction kinetics (Semlow and Staley, 2012). In the case of pre-mRNA splicing and 
its quality control mechanisms, these antagonistic activities are reflected by the 
anterograde reactions during splice cycle progression with complex assembly, 
snRNA unwinding, and snRNP rearrangements, while retrograde directionality is 
represented by the disassembly kinetics of DEXD/H-box ATPases, which enforce the 
rejection of spliceosomal transitions and complex conversions.  
Ideally, optimal splice substrates are continuously processed, as the accurate 
spliceosomal assembly and immediate complex conversions support highly dynamic 
splicing kinetics promoting productive splice cycle progression. In contrast to the 
ideal splicing cycle, spliceosomes are challenged at suboptimal splice substrates, 
e.g. by poor recognition of weak splice sites, pre-mRNA folding constrains, or 
presence of faulty RNA binding proteins, which compromise splicing dynamics. Here, 
due to impaired transition between different spliceosomal conformations and slow 
conversion reaction kinetics the equilibrium shifts towards the retrograde rejection 
pathway, which entails the disengagement and discarding of the splice substrate 
mediated via the proofreading DEXD/H-box ATPase enzymes.   
In this context, the ubiquitin-like protein Hub1 might constitute an additional 
layer of quality control at an early stage of the splicing pathway. For this, Hub1 
appears to associate with the spliceosome in order to facilitate the correct assembly 
and proper engagement of spliceosomal subcomplexes on suboptimal splice 
substrates. Extending the kinetic proofreading model presented earlier, Hub1 could 
mediate two non-mutually exclusive activities.  
On the one hand, Hub1 might induce conformational changes and thereby 
convey spliceosomal flexibility and robustness to tolerate minor deficiencies in 
suboptimal substrates. In this case, inhibition of Hub1 activity by in vivo depletion or 
mutation would not affect constitutive splicing of ideal splice substrates, but defective 
splicing factors or aberrant RNA would cause spontaneous stalling of active 
spliceosomes. As Hub1 binding might induce global conformational changes in 
spliceosomal proteins, as shown for Snu66, it is likely that Hub1-deprived 
spliceosomes are structurally restricted.  
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Figure 27: Proposed model for Hub1’s crucial role in pre-mRNA splicing 
Optimal splice substrates (left panel) are efficiently recognized by the spliceosomal snRNPs (colored 
circles), as crucial RNA sequences within the intron-containing transcript (grey boxes) mediate the 
accurate assembly by snRNA/mRNA base paring. The initial step of exon definition and splice site 
recognition is regulated by auxiliary SR proteins (green) and repressive hnRNP factors (red). After 
U4/U6.U5 tri-snRNP incorporation the spliceosome formation and activation is scrutinized by 
proofreading enzymes. After satisfying the quality control, RNA helicases and ATPases promote the 
spliceosome activation and splicing reaction with subsequent dissociation of the spliced mRNA and late 
snRNP complexes. In contrast, suboptimal splice substrates (serrated lines) interfere with proper 
spliceosomal complex formation and efficient recognition by the snRNPs (dotted line), thus requiring the 
qualifying factor Hub1 (middle panel). Hub1 facilitates the correct assembly and enables compromised 
spliceosomes to process suboptimal splice substrates by conveying structural flexibility (e.g. by binding 
to tri-snRNP protein Snu66 (red)) and modulating the enzymatic activities of promoting enzymes, 
respectively. Thus, the ubiquitin-like protein Hub1 is a crucial factor for faithful pre-mRNA splicing of 
distinct splice sites. Accordingly, inactivation of Hub1 (by RNAi or mutant alleles of Hub1) leads to 
stalling of spliceosomal complexes on suboptimal splice substrates as the Hub1-assisted assembly is 
abrogated (right panel). Hub1-deficient spliceosomes fail to properly engage in the correct conformation 
in order to initiate global RNA/protein rearrangements for the splice cycle progression and transition to 
spliceosomal activation. Defective and stalled splicing intermediates are detected by proofreading 
DExD/H-box ATPases and subjected to spliceosomal disengagement and release of the misspliced 
mRNA. Hence, Hub1 inactivation causes continuous splicing defects and the accumulation of aberrantly 
spliced transcripts leading to cellular stress, cell cycle defects and subsequent apoptosis.  
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This rigidness would impinge on the splicing processivity of suboptimal substrates 
and thereby entail the rejection of splicing intermediates by the proofreading 
surveillance enzymes.  
On the other hand, Hub1 could act directly on the quality control factors for 
pre-mRNA splicing by modulating the activity and stringency of the proofreading 
enzymes in order to adjust the accuracy and tolerance by which spliceosomal 
intermediates are scrutinized. Here, Hub1 inactivation and subsequent alterations in 
proofreading factors would result in the premature disengagement of suboptimal 
complexes or random stalling of defective spliceosomes. 
Several lines of evidence support a crucial role of Hub1 at the crossroads 
between the early steps of spliceosome assembly and the formation of the activated 
complex Bact. After the early spliceosomal subunits U1 and U2 snRNP have defined 
the exon-intron boundaries, the U4/U6.U5 tri-snRNP and the PRP19/NTC are 
recruited to form the pre-catalytic spliceosomal complex B. For further activation the 
RNA/protein networks has to undergo major rearrangements including snRNA 
unwinding and re-establishing of new base paring. In the proposed model Hub1 
facilitates the correct spliceosomal assembly and engagement of snRNAs on 
suboptimal splice substrates during this complex conversion. This is accomplished by 
the interaction of Hub1 with the tri-snRNP factor hSnu66, which presumably initiates 
conformational changes and structural rearrangements. In addition to the Hub1-
Snu66 interaction via the HIND, the opposing surface on Hub1 is recognized by a 
pivotal, yet unidentified, component of the spliceosome to further promote processing 
of suboptimal splice substrates. Here, the association with Hub1 could stimulate the 
enzymatic activity of an ATP-driven helicase to catalyze splice cycle progression.  
Intriguingly, the ubiquitin-like fold might serve as a general binding module in 
the spliceosomal protein network. Recent structural bioinformatics analyses have 
identified several ubiquitin-like domains in different spliceosomal proteins including 
SF3A120, SAP18 and XAP-5, which function at late stages of the splicing cycle, 
where proofreading surveillance is most prevalent (Korneta et al., 2012). This 
indicates that the transient association with ubiquitin-like domain proteins represents 
a fundamental principle during spliceosomal complex formation and conversion. 
Here, the ubiquitin-like protein Hub1 appears to play a unique role as it facilitates the 
correct assembly and engagement of spliceosomal subcomplexes and ensures 
proper proofreading at early stages of the splicing process.  
Taken together, the splicing data, the tight association with central splicing 
components, and the detrimental phenotypes of Hub1 depletion in eukaryotic cells 
suggest a conserved, pivotal function of Hub1 in the context of pre-mRNA splicing 
quality control to ensure high fidelity and faithful splice cycle progression on 
suboptimal splice substrates.  
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6 Material and Methods 
Basic molecular biological and biochemical methods were performed according to 
standard techniques (Maniatis et al., 1989; Ausubel et al., 1988) or based on the 
manufacturers' instructions. Newly established and modified techniques are 
described below in more detail. Unless otherwise mentioned, chemicals and reagents 
were purchased from Amersham-Pharmacia, Applied Biosystems, Biomol, Biorad, 
Fluka, Invitrogen, Jackson and Jackson, Kodak, Merck, New England Biolabs, 
Promega, Roth, Roche, Serva or Sigma Aldrich. 
 
6.1 Cell biology 
6.1.1 Human cell lines and transfections  
The established human cell lines HeLa, U2OS and HEK293T were cultured at 37°C, 
6% CO2 in Dulbecco's Modified Eagle Medium (DMEM) high glucose with GlutaMAX 
(Invitrogen), supplemented with 10% fetal calf serum (Biochrom). HEK 293T and 
HeLa cells were transfected using the calcium phosphate precipitation technique with 
HBS buffer and BES buffer, respectively, as described previously (Bartke et al., 
2004). Lipofectamine 2000 (Invitrogen) or Fugene HD (Roche) was used to transfect 
U2OS and HeLa cells. For RNAi experiments, cells were transfected with siRNA 
duplexes by RNAiMax (Invitrogen) or via electroporation with the Amaxa Nucelofector 
II system (Lonza) according to the manufacturer’s protocol. U2OS cells stably 
expressing GFP-Hub1 WT, GFP-Hub1 D22A, hSnu66 WT-GFP, hSnu66ΔHIND-GFP 
and free GFP were generated by selecting cells under 750 -1000 μg/ml G418 (Sigma 
Aldrich) after lipofection for 3-4 weeks. Single G418-resistant colonies were isolated 
using cloning discs and expanded for later analysis. To further enrich and purify 
GFP-positive cells fluorescence-activated cell sorting was performed using the 
FACSAria cell sorter system (Becton Dickinson).  
In experiments with RNA Polymerase inhibition, cells were treated with 
actinomycin D (5 μM), α-Amanitin (25 μg/ml) or 5,6-dichloro-1-beta-D-ribofuranosyl-
benzimidazole (DRB, 25 μg/ml) (all Sigma-Aldrich) for indicated time intervals.  
 
6.1.2 Mammalian expression plasmids and siRNA 
Standard cloning techniques were used to generate mammalian expression 
constructs with vectors of the pCMV-Tag2/3/4 (Stratagene), pcDNA3.1 and pUB6 
(both Invitrogen) series as well as pCI/pCI-Neo (Promega), pEGFP and pDsRed 
(Clontech) and p3xFlag-CMV-10 (Sigma-Aldrich) vectors. Plasmids with point 
mutations were constructed by site-directed mutagenesis using target specific 
primers in PCR reactions. Genomic fragments of fibronection 1 (FN1), tropomyosin 1 
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a (TPM), myeloid cell leukemia sequence 1 (MCL1), v-akt murine thymoma viral 
oncogene homolog 1 (AKT) and aurora kinase A (AURKA) for minigene constructs 
were amplified from genomic human DNA (U2OS) by PCR and subcloned into 
modified pUB6/V5 vectors (Invitrogen). For RNAi siRNA sequences were designed 
as 19- or 21-mer duplexes with 3’ TT-overhangs according to stringent criteria 
previously described (Jagla et al., 2005) and purchased from MWG. siRNA duplexes 
targeting Hub1 in human cells were iHub1_1 GGA AGA AGG UCC GCG UUAA, 
iHub1_2 CAA GAU UGU CCU GAA GAA G, iHub1_3 AUA GAU GAG AAU CCU 
CAUC, iHub1_4 UGC AAC ACG GAU GAU ACCA, iHub1_5 GGG AAG AAG GUC 
CGC GUUA. For knockdown of hSnu66 siRNA sihSnu66_1 CUA ACA AAC UCC 
GGG CAAA or sihSnu66_3 GUA UGA CGA AGA GCU UGA ATT, for ASF/SF2 
siSRSF1_5 GGA CUG CCU CCA AGU GGA ATT or siSRSF1_6 GGC AGG AUU 
UAA AGG AUC ATT for URH49 AAA GGC CUA GCC AUC ACU UUU and for 
UAP56 AAG GGC UUG GCU AUC ACA UUU (both described in Kapadia et al., 
2006) were used. The GL2 siRNA targeting luciferase (Elbashir et al., 2001) CGU 
ACG CGG AAU ACU UCGA was used as knockdown control. RNAi of Son was 
performed with Silencer pre-designed siRNA (ID# 143161) from Applied Biosystems / 
Ambion.  
 
6.1.3 Flow cytometry 
DNA histograms were obtained by flow cytometry of propidium iodide (PI)-stained 
ethanol-fixed cells using standard protocols. Briefly, cells were harvested by 
trypsinization and washed with ice-cold PBS. For fixation, cells were resuspended in 
300 μl PBS and 700 μl cold EtOH (-20°C) and incubated on ice. Afterwards fixed 
cells were washed twice with PBS and subsequently stained in PI-buffer (PBS, 100 
μg/ml propidium iodide (Sigma Aldrich), 200 μg/ml RNase A (Roche)) for one hour. 
Data was acquired on a FACSCalibur system with CELLQuest software (Becton 
Dickinson) and further analyzed with FlowJo software (Tree Star). HeLa cells were 
synchronized following standard double-thymidine block protocols using 2 mM 
thymidine. 
 
6.1.4 Immunofluorescence, FISH and live cell microscopy 
For standard immunofluorescence microscopy, cells were seeded and transfected on 
glass coverslips (Roth). Cells were washed twice with PBS and fixed in 3.7% fresh 
paraformaldehyde (PFA) / PBS for 18 min at room temperature. After fixation, 
residual formaldehyde was inactivated by quenching with PBS-glycine (30 mM) and 
cells were washed three times in PBS. Permeabilisation of cells was performed using 
PBS-Triton X-100 0.4% (6 min), followed by three PBS-Tween (Tween 0.05%; PBS-
T) washing steps and blocking in PBS-T with 2% BSA for 1 h at room temperature. 
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Coverslips were incubated with primary antibody for 3 h (appropriate dilutions in 
blocking buffer) and then washed three times in PBS-T. After incubation with 
secondary antibody, cover slips were mounted using DAPI-containing mounting 
medium (Vectashield, Vector Labs). For pre-extraction experiments cells were 
permeabilized in CSK buffer (100 mM NaCl, 300 mM sucrose, 10 mM PIPES pH 6.8) 
supplemented with 0.4% Triton X-100 and complete protease inhibitors (Roche) for 8 
min at 4°C. After two gentle wash-out steps with detergent free CSK buffer, cells 
were fixed with 3.7% formaldehyde. The subsequent antibody staining was 
performed according to the abovementioned standard protocol.  
The RNA FISH method to visualize poly-adenylated mRNA using 
fluorescently labeled poly-(dT)70-TRITC probes was adapted from previous protocols 
(Tokunaga and Tani, 2008). HeLa or U2OS cells grown on glass slides were fixed in 
3.7% fresh paraformaldehyde / PBS for 15 min at room temperature. After PFA 
quenching and permeabilisation with 0.5% PBS-Triton X-100 (5 min at 4°C) cells 
were washed with 2xSSC (300 mM NaCl  , 30 mM Na3Citrate·2H2O pH 7.0). Poly-
adenylated mRNA was stained with the hybridization solution (2xSSC, 20 % 
formamide, 1 mg/ml tRNA, 10 % dextran sulfate and 2 μg TRITC labeled poly-(dT)70 
probe) in a sealed humid chamber at 37°C overnight. After three 2xSSC washing 
steps with DAPI as nuclear counterstain slides were mounted and sealed for 
microscopy analysis.  
Images were acquired on a Zeiss AxioImager Z1 microscope equipped with 
an AxioCam MRm Rev.3 camera. Image acquisition was carried out using AxioVision 
Rel. 4.7 software (Zeiss).  
For fluorescence time-lapse microscopy, HeLa H2B-GFP cells were seeded 
into 4 well μ-dishes (ibidi) after RNAi transfection and transferred into the live cell 
imaging system, BioStation IM (Nikon). Images were acquired every 8 min over a 
time frame of 24–48 h with BioStation IM software and further processed by ImageJ 
and Photoshop (Adobe). 
 
6.1.5 Cell lysis and immunoprecipitation 
For immunoprecipitation, cells were harvested, washed in ice-cold PBS and cell 
pellets were lysed in 5x pellet volumes of immunoprecipitation buffer (50 mM HEPES 
pH 7.2, 150 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, 1 mM PMSF, and complete 
protease inhibitors (Roche)) at 4°C for 30 min with several passages through a 25 
gauge needle attached to a syringe. After removal of cell debris by centrifugation (10 
min, 16000xg, 4°C), cleared lysates were incubated with anti-FLAG M2 affinity gel 
(Sigma-Aldrich), anti-c-Myc-agarose (Sigma-Aldrich) or GFP trap (Chromotek) for 2 h 
at 4°C. The affinity matrix was washed four times with immunoprecipitation buffer and 
eluted in Laemmli SDS buffer for later analysis by SDS-PAGE and immunoblotting.  
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For caspase activation assay, cytosolic extracts were prepared as described 
previously (Deveraux et al., 1999). In immunoprecipitation experiments with hSnu66 
WT or ΔHIND co-purifying protein interactors were identified by mass spectrometry 
using LTQ-Orbitrap mass spectrometers as a service of the MPI core facility.  
 
6.1.6 Antibodies 
Antibodies used in this study were anti-α-tubulin (DM1A, Sigma Aldrich), anti-
caspase-7 (C7, Cell Signaling), anti-caspase-3 (8G10, Cell Signaling), anti-GFP 
(clone B-2, Santa Cruz and ab1218, Abcam), hnRNP I (Z-22, Santa Cruz), anti-lamin 
A/C (clone 636, Santa Cruz), anti-c-Myc (clone 9E10, Sigma Aldrich), anti-p21 (clone 
187, Santa Cruz), anti-p53 (clone DO-1, Santa Cruz), anti-PRPF8 (ab87433, Abcam), 
anti-TAP/PAP (Sigma Aldrich), anti-hSnu66 (A301-423A, Bethyl), anti-SC35 
(ab11826, Abcam), anti-Son (HPA023535, Sigma Aldrich), anti-2,2,7-
trimethylguanosine (K121, Calbiochem), anti-U1A (ab55751, Abcam), anti-U2AF65 
(ab37483, Abcam), anti-Sm antigen Y12 (ab3138, Abcam).  
For immunofluorescence, Alexa Fluor 488- and Alexa Fluor 555-labeled 
secondary goat anti-mouse and donkey anti-rabbit / anti-mouse antibodies from 
Invitrogen were applied. Hub1-specific antibodies against recombinant S. cerevisiae 
Hub1 and human Hub1, respectively, were affinity-purified from serum of immunized 
rabbits (see chapter 6.2.12). For standard applications antibodies were diluted 
1:1000 to 1:5000 for immunoblot analysis and 1:200 to 1:2000 for 
immunofluorescence detection. 
 
6.1.7 Exon-specific alternative splicing microarray 
For genome-wide analysis of altered splicing patterns in Hub1-depleted U2OS cells, 
total RNA was isolated from Hub1 or control RNAi treated cells (see section 6.2.4) 
50-60 h after transfection. Experiments were performed in biological triplicates with 
each sample tested for cell viability and fitness to avoid indirect effects by cell 
degeneration or apoptosis as observed at late stages of Hub1 knockdown. Further 
processing of the RNA samples including quality control of total RNA, reduction of 
ribosomal RNA, cDNA synthesis and purification, fragmentation and labeling were 
conducted by Atlas Biolabs GmbH (Berlin). Finally, the labeled cDNA probes were 
hybridized against an Affymetrix GeneChip Human Exon 1.0 ST, which utilizes 1.4 
million probe sets to target over 1 million exon for genome-wide exon-level 
expression profiling. The microarray is designed to provide a comprehensive 
coverage of the transcriptome comprising of validated, annotated sequences from 
various transcript and EST databases as well as predicted mRNA sequences based 
on bioinformatics analyses of genome projects allowing the identification of 
previously unidentified splice variants. The exon-specific microarray combines mRNA 
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expression profiling with quantitative exon-specific probes and allows quantification 
of alternatively splices transcripts and the identification of newly generated isoforms 
as multiple probes per exon are targeted to sequences along the entire length of the 
respective transcript (≥ 4 probes per probe selection region e.g. individual exons). 
The following computational analysis includes data normalization, quality control 
measures and algorithms for alternative splicing detection. Here, the entropy-based 
ARH prediction method was applied to identify probe sets which exhibit significant 
alterations in individual exonic sequences (relative exon expression) without changes 
in overall transcript expression levels (Rasche and Herwig, 2010). After this process, 
high confidence hits are translated into the splicing index (SI), statistically tested and 
ranked. The final data set gives strong indications which transcripts undergo 
alternative splicing and changes in splicing patterns upon a certain stimulus or 
treatment, here, after Hub1 depletion.  
 
6.1.8 Yeast strains and plasmids 
Complementation assays with S. cerevisiae and S. pombe strains, western blot 
analysis and SRC1 alternative splicing assays used in this study were described in 
detail previously (Mishra et al., 2011). p415 ADH plasmid harboring coding 
sequences of S. cerevisiae, S. pombe and human HUB1 were used for 
complementation of S. cerevisiae hub1Δ mutants. pREP81 plasmid harboring coding 
sequences for HUB1 orthologs were used for complementation of the S. pombe 
mutant. Complementation experiments with S. pombe and S. cerevisiae hub1Δ cells 
were performed in collaboration with S.K. Mishra. 
For yeast two-hybrid screening of whole cDNA libraries, potential binding 
factors were expressed as Gal4 activation domain fusion proteins (AD-fusion), 
whereas the bait protein carries the Gal4 DNA binding domain. In case of physical 
interaction between the two fusion proteins reporter gene expression (HIS3 and 
ADE2) was induced which allows growth on selective media of the otherwise 
auxotrophic cells (SC-Ura-Trp-His: 3.5 % bacto-yeast nitrogen base, 2 % glucose, 
0.2 % amino acid mix). Here, Hub1 served as the BD-fusion bait protein for screening 
of human cDNA libraries from different tissues with high transcript coverage (average 
insert size ≥ 2.1 kb). Based on data showing that Hub1 is ubiquitously expressed in 
human cells, but particularly up-regulated in brain tissue (Friedmann et al., 2001), 
libraries of fetal brain tissue and HeLa cells cDNAs were selected (Invitrogen). After 
the optimization of transformation efficiency the two-hybrid yeast strain PJ69-7A 
harboring the Hub1-pGBDU construct was used to screen the human cDNA libraries. 
Intriguingly, human BD-Hub1 exhibited auto-activation activity of the HIS3 reporter 
gene, thus the addition of 3-amino-1,2,4-triazole (3-AT) to the growth media (2 - 5 
mM) was required to ensure restrictive screening conditions. After the candidates 
were tested for auto-activation after FOA-shuffle, the -Ura-Trp-His positive clones 
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were subjected to further interaction validation using standard assays like X-Gal 
overlay or growth on -Ade plates.  
 
6.2 Molecular biology  
6.2.1 Preparation and transformation of chemically competent E. coli  
E. coli strains used for cloning or protein expression: 
XL1-Blue MR  Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac 
BL21 Codon Plus (DE3)-RIL  B F- ompT hsdS(rB- mB-) dcm+ Tet
r gal λ(DE3) 
endA Hte [argU ileY leuW Camr] 
BL21 Rosetta 2 Φ DE3 F- ompT hsdSB(rB- mB-) gal dcm pRARE2 CamR 
 
When culturing E. coli strains under standard conditions, e.g. for plasmid DNA 
preparation, LB media (1 % bacto-tryptone, 0.5 % yeast extract, 1 % NaCl) or LB 1.5 
% agarose plates were used. Plasmid-containing bacteria were selected by their 
antibiotic resistance under 50 μg/ml Ampicillin or 30 μg/ml Kanamycin at 37 °C. The 
absorption of liquid cultures was measured with a standard spectrophotometer at a 
wavelength of 600 nm to determine optical density (OD600nm). 
To obtain highly competent E. coli cells were prepared according to the Inoue 
protocol (Inoue et al., 1990). Briefly, the pre-culture grown 4-5 h at 37 °C in SOB (2 
% bacto-tryptone, 0.5 % yeast extract, 10 mM NaCl, 2.5 mM KCl, pH 7.0 NaOH) 
served as inoculant for the main culture (≥ 500 ml) which was incubated at lower 
temperature (18 °C) overnight. Next day, when the cell suspension had reached 
OD600nm 0.5 - 0.6, the main cultures were cooled down in flasks for 10 min in an ice 
bath. After centrifugation, cells were resuspended and washed in pre-chilled Inoue 
transformation buffer (55 mM MnCl2, 250 mM KCl, 15 mM CaCl2, 10 mM PIPES pH 
6.7). Cells were collected by centrifugation and resuspended again in Inoue buffer. 
DMSO was added slowly to the cell suspension to a final concentration of 7.5 % and 
further incubated in an ice bath for 10 min. Finally, competent cells were aliqouted, 
snap frozen in liquid nitrogen and stored in PCR tubes at -80 °C until use. 
For transformation, competent cells were thawed on ice and incubated with 1-
4 μl of plasmid DNA suspension in TE. After 10 - 30 min E. coli cells were heat-
shocked for 1 min at 42 °C in a water bath and immediately chilled on ice for 
recovery. Next, growth media was added to the suspension for further cell 
proliferation and incubated at 37 °C on a shaking device. Finally, cells were streaked 
on LB plates containing the appropriate selection antibiotics and grown overnight at 
37 °C. To enforce high transformation efficiency, 0.2 % β-mercaptoethanol was 
added to E. coli cells prior the addition of DNA. 
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6.2.2 Isolation of plasmid DNA 
Small-scale (mini) preparations of plasmid DNA were performed using kits from 
Qiagen or Bioneer according to the manufacturers’ protocols. For mammalian cell 
culture large quantities of highly pure DNA were necessary in order to prevent 
cytotoxic effects during transfection caused by residual endotoxins. For this, Qiagen 
or Sigma-Aldrich maxi kits with optimized protocol were used for plasmid DNA 
purification after alkaline lysis from E. coli overnight cultures (250 - 400 ml). The 
isolated DNA was further concentrated by an isopropanol precipitation step mixing 
eluate TE buffer with isopropanol and 3 M Na-Acetate pH 5.2 in a ratio of 10:7:1. 
After centrifugation at 5000xg for 30-60 min at 4°C the resulting DNA pellet was 
washed with 70 % EtOH and finally resuspended in TE buffer. DNA concentration 
and purity was measured using the Nanodrop (Thermo Scientific). 
 
6.2.3 Polymerase chain reaction and site directed mutagenesis 
Polymerase chain reaction was conducted according to the manufacturer’s protocols. 
For DNA amplification, DNA polymerases Phusion (NEB) and Pfu Turbo (Aligent) 
were used with dNTPs solution mix (NEB) and the respective buffers. Point mutants 
were introduced by site-directed mutagenesis using primers carrying the modified 
sequence flanked by 10-15 nt overhangs for correct targeting to the designated DNA 
site. PCR products were subsequently digested with DpnI restriction enzyme (NEB) 
for 1-2 h, heat inactivated and transformed into E. coli. 
 
6.2.4 DNA restriction, ligation and cloning  
In order to introduce specific PCR fragments into expression vectors, 1-5 μg of DNA 
were incubated with 5-10 U of appropriate DNA restriction enzymes (NEB) in the 
corresponding buffer systems following standard cloning techniques. While plasmids 
and plasmid-derived inserts were digested by endonucleases for 1 - 2 h, PCR 
products were digested overnight. Cut vectors were subjected to calf intestinal 
phosphatase (CIP, NEB) treatment for 1 h to avoid re-ligation of linear DNA. After 
restriction, digested DNA fragments were analyzed by agarose gel electrophoresis 
and subsequently re-isolated using gel extraction kits (see chapter 6.2.6). Finally, 
DNA fragments (in 3-5 fold excess) were ligated into vectors via complementary 
cohesive ends using standard T4 ligase or the derived Quick T4 ligase (both NEB) in 
their respective buffers. The Quick T4 ligation reaction was performed for 5-30 min at 
RT while standard T4 reactions were incubated at 16°C overnight until transformation 
into chemically competent bacteria. 
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6.2.5 RNA-purification, RT-PCR and splicing gels 
Total RNA was isolated from control or Hub1 RNAi-transfected cells using the 
RNeasy kit (Qiagen) or the High Pure RNA Isolation kit (Roche) according to the 
manufacturer protocols. Reverse transcription was performed using the Transcriptor 
First Strand cDNA Synthesis Kit (Roche) with random hexamer or poly-(dT) primers. 
Transcript specific PCR was performed using PfuTurbo polymerase (Aligent) and 
subsequently analyzed on 2-2.5% ethidium bromide containing TBE agarose gels. 
 
6.2.6 Gel electrophoresis of DNA and purification from agarose gels 
For the separation of PCR fragments, cloning intermediates or RT-PCR products, 
DNA samples were loaded with orange G sample dye (5 % glycerol, 0.05 % SDS, 5 
mM EDTA pH 8.0) on 1-2 % TBE (90 mM Tris-borate, 2 mM EDTA pH 8.0) agarose 
gels containing 0.005% ethidium bromide. Depending on DNA fragment size and 
agarose concentration gel electrophoresis was performed in Tris-borate buffered 
chambers for 30-90 min at 10-15 V/cm and analyzed in GenoSmart UV 
transillumination documentation system. For subsequent cloning steps, PCR or 
restriction DNA fragments were isolated following gel electrophoresis. The 
corresponding bands were excised from the gel on an UV transilluminator screen, 
DNA was solubilized and subsequently purified using standard DNA gel extraction 
kits (Bioneer, Macherey&Nagel). 
 
6.2.7 DNA sequencing  
DNA sequencing of cloning constructs and PCR products was performed by the core 
facility service of the MPIBC using the Sanger dideoxy terminator cycle sequencing 
chemistry with the ABI BigDye kit on an ABI 3730 48-capillary sequencer and 36 cm 
capillaries. 
 
6.2.8 Plasmids for recombinant protein expression in E. coli 
For recombinant protein expression in E. coli following plasmids were used: pET 
(pET24b(+) and pET28a/b/c(+) (Novagen) for 6xHis-tagged proteins and GST-tagged 
proteins were expressed using the pGEX vector series (pGEX4T1/2/3 and pGEX5X1) 
(Amersham). 
 
6.2.9 Purification of recombinant proteins from E. coli 
E. coli BL21(DE3)/RIL and BL21 Rosetta cell pre-cultures were inoculated in 50 ml 
antibiotic-containing LB or TB (Terrific Broth, 1.2 % bacto-tryptone, 2.4 % yeast 
extract, 0.4 % glycerol NaCl, 10 % TB salt (170 mM KH2PO4, 720 mM K2HPO4 in 
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H2O) media and cultured at 25°C overnight. For recombinant protein expression 
these cultures served as inoculants for larger volumina starting OD600 nm at 0.2. Then 
E. coli were shifted to 37°C until OD600 nm of 0.4-0.7 was reached, and protein 
expression was induced by the addition of 1 mM IPTG for 2-5 h at RT.  
In the case of GST-fusion proteins, after cells were pelleted (6000xg, 10 min, 
4°C) and resuspended in lysis buffer (10 mM Na2HPO4, 1.8 mM KH2PO4, 400 mM 
NaCl, 2.7 mM KCl, pH of 7.4, 1 mM DTT), enzymatic cell wall digestion by lysozyme 
on ice for 30 min preceded mechanical lysis with EmulsiFlex-C3 cell disruptor 
(Avestin). After 3-5 shearing cycles, lysates were supplemented with 2 mM PMSF 
and detergent (0.5 % Triton-X-100 or NP40) and transferred to polypropylene tubes 
for removal of remaining intact cells and debris by centrifugation (30 min, 20000xg, 
4°C). For affinity-purification of the recombinant GST-fusion protein the cleared 
supernatants were loaded onto ethanol-free Glutathione Sepharose 4Fast Flow 
columns (GE healthcare) and incubated for 2 h at 4°C on a rotation wheel. 
Subsequently, columns were extensively washed with ca. 300 column volumes GST 
washing buffer (10 mM Na2HPO4, 1.8 mM KH2PO4, 400 mM NaCl, 2.7 mM KCl, pH of 
7.4, 1 mM DTT, 2 mM PMSF, 0.5 % Triton-X-100). Finally, affinity matrix bound 
proteins were eluted with 6 column volumes GST elution buffer (PBS, 50 mM 
glutathione, pH 7.5) in several aliquots, which were analyzed by protein 
concentration measurements and SDS PAGE, to ensure successful and efficient 
purification. The eluate was dialyzed against glycerol-containing buffers of choice 
prior to freezing in liquid nitrogen. 
Similarly, 6xHis-tagged fusion proteins were purified from E. coli lysates after 
induction, expression and harvest. Here, cell pellets were resuspended in Ni-NTA 
buffer (50 mM NaH2PO4 pH 8.0, 300 mM NaCl, 20 mM imidazole) before lysis via 
lysozyme digestion and mechanical cell disruption (see above). After centrifugation 
cleared lysates were applied onto Ni-NTA agarose columns (Qiagen) and incubated 
for 2 h at 4°C in order to couple 6xHis-tagged proteins to the affinity matrix. Extensive 
washing removed unspecific protein binding factors, followed by elution with Ni-NTA 
elution buffer (50 mM NaH2PO4 pH 8.0, 150 mM NaCl, 250 mM imidazole). The 
eluates were analyzed by protein concentration measurements and SDS PAGE and 
dialyzed against glycerol-containing buffers of choice prior to freezing in liquid 
nitrogen. 
To obtain highly pure recombinant proteins, e.g. for crystal structure 
determination additional biophysical methods like gel filtration were applied in 
collaboration with groups of the NMR department and the MPIBC core facility using 
Äkta avant systems (GE). 
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6.2.10 Determination of protein concentrations  
Protein concentrations of lysates and purified proteins were measured using a 
modified Bradford method, the Bio-Rad Protein assay, combined with standard 
spectrophotometers (Eppendorf) or alternatively, with NanoDrop (Thermo). 
 
6.2.11 CNBr coupling 
For antibody purification from serum the epitope containing peptide or its respective 
recombinant full-length protein was covalently coupled to a CNBr sepharose matrix. 
For this, the pre-activated CNBr sepharose 4 fast flow (GE Healthcare) was first 
resuspended in 1 mM HCl for 30 min and then transferred to a Buchner funnel where 
the matrix was washed with 15 gel volumes of cold 1 mM HCl and subsequently with 
coupling buffer (0.5 M NaCl, 0.1 M NaHCO3 pH 8.3). The coupling was performed by 
incubating the unloaded matrix with the protein or peptide of interest overnight at 4°C 
or for 3-4 h at RT. Coupling efficiency was tested by taking samples before and after 
coupling and during washing steps. In order to avoid precipitation, the protein was 
dialyzed against the coupling buffer prior to coupling. After covalent attachment of the 
protein to the matrix, the remaining supernatant was removed, the column was 
washed before uncoupled sites were blocked by ethanolamine (1 M at pH 9.0) for 2 h 
at RT. Finally, free ethanolamine was removed by several washing steps with PBS 
and the affinity matrix was used for antibody purification. The columns were stored in 
PBS / 0.1 % azide at 4°C. 
 
6.2.12 Antibody purification 
For generation of Hub1 specific antibodies rabbits were immunized with recombinant 
Hub1 supported by TiterMax Gold adjuvant (Sigma). The immunization injection, 
boosting and bleeding was conducted by the animal facilities of the MPIBC. A crude 
serum was obtained after the final bleed had been incubated for initial agglutination 
at 37 °C for 30-60 min. After removal of clogged material an additional incubation at 
4°C overnight allowed contraction of residual material. The serum was recovered as 
the supernatant of the blood sample after centrifugation (10000xg, 10 min, 4°C) and 
stored in aliquots at -20°C.  
In an additional step, the Hub1 specific antibodies were further purified and 
enriched. Therefore, the CNBr coupled Hub1 column served as an affinity matrix and 
was incubated with a fraction of the crude serum at 4°C using a circulation pump. 
The matrix was washed several times with PBS to remove unspecific serum proteins 
and bound Hub1-specific antibodies were subsequently eluted by pH shift (100 mM 
glycine, 100 mM NaCl pH 2.5). The eluate’s pH was immediately neutralized by the 
addition of 100 mM Tris (pH 9.0) buffer. Finally, the antibody concentration of the 
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collected fractions was measured with the NanoDrop spectrometer (Thermo) and 
fractions were stored at -20°C after the addition of glycerol.  
 
6.2.13 Polyacrylamide gel electrophoresis and immunoblotting  
Protein samples were denatured in Laemmli sample buffer and separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis using 4-12% NuPAGE Bis-Tris 
gradient gels in combination with MES and MOPS buffer (Invitrogen). This system 
provides a wide range of molecular weight separation that allows high resolution of 
small sized proteins like Hub1 (< 10 kDa) as well as large proteins like PRPF8 (220 
kDa) in the same gel. After SDS PAGE proteins were transferred to methanol-
activated PVDF membranes (Millipore) using a semi-dry blotting device (MPI 
engineering) for 90 min with a constant current of 0.8 mA/cm2. The transfer was 
supported by NuPAGE transfer buffer (25 mM Bicine, 25 mM Bis-Tris, 1 % EDTA and 
20% methanol). Subsequently, PVDF membranes were blocked using 5% w/v skim 
milk powder in PBS-T and incubated with primary antibody (5% w/v skim milk powder 
in PBS-T) for 1-3 h or overnight at 4°C. After extensive washing with PBS-T the 
membranes were incubated with species-specific secondary antibodies coupled to 
HRP for chemiluminiscence detection (ECL – Western blot Detection Kit, Amersham) 
on conventional films (Kodak) or CCD cameras (Fuji).  
 
6.2.14 Structure determination of the human Hub1-HIND complex 
The crystal structure of human Hub1 in complex with hSnu66’s HIND was solved in 
close collaboration with Kaja Kowalska of the NMR department at the MPIBC 
(Kowalska, 2012).  
For crystallization 6xHis-tagged human Hub1 was expressed in BL21-
CodonPlus (DE3)-RIL cells (Stratagene) and the recombinant protein was purified via 
Ni-NTA agarose beads, followed by gel filtration on Superdex 75 (GE Healthcare) in 
PBS buffer. Proper folding of the protein was analyzed by 1D NMR spectrum 
recorded by a 600-MHz Bruker NMR spectrometer. The hSnu66 HIND peptide, 
comprising residues 117 - 135 of hSnu66, containing the sequence 
SLSIEETNKLRAKLGLKPL, was chemically synthesized in the core facility of the 
MPIBC.  
For crystallization, purified Hub1 was mixed with the HIND peptide at a molar 
ratio of 1:3 and the complex was separated by gel filtration on Superdex 75 (GE 
Healthcare) in 10 mM Tris/HCl pH 8.0, 100 mM NaCl, and 5 mM β-mercaptoethanol. 
The complex was concentrated to 10-13 mg/mL and crystallized at 20 °C, using the 
sitting drop vapor diffusion method. The 2 - 3 μl drops consisted of a 1:1 (vol/vol) 
mixture of protein solution and well solution. Crystals appeared after 3 days and grew 
to final size after 2 weeks of incubation. The best diffracting crystals of the human 
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Hub1/HIND complex grew in 0.1 M Tris/HCl pH 9.0, 0.15 M sodium acetate, 20% 
(w/v) PEG 4000. Crystals were soaked in cryoprotection solution containing mother 
liquor supplemented with 30% glycerol and were snap frozen in liquid nitrogen.  
 For data collection and structure determination a high quality X-ray dataset up 
to 2.0 Å was collected at the Swiss Light Source beamline PXII at Paul Scherrer 
Institute (Villigen, Switzerland). The collected data was integrated, scaled and 
merged by XDS and XSCALE programs (Kabsch, 1993) in space group P21212. The 
structure was determined by molecular replacement using the Molrep program from 
the CCP4 suite ccp (Collaborative Computational Project, Number 4, 1994) and the 
structure of the ScHub1/HINDII complex as a search model (PDB entry 3PLV). 
Refinement and model building were carried out with the REFMAC5 (Collaborative 
Computational Project, Number 4, 1994) and XtalViev/Xfit (McRee, 1999). The 
Arp/Warp program (Lamzin and Wilson, 1993) was used to add water molecules. 
Certain solvent-exposed side-chains without clear electron density were removed 
from the model. Detailed data collection and refinement statistics are shown in the 
appendix 12.3. Residues W47 and Y48 of human Hub1 were found to lie in 
prohibited regions of the Ramachandran plot. These disallowed conformations are 
forced by crystal contacts with symmetry related molecules. The Ramachandran plot 
distribution for residues in the structure was 95.4% in most favored regions, 3.4% in 
allowed regions, 1.2% in disallowed regions. All structural-model figures were 
generated by Pymol. 
 
6.2.15 Software 
For bioinformatics analysis, DNA and protein sequences were obtained from 
resources of the National Center for Biotechnology Information (NCBI) and the 
Ensembl project (http://www.ensembl.org/). Sequence characterization, alignments 
and processing was carried out using Lasergene software Vers .9 (DNA Star) 
combined with Basic Local Alignment Search Tools (BLAST). Data mining was 
conducted using various data-base platforms including Universal Protein Resource 
(UniProt), Simple Modular Architecture Research Tool (SMART), Eukaryotic linear 
motif resource (ELM), Saccharomyces Genome Database (SGD), 
Schizosaccharomyces pombe Database (PomBase). Protein structures were 
visualized with Pymol and Swiss-PDB viewer (SIB) and external NMR structures 
were obtained from the protein data bank (PDB) and Research Collaboratory for 
Structural Bioinformatics (RCSB). Flow cytometry data was analyzed using FlowJo 
(TreeStar) and CellQuestPro (BD). 
The exon-specific microarray datasets as well as EST and sequencing data on 
alternative splicing and mRNA isoforms were retrieved from Ensembl and the 
Alternative Splicing Database project (ASD) and analyzed using AltAnalyze (version 
2.0.8), Affymetrix Power Tools software together with the Integrated Genome 
Material and Methods 
 119
Browser (IGB; version 7.0.1). Texts, graphs and tables were prepared using Excel, 
Word (both Microsoft) and Prism (GraphPad), images were prepared using 
Powerpoint (Microsoft), Photoshop and Illustrator (both Adobe).  
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9 Abbreviations 
APS ammonium peroxodisulphate 
ATP adenosine triphosphate 
BES N,N-Bis(2-hydroxyethyl)-2-
aminoethansulfonate 
bp base pairs 
BSA bovine serum albumin 
BPS branch point sequence 
C- carboxy- 
Cdc cell division cycle 
CDK cell cycle dependent kinase 
cDNA complementary DNA 
Cy3 carbocyanin 3 
Da Dalton 
DAPI 4',6-diamidino-2-phenylindole 
DExD/H RNA helicase consensus motif 
DMEM Dulbecco modified Eagle's minimal 
essential medium  
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTPs deoxyribonucleotides 
ds double-stranded 
DTT dithiothreitol 
ECL enhanced chemiluminescence 
EDTA ethylenediamintetraacetat 
EGFP enhanced GFP  
FACS fluorescence activated cell sorter 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FPLC fast protein liquid chromato-graphy 
GFP green fluorescent protein 
GST glutathione S-transferase 
GTP guanosine triphosphate 
h hour 
H histone 
HBS HEPES buffered saline 
HEPES N-(2-hydroxyethyl)-piperazin-N’-(2-
ethansulfonate) 
Hn heterogenous nuclear 
IAP inhibitor of apoptosis protein 
IgG immunoglobulin G 
IκB inhibitor of nuclear factor κB  
IP immunoprecipitation 
IPTG isopropyl-ß-D-thiogalacto-
pyranoside 
kb kilobases 
kDa kilo Dalton 
M molar 
mAb monoclonal antibody 
min minute 
MOPS 3-(N-morpholino)-propane 
sulfonate 
mRNA messenger RNA 
MT microtubule 
3mG 2,2,7-trimethylguanosine 
N- amino- 
NFκB nuclear factor κB   
Ni-NTA nickel-nitrilo triacetate 
NLS nuclear-localization sequence 
NP-40 Nonidet P-40 
nt nucleotides 
NTP nucleoside triphosphate 
OD optical density 
Oligo oligonucleotide 
ORF  open reading frame 
pAb  polyclonal antibody 
PAGE  Polyacrylamide gel  
  electrophoresis 
PBS  phospate buffered saline 
PCR  polymerase chain reaction 
PEG  polyethylene glycol 
PIPES piperazin-N,N’-bis(2-
ethansulfonsäure) 
Plk  Polo-like kinase 
PMSF  phenylmethyl-sulphonylfluoride 
PPT  polypyrimidine track 
PRP  pre-mRNA processing 
R  Purine base 
RNA  ribonucleic acid 
RNase  ribonuclease 
RNAi  RNA-Interference 
RRM  RNA recognition motif 
RT  room temperature  
RT-PCR reverse transcription PCR 
shRNA  short hairpin RNA 
s.d.  standard deviation 
SDS  sodium dodecylsulfate 
siRNA  small interfering RNA 
SR  serine-arginine rich 
ss  splice site 
TBS  Tris-buffered saline 
TCA  trichloroactetic acid 
TE  Tris-EDTA buffer 
Tris Tris-(hydroxymethyl)-
aminomethan 
TRITC tetramethylrhodamine 
isothiocyanate 
U snRNA uridine-rich small nuclear RNA 
U snRNP uridine-rich small nuclear 
ribonucleoprotein 
V  Volts 
W  Watts 
WB  Western blot/Immunoblot 
WT  wild type 
W/v  weight per volume 
Y Pyrimidine base 
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12 Appendix 
12.1 Affymetrix Human Exon 1.0 ST microarray data 
Summary of exon-specific microarray data after CEL expression profile analysis via Affymetrix 
Powertools. Relative and absolute expression profiles of individual probes after Hub1 or control 
knockdown in U2OS cells were processed using the ARH method (Rasche and Herwig, 2010), resulting 
in metascores based on Splice index (SI), p-value (P, log10) and arh-value (arh, > 0.03 significant). The 
metascores are ranked according to unfiltered (0), filtered for cross-hybridization and expression 
constrains (1) and intensity > mean intensity filter (2).   
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12.2 Microarray mRNA expression analysis  
The table summarizes the 100 most strongly affected transcripts upon Hub1 knockdown in U2OS cells 
compared to control RNAi treated cells (performed in biological triplicates). The absolute fold change of 
gene expression is shown for 31 up (green) and 69 down-regulated mRNAs. 
  
Probe Id p-Value log (fold_change) fold_change
2502842 0.0327 -1.7533 -3.3714
3375999 0.0097 -1.7567 -3.3792
3571667 0.0020 -1.7633 -3.3948
3126368 0.0039 -1.7633 -3.3948
2333136 0.0185 -1.7667 -3.4027
3758928 0.0032 -1.7767 -3.4263
2604998 0.0087 -1.7767 -3.4263
3629103 0.0015 -1.7867 -3.4502
3749528 0.0010 -1.7900 -3.4581
3573933 0.0011 -1.7933 -3.4661
3900091 0.0154 -1.7933 -3.4661
3376556 0.0035 -1.8000 -3.4822
2360700 0.0070 -1.8033 -3.4903
3703112 0.0111 -1.8033 -3.4903
3281703 0.0156 -1.8100 -3.5064
3933923 0.0232 -1.8133 -3.5145
2409069 0.0000 -1.8167 -3.5227
Probe Id p-Value log (fold_change) fold_change 2413153 0.0019 -1.8200 -3.5308
2731332 0.0163 3.4167 10.6787 3995392 0.0009 -1.8300 -3.5554
3143112 0.0029 2.9533 7.7454 3175971 0.0137 -1.8367 -3.5718
2582124 0.0089 2.8400 7.1602 4022370 0.0052 -1.8367 -3.5718
2530713 0.0060 2.7533 6.7427 3649811 0.0131 -1.8400 -3.5801
2844293 0.0497 2.5000 5.6569 3861786 0.0154 -1.8400 -3.5801
3740628 0.0223 2.4700 5.5404 3959613 0.0161 -1.8400 -3.5801
3959688 0.0033 2.3900 5.2416 3445123 0.0007 -1.8433 -3.5884
2565349 0.0234 2.3267 5.0164 3551728 0.0088 -1.8433 -3.5884
3740574 0.0072 2.2367 4.7131 2796066 0.0198 -1.8533 -3.6133
3470340 0.0115 2.2167 4.6482 3936913 0.0007 -1.8567 -3.6217
3959700 0.0261 2.1700 4.5002 3607510 0.0467 -1.8700 -3.6553
3740610 0.0021 2.1567 4.4588 3706219 0.0281 -1.8700 -3.6553
3959684 0.0099 2.1333 4.3873 2474240 0.0081 -1.8733 -3.6638
3958389 0.0084 2.1267 4.3671 3850660 0.0025 -1.8800 -3.6808
3551788 0.0389 2.0900 4.2575 3873115 0.0272 -1.8933 -3.7149
3740576 0.0174 2.0700 4.1989 2790486 0.0169 -1.8933 -3.7149
3740548 0.0124 2.0467 4.1315 3601955 0.0011 -1.9000 -3.7321
3958393 0.0008 1.9967 3.9908 2427007 0.0026 -1.9267 -3.8018
3275506 0.0097 1.9700 3.9177 3947227 0.0171 -1.9300 -3.8106
7385547 0.0080 1.9467 3.8548 3331903 0.0160 -1.9300 -3.8106
2406293 0.0026 1.9400 3.8371 2536303 0.0008 -1.9367 -3.8282
3181976 0.0123 1.9067 3.7494 3619945 0.0004 -1.9400 -3.8371
2565203 0.0289 1.8467 3.5967 2776088 0.0100 -1.9400 -3.8371
3740550 0.0142 1.8333 3.5636 2939232 0.0163 -1.9400 -3.8371
2700365 0.0324 1.8167 3.5227 3435362 0.0224 -1.9467 -3.8548
2949093 0.0387 1.8100 3.5064 3944922 0.0004 -1.9567 -3.8816
3740580 0.0181 1.8067 3.4983 2884623 0.0106 -1.9667 -3.9086
3275504 0.0290 1.8000 3.4822 3108526 0.0002 -1.9967 -3.9908
3212366 0.0007 1.7867 3.4502 2873785 0.0322 -2.0400 -4.1125
2844309 0.0453 1.7767 3.4263 3719210 0.0003 -2.0433 -4.1220
3095313 0.0117 1.7700 3.4105 3798829 0.0048 -2.0633 -4.1795
2485636 0.0108 -2.0700 -4.1989
3407849 0.0036 -2.0733 -4.2086
3439178 0.0392 -2.0933 -4.2673
3984655 0.0385 -2.0967 -4.2772
3708245 0.0214 -2.1033 -4.2970
3886223 0.0149 -2.1567 -4.4588
2659560 0.0285 -2.1667 -4.4898
2900051 0.0076 -2.1733 -4.5106
2876608 0.0117 -2.1867 -4.5525
2564520 0.0293 -2.1900 -4.5631
3349293 0.0000 -2.1900 -4.5631
3351841 0.0274 -2.2267 -4.6805
3591365 0.0040 -2.2367 -4.7131
2469252 0.0090 -2.2467 -4.7459
2352804 0.0233 -2.2600 -4.7899
3279058 0.0090 -2.2667 -4.8121
2947063 0.0120 -2.2733 -4.8344
3445028 0.0199 -2.3200 -4.9933
3772158 0.0466 -2.3467 -5.0865
3852565 0.0055 -2.3700 -5.1694
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12.3 Data collection and refinement statistics 
 
Data collection and refinement statistics for the human Hub1-HIND complex. 
Space group 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
Resolution (Å) 
Completeness (%) 
Rmerge 
I/σ(I) 
Redundancy 
P 21212 
 
87.51, 103.63, 67 
90, 90, 90 
50 - 2.0 (2.1 - 2.0)* 
99.7 (99.8) 
6.4 (34.8) 
21.9 (4.48) 
7.32 (7.2) 
Refinement 
No. of reflections 
Resolution (Å) 
Rwork /  Rfree (%) 
No. atoms 
Protein 
Water 
Overall B (Å2) 
r. m. s. deviations 
Bond length (Å) 
Bond angles (o) 
35644 
20 - 2.0 
21.5 / 26.6 
 
5376 
206 
30.6 
 
0.01 
1.43 
*Values in parentheses are for highest-resolution shell. 
